Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 4.2.1.1 - carbonic anhydrase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Achlorhydria
Achlorhydria induced changes in gastrin, somatostatin, H+/K(+)-ATPase and carbonic anhydrase in the sheep.
Acid-Base Imbalance
BLOOD CARBONIC ANHYDRASE ACTIVITY-A POSSIBLE ROLE IN THE PRODUCTION OF ACID-BASE IMBALANCE IN CHILDREN AND INFANTS.
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Acidosis
: Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates.
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
A Multifunctional Graphene Oxide Platform for Targeting Cancer.
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Acetazolamide and exercise in sojourners to 6,300 meters--a preliminary study.
Acetazolamide on the ventral medulla of the cat increases phrenic output and delays the ventilatory response to CO2.
Acetazolamide, alternate carbonic anhydrase inhibitors and hypoglycaemic agents: comparing enzymatic with diuresis induced metabolic acidosis following intraocular surgery in diabetes.
Acetazolamide, metabolic acidosis, and intraocular pressure.
Acetylcholine-induced intracellular acidosis in rabbit salivary gland acinar cells.
Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts.
Acid-base status determines the renal expression of Ca2+ and mg2+ transport proteins.
Acid-base status in the toad Bufo viridis in vivo.
Acidosis inhibits the hypocalcemic effect of acetazolamide.
Adaptive changes of H+ and/or bicarbonate transport in chronic metabolic acidosis: its quantitative evaluation by using isolated perfused kidney.
Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide.
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Association of acetazolamide infusion with headache and cranial artery dilation in healthy volunteers.
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Axial skeletal malformations induced by acetazolamide in rabbits.
Bicarbonate transport in collecting tubules from outer stripe of outer medulla of rabbit kidneys.
Binding of carbonic anhydrase IX to 45S rDNA genes is prevented by exportin-1 in hypoxic cells.
Body water and electrolyte responses to acetazolamide in humans.
Brain carbonic acid acidosis after acetazolamide.
CA IX Stabilizes Intracellular pH to Maintain Metabolic Reprogramming and Proliferation in Hypoxia.
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Carbonic anhydrase II and IV mRNA in rabbit nephron segments: stimulation during metabolic acidosis.
Carbonic anhydrase II deficiency a novel mutation.
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency.
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Carbonic anhydrase II deficiency: report of a novel mutation.
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
Carbonic anhydrase II in the developing and adult human brain.
Carbonic anhydrase II mRNA is induced in rabbit kidney cortex during chronic metabolic acidosis.
Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization.
Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension.
Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.
Carbonic anhydrase inhibition. IV. The effects of metabolic acidosis on the response to diamox.
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia.
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Carbonic Anhydrase IX as an Anticancer therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain.
Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis.
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.
Carbonic anhydrase IX: A hypoxia-controlled "catalyst" of cell migration.
Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts.
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Cerebrospinal fluid ions in metabolic acidosis in dogs: effects of acetazolamide.
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
CO(2)/H(+) chemoreception in the cat pre-Bötzinger complex in vivo.
CO2 retention as a basis for increased toxicity of salicylate with acetazolamide: avoidance of increased toxicity with benzolamide.
Comparison of carbonic anhydrase in neonatal and maternal red blood cells with different levels of acidosis in newborn calves.
Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.
Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy.
Contractile function of papillary muscles with carbonic anhydrase inhibitors.
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
CSF bicarbonate regulation in respiratory acidosis and alkalosis.
Determination of carbonic anhydrase C and beta 2-microglobulin by radioimmunoassay in urine of heavy-metal-exposed subjects and patients with renal tubular acidosis.
Diuretic complications.
Diuretic therapy and exercise performance.
Diuretics and disorders of calcium homeostasis.
Does Aerobic Respiration Produce Carbon Dioxide or Hydrogen Ion and Bicarbonate?
Drug and chemical-induced metabolic acidosis.
Drug-induced acid-base disorders.
Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.
Effect of carbonic anhydrase inhibitors and acidosis in choroid plexus epithelial cell sodium and potassium.
Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients.
Effect of metabolic acidosis on glucose reabsorption in rats with acute hyperglycemia.
Effect of metabolic acidosis on hydrogen ion excretion in a pigtail macaque with erythrocyte carbonic anhydrase I deficiency.
Effects of acidosis and carbonic anhydrase inhibition in the elasmobranch rectal gland.
Effects of chronic acetazolamide administration on fluid flux from the pulmonary vasculature at rest and during exercise in horses.
Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.
Elimination of CO2 in patients with carbonic anhydrase II deficiency, with studies of respiratory function at rest.
Enzymatically inactive red cell carbonic anhydrase B in a family with renal tubular acidosis.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Expression of carbonic anhydrase IV in carbonic anhydrase II-deficient mice.
Expression of carbonic anhydrase IV in mouse placenta.
Expression of carbonic anhydrase IV mRNA in rabbit kidney: stimulation by metabolic acidosis.
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Extrinsic acidosis suppresses glycolysis and migration while increasing network formation in pulmonary microvascular endothelial cells.
Focal CO2/H+ alters phrenic motor output response to chemical stimulation of cat pre-Botzinger complex in vivo.
Generation of nitric oxide from nitrite by carbonic anhydrase: A possible link between metabolic activity and vasodilation.
Genetic mutation of Kcnj16 identifies Kir5.1-containing channels as key regulators of acute and chronic pH homeostasis.
High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
Hypercarbia and acidosis associated with carbonic anhydrase inhibition: a hazard of topical mafenide acetate use in renal failure.
Hyperkalaemia induced by carbonic anhydrase inhibitor.
Hypokalaemia and Renal Tubular Acidosis due to Abuse of Nurofen Plus.
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Hypoxia and energetic tumour metabolism.
Hypoxia related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin's lymphoma.
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.
Hypoxia-inducible carbonic anhydrase IX expression is insufficient to alleviate intracellular metabolic acidosis in the muscle of zebrafish, Danio rerio.
Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Inactive form of erythrocyte carbonic anhydrase B in patients with primary renal tubular acidosis.
Indirect evidence for the presence of non-specific anion channels in rabbit mandibular salivary gland acinar cells.
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Influence of carbonic anhydrase inhibition on renal effects of acute respiratory alkalosis and acidosis in human subjects.
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Intracellular carbonic anhydrase activity and its role in GABA-induced acidosis in isolated rat hippocampal pyramidal neurones.
Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis.
Mapping of the cerebral response to acetazolamide using graded asymmetric spin echo EPI.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Metabolic acidosis stimulates carbonic anhydrase activity in rabbit proximal tubule and medullary collecting duct.
Metabolic Acidosis with Ophthalmic Dorzolamide in a Neonate.
Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors.
Molecular basis of human carbonic anhydrase II deficiency.
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy.
Ocular and systemic effects of acetazolamide in nephrectomized rabbits.
Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabolic and respiratory acidosis.
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Osteopetrosis: some unusual radiological features with a short review.
Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium.
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide.
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Postnatal disappearance of type A intercalated cells in carbonic anhydrase II-deficient mice.
Promoter activity of carbonic anhydrase II regulatory regions in cultured renal proximal tubular cells.
Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats.
Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat.
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Red blood cell carbonic anhydrase activity in children with distal renal tubular acidosis.
Remodeling the cellular profile of collecting ducts by chronic carbonic anhydrase inhibition.
Renal and systemic pH imaging by contrast-enhanced MRI.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Resistance of hippocampal synaptic transmission to hypoxia in carbonic anhydrase II-deficient mice.
Retinal pH and Acid Regulation During Metabolic Acidosis.
S0859, an N-cyanosulphonamide inhibitor of sodium-bicarbonate cotransport in the heart.
Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis.
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
Sjögren's syndrome--study of autoantigens and autoantibodies.
Stimulation of renal sulfate secretion by metabolic acidosis requires Na+/H+ exchange induction and carbonic anhydrase.
Subgroups of Sjögren syndrome patients according to serological profiles.
The effect of acetazolamide and carbonic anhydrase inhibition on erythrocyte 2,3-diphosphoglycerate content and metabolism.
The effect of antiepileptic drugs on the kidney function and structure.
The neurology of carbonic anhydrase type II deficiency syndrome.
The renal excretion of hydrogen ion in renal tubular acidosis. II. Quantitative response to the carbonic anhydrase inhibitor, acetazolamide.
The role of carbonic anhydrase in gastric mucosal protection with special reference to H+ back diffusion and concomitant metabolic acidosis induced by acetazolamide.
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond.
The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition.
Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.
Time course of the response to recombinant growth hormone in acidotic mice.
Topiramate and metabolic acidosis in infants and toddlers.
Topiramate and metabolic acidosis in pediatric epilepsy.
Topiramate and metabolic acidosis: a case series and review of the literature.
Topiramate and metabolic acidosis: an evolving story.
Topiramate and severe metabolic acidosis: case report.
Topiramate in Migraine Prevention: A 2016 Perspective.
Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
Topiramate Overdose: Clinical and Laboratory Features.
Topiramate-induced nephrolithiasis.
Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa.
Transfusion of carbonic anhydrase-replete erythrocytes fails to correct the acidification defect in the syndrome of osteopetrosis, renal tubular acidosis, and cerebral calcification (carbonic anhydrase-II deficiency).
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
Use of diuretics in chronic renal failure.
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors in patients with chronic respiratory insufficiency. I. Ventilation, gas exchange, and gas tension in the blood, at rest and during muscular exercise of various intensity]
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors, in patients with chronic respiratory insufficiency. II. Tissue oxygenation and anerobic metabolism during muscular exercise]
[Effect of purinergic agents on ion movement in submaxillary glands]
[Effects of carbonic anhydrase inhibition and of acidosis due to ammonium chloride on the ventilatory response to CO2 in chronic respiratory insufficiency]
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
[Osteopetrosis and renal acidosis: a new case of this rare syndrome]
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
[Recent progress in molecular biology of inherited tubular transport abnormalities]
[Renal acidosis with aminoaciduria following inhibition of carbonic anhydrase with diamox.]
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
[The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?]
[Two cases of urolithiasis induced by topiramate].
[Ventilatory action of acetazolamide. IV. Effects of extracellular acidosis & alkalosis on inhibition of globular anhydrase by acetazolamide.]
Acidosis, Lactic
Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment.
Drug-induced acid-base disorders.
Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats.
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Acidosis, Renal Tubular
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Carbonic anhydrase II deficiency a novel mutation.
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency.
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Carbonic anhydrase II deficiency: report of a novel mutation.
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
Carbonic anhydrase II in the developing and adult human brain.
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
Determination of carbonic anhydrase C and beta 2-microglobulin by radioimmunoassay in urine of heavy-metal-exposed subjects and patients with renal tubular acidosis.
Drug-induced acid-base disorders.
Enzymatically inactive red cell carbonic anhydrase B in a family with renal tubular acidosis.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Hypokalaemia and Renal Tubular Acidosis due to Abuse of Nurofen Plus.
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Inactive form of erythrocyte carbonic anhydrase B in patients with primary renal tubular acidosis.
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Molecular basis of human carbonic anhydrase II deficiency.
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy.
Osteopetrosis: some unusual radiological features with a short review.
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Promoter activity of carbonic anhydrase II regulatory regions in cultured renal proximal tubular cells.
Quantitative high resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in the rat.
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Red blood cell carbonic anhydrase activity in children with distal renal tubular acidosis.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Sjögren's syndrome--study of autoantigens and autoantibodies.
Subgroups of Sjögren syndrome patients according to serological profiles.
The effect of antiepileptic drugs on the kidney function and structure.
The neurology of carbonic anhydrase type II deficiency syndrome.
The renal excretion of hydrogen ion in renal tubular acidosis. II. Quantitative response to the carbonic anhydrase inhibitor, acetazolamide.
Topiramate and severe metabolic acidosis: case report.
Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase.
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
[Recent progress in molecular biology of inherited tubular transport abnormalities]
[Two cases of urolithiasis induced by topiramate].
Acidosis, Respiratory
Adaptation to respiratory acidosis in the turtle bladder.
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
CO2 retention as a basis for increased toxicity of salicylate with acetazolamide: avoidance of increased toxicity with benzolamide.
Drug-induced acid-base disorders.
Dual contribution theory of regulation of CSF HCO3 in respiratory acidosis.
Effect of carbonic anhydrase on carbon dioxide tension of urine and plasma during respiratory acidosis.
Effects of acidosis and carbonic anhydrase inhibition in the elasmobranch rectal gland.
Effects of acute and chronic acetazolamide on resting ventilation and ventilatory responses in men.
Effects of carbonic anhydrase inhibition on the acid base status in lamprey and trout.
Effects of the carbonic anhydrase inhibitor "6063" (diamox) on respiration and electrolyte metabolism of patients with respiratory acidosis.
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Optic nerve pH and PO2: the effects of carbonic anhydrase inhibition, and metabolic and respiratory acidosis.
Respiratory acidosis in carbonic anhydrase II-deficient mice.
Respiratory and renal effects of a carbonic anhydrase inhibitor (diamox) on acid-base balance in normal man and in patients with respiratory acidosis.
Roles of gill and red cell carbonic anhydrase in elasmobranch HCO3- and CO2 excretion.
The apparent buffer value of cerebrospinal fluid in acute hypercapnia.
The CSF HCO3 increase in hypercapnia relationshp to HCO3, glutamate, glutamine and NH3 in brain.
The effects of the carbonic anhydrase inhibitor 6063 on electrolytes and acid-base balance in two normal subjects and two patients with respiratory acidosis.
The effects of the carbonic anhydrase inhibitor acetazoleamide on chronic respiratory acidosis.
The treatment of respiratory acidosis with a potent carbonic anhydrase inhibitor (dichlorphenamide).
[Acid-base equilibrium and the brain]
[CARBONIC ANHYDRASE INHIBITORS IN THE TREATMENT OF RESPIRATORY ACIDOSIS.]
[The role of carbonic anhydrase in the buffer mechanism of cerebrospinal fluid in acute respiratory acidosis (author's transl)]
[Trial of a carbonic anhydrase inhibitor, dichlorphenamide, in the treatment of respiratory acidosis.]
Acquired Immunodeficiency Syndrome
Carbonic Anhydrase Activators. Part 19 Spectroscopic and Kinetic Investigations for the Interaction of Isozymes I and II With Primary Amines.
Design of miniproteins by the transfer of active sites onto small-size scaffolds.
Gas transfer in dogfish: a unique model of CO2 excretion.
Leaf Proteome Analysis Reveals Prospective Drought and Heat Stress Response Mechanisms in Soybean.
Synergistic role of bacterial urease and carbonic anhydrase in carbonate mineralization.
Acute Kidney Injury
Relationship of renal prostaglandins to three diuretics.
Renal handling and plasma elimination kinetics of carbonic anhydrase isoenzymes I, II and III in the rat.
Acute Lung Injury
Carbonic anhydrase inhibitor attenuates ischemia-reperfusion induced acute lung injury.
Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis.
Addison Disease
The effects of carbonic anhydrase inhibitor in Addison's disease.
Adenocarcinoma
1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors.
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging.
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Biologic instability of pancreatic cancer xenografts in the nude mouse.
Carbonic anhydrase II gene expression in cell lines from human pancreatic adenocarcinoma.
Carbonic anhydrase II gene expression in mouse pancreatic duct cells.
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Carbonic anhydrase IX expression in prostate cancer.
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri.
Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix.
CuZnSOD and MnSOD inhibit metabolic stress-induced necrosis and multicellular tumour spheroid growth.
Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3.
Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas.
HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Paxillin and Carbonic Anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.
Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas.
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
The significance of carbonic anhydrase expression in human colorectal cancer.
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
Tumor necrosis factor-alpha induces the expression of carbonic anhydrase II in pancreatic adenocarcinoma cells.
[Clinicopathological significance of the expression of carbonic anhydrase I and II in human pancreatic cancer].
Adenocarcinoma of Lung
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients.
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma.
Adenocarcinoma, Mucinous
The Expression of Glut-1, CAIX, and MCT4 in Mucinous Carcinoma.
Adenoma
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Histogenetic stereological reconstruction of rat basophilic, clear, and oncocytic neoplastic renal cell lesions using carbonic anhydrase type II-PAS double-stained sections.
Histological features of advanced colorectal adenomas detected by endoscopy and fecal immunochemical test.
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
Immunohistochemical study of carbonic anhydrase in mixed tumours and adenomas of sweat and sebaceous glands.
RT-PCR detection of fibronectin EDA+ and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma.
Serrated adenoma of the colorectum undergoes a proliferation versus differentiation process: new conceptual interpretation of morphogenesis.
Adenoma, Oxyphilic
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Immunohistochemical localization of two types of carbonic anhydrase isozymes in oncocytoma and oncocytic epithelial cells.
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Adenoma, Pleomorphic
[Histogenesis of pleomorphic adenomas of the salivary glands]
Adenomatous Polyposis Coli
Analysis of protein profiling studies of ?-thalassemia/Hb E disease.
Adrenocortical Adenoma
Carbonic anhydrases in the human adrenal gland and its disorders: Immunohistochemical and biochemical studies of the enzymes.
Adrenoleukodystrophy
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Ageusia
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
Agranulocytosis
Topiramate induced agranulocytosis.
Albuminuria
Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF.
Alkalosis
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?
Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis.
Carbonic anhydrase 2-like and Na?-K?-ATPase ? gene expression in medaka (Oryzias latipes) under carbonate alkalinity stress.
Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials.
Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition.
Drug-induced acid-base disorders.
Effects of acetazolamide on cerebrospinal fluid ions in metabolic alkalosis in dogs.
Functional interaction of carbonic anhydrase and chloride/bicarbonate exchange in human platelets.
Influence of alterations in acid-base conditions on intracellular pH of intact renal cortex.
Metabolic alkalosis.
Proximal tubular acidification in metabolic alkalosis.
Roles of gill and red cell carbonic anhydrase in elasmobranch HCO3- and CO2 excretion.
The effect of metabolic alkalosis, hypotension and inhibitors of carbonic anhydrase on fluid secretion by rat testes.
The Warburg Effect and the Hallmarks of Cancer.
Trial sequential analysis suggested the potential overestimated effect of carbonic anhydrase inhibitor for respiratory failure and metabolic alkalosis.
V-H+ -ATPase translocation during blood alkalosis in dogfish gills: interaction with carbonic anhydrase and involvement in the postfeeding alkaline tide.
[Diuretics; their characteristics and future development]
[Ventilatory action of acetazolamide. IV. Effects of extracellular acidosis & alkalosis on inhibition of globular anhydrase by acetazolamide.]
Alkalosis, Respiratory
Acetazolamide suppresses the prevalence of augmented breaths during exposure to hypoxia.
Gymnocypris przewalskii decreases cytosolic carbonic anhydrase expression to compensate for respiratory alkalosis and osmoregulation in the saline-alkaline lake Qinghai.
Influence of carbonic anhydrase inhibition on renal effects of acute respiratory alkalosis and acidosis in human subjects.
alpha-Thalassemia
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
Altitude Sickness
Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain.
Acetazolamide impairs fear memory consolidation in rodents.
Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide.
Anuric Acute Kidney Injury Induced by Acute Mountain Sickness Prophylaxis With Acetazolamide.
Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level.
Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats.
Carbonic anhydrase inhibitors and high altitude illnesses.
Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction.
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Determination of acetazolamide in human serum by enzymatic assay.
Diuretic therapy and exercise performance.
Effect of acetazolamide and methazolamide on diaphragm and dorsiflexor fatigue: a randomized controlled trial.
Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat.
Evaluating off-label uses of acetazolamide.
Heterocyclic compounds as carbonic anhydrase inhibitor.
High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema.
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Novel application of acetazolamide to reduce cerebrospinal fluid production in patients undergoing thoracoabdominal aortic surgery.
Pharmacology of acute mountain sickness: old drugs and newer thinking.
Relationship of altitude mountain sickness and smoking: a Catalan traveller's cohort study.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Synthesis and evaluation of 4-(1,3,4-oxadiazol-2-yl)-benzenesulfonamides as potent carbonic anhydrase inhibitors.
Usual clinical dose of acetazolamide does not alter cerebral blood flow velocity.
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Alzheimer Disease
Activation of Two Different Drugs Used in Alzheimer's Disease Treatment on Human Carbonic Anhydrase Isozymes I and II Activity: an In Vitro Study.
Carbonic anhydrase activation profile of indole-based derivatives.
Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
Carbonic anhydrase gating of attention: memory therapy and enhancement.
Cholinesterases, ?-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus.
Five- and Six-Membered Nitrogen-Containing Compounds as Selective Carbonic Anhydrase Activators.
Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases.
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Novel sulfamate derivatives of menthol: Synthesis, characterization, and cholinesterases and carbonic anhydrase enzymes inhibition properties.
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
[Study on mechanisms of anti-Alzheimer's disease action of absorbed components of Gardeniae Fructus based on network pharmacology].
Ameloblastoma
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Amyotrophic Lateral Sclerosis
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.
Anaphylaxis
Characterization of two strains of selectively bred guinea-pigs. I. Skin transplantation experiments and screening for erythrocyte enzyme polymorphism.
Anemia
Anti-carbonic anhydrase antibodies in iron deficiency anemia.
Blood carbonic anhydrase activity in anemia, with a note on polycythemia vera.
Carbonic andydrase isoenzyme B in erythrocytes of subjects with different types of anemia.
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
EFFECT OF A CARBONIC ANHYDRASE INHIBITOR (DICHLORPHENAMIDE) ON SICKLE CELL ANEMIA.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Possible correlation between the zinc and copper concentrations involved in the pathogenesis of various forms of anemia.
Significance of blood carbonic anhydrase activity in anemia.
The pattern of carbon dioxide excretion in the rainbow trout Salmo gairdneri.
Zinc deficiency states and carbonic anhydrase isozyme in experimental hemolytic and bleeding anemia of rabbits.
[Erythrocyte carbonic anhydrase in subjects on periodic hemodialysis]
[Erythrocyte carbonic anhydrase isozymes in patients with iron deficiency anemia and their clinical significances (author's transl)]
Anemia, Aplastic
Antibodies against Carbonic Anhydrase in Patients with Aplastic Anemia.
Aplastic anemia resulting from the use of carbonic anhydrase inhibitors.
Identification of carbonic anhydrase I immunodominant epitopes recognized by specific autoantibodies which indicate an improved prognosis in patients with malignancy after autologous stem cell transplantation.
Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia.
Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis.
Anemia, Hemolytic
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Anemia, Iron-Deficiency
Anti-carbonic anhydrase antibodies in iron deficiency anemia.
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
[Erythrocyte carbonic anhydrase isozymes in patients with iron deficiency anemia and their clinical significances (author's transl)]
Anemia, Megaloblastic
Red-cell carbonic anhydrase isoenyzmes in megaloblastic anaemia.
Anemia, Pernicious
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Zinc and carbonic anhydrase content of red cells in normals and in pernicious anemia.
Anemia, Sickle Cell
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
EFFECT OF A CARBONIC ANHYDRASE INHIBITOR (DICHLORPHENAMIDE) ON SICKLE CELL ANEMIA.
Angina Pectoris
The chemistry and pharmacology of alkaloids and allied nitrogen compounds from Artemisia species: A review.
Angiomatosis
Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds.
Angiomyolipoma
Activation of the ER stress and calcium signaling in angiomyolipoma.
Anthracosis
[Blood carbonic anhydrase activity in anthracosis (anthracosilicosis) and pulmonary emphysema]
Anuria
Acute renal failure from the use of acetazolamide (Diamox).
Aortic Aneurysm, Abdominal
Autoantigenicity of carbonic anhydrase 1 in patients with abdominal aortic aneurysm, revealed by proteomic surveillance.
Aortic Valve Stenosis
Carbonic anhydrase XII in valve interstitial cells promotes the regression of calcific aortic valve stenosis.
Apnea
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Arterial Occlusive Diseases
Heparin cofactor II: a simple assay method and results of its clinical application.
Arthralgia
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Arthritis
7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors.
AHR-15010--a novel anti-arthritic agent.
Carbonic anhydrase inhibitors are antiarthritic in the rat.
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Arthritis, Rheumatoid
Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.
Carbonic anhydrase II autoantibody and oxidative stress in rheumatoid arthritis.
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Changes in zinc and zinc-dependent enzymes in rheumatoid patients during penicillamine treatment.
Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis.
Discovery of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Management of Rheumatoid Arthritis.
Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.
In pursuit of B-cell synovial autoantigens in rheumatoid arthritis: Confirmation of citrullinated fibrinogen, detection of vimentin, and introducing carbonic anhydrase as a possible new synovial autoantigen.
Pain Relieving Effect of-NSAIDs-CAIs Hybrid Molecules: Systemic and Intra-Articular Treatments against Rheumatoid Arthritis.
Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Ascariasis
Ascaris lumbricoides ? carbonic anhydrase: a potential target enzyme for treatment of ascariasis.
Homology modeling and molecular dynamics dimulation study of ? carbonic anhydrase of Ascaris lumbricoides.
Asthma
A comparison of the effects of inhaled furosemide and ethacrynic acid on sodium-metabisulfite-induced bronchoconstriction in subjects with asthma.
The effect of inhaled furosemide and acetazolamide on bronchoconstriction induced by deep inspiration in asthma.
Astrocytoma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma.
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
Ataxia
Aberrant IP3 receptor activities revealed by comprehensive analysis of pathological mutations causing spinocerebellar ataxia 29.
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Acetazolamide-responsive ataxia.
Episodic ataxia: a case report and review of literature.
RNAi silencing of P/Q-type calcium channels in Purkinje neurons of adult mouse leads to episodic ataxia type 2.
Roles of inositol 1,4,5-trisphosphate receptors in spinocerebellar ataxias.
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
[Treatment options for nystagmus].
Atherosclerosis
Atherosclerosis: The carbonic anhydrase, carbon dioxide, calcium concerted theory.
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Strong association of glaucoma with atherosclerosis.
The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.
Atrial Fibrillation
Re-expression of alpha skeletal actin as a marker for dedifferentiation in cardiac pathologies.
Atypical Squamous Cells of the Cervix
"Equivocal" High-Risk HPV DNA Tests Performed on ThinPrep Specimens After ASC-US Diagnoses Are Associated With an Increased Incidence of CIN3: A Cytologic/Histologic Review of 315 Cases.
Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
Detection of high risk human papillomavirus cervical infections by the hybrid capture in Asunción, Paraguay.
Detection of HPV DNA in cervical specimens collected in cytologic solution by ligation-dependent PCR.
High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization.
Autoimmune Diseases
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Autoimmune pancreatitis.
Carbonic anhydrase antibody in sera from patients with endometriosis.
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Carbonic anhydrase III: a new target for autoantibodies in autoimmune diseases.
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia.
Autoimmune Pancreatitis
Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis.
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Autoimmune chronic pancreatitis.
Autoimmune pancreatitis.
Differentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies.
Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin.
Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?
Helicobacter pylori and pancreatic diseases.
Low-avidity antibodies to carbonic anhydrase-I and -II in autoimmune chronic pancreatitis.
Potential for differential diagnosis of autoimmune pancreatitis and pancreatic cancer using carbonic anhydrase II antibody.
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer.
What are the useful biological and functional markers of early-stage chronic pancreatitis?
[Autoimmune pancreatitis: inflammatory pseudotumor, multifocal fibrosclerosis, portal hypertension, and long-term outcome]
Azotemia
Use of diuretics in chronic renal failure.
Babesiosis
Plasma levels of zinc, copper, copper/zinc ratio, and activity of carbonic anhydrase in equine piroplasmosis.
Bacteremia
Capnophilic Enterobacteriaceae.
Bacterial Infections
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
beta-Thalassemia
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase.
Blepharitis
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
Blister
[Encapsulated filtering blebs--incidence and methods of treatment]
Bone Diseases
Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders.
Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine.
Bone Diseases, Developmental
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Bone Diseases, Metabolic
A proteomic study of protein variation between osteopenic and age-matched control bone tissue.
Bone Resorption
1 alpha,25-dihydroxyvitamin D3 regulates the transcription of carbonic anhydrase II mRNA in avian myelomonocytes.
17 beta-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase II in ovariectomized rats.
A comparison of the effects of inhibitors of carbonic anhydrase on osteoclastic bone resorption and purified carbonic anhydrase isozyme II.
A facilitative role for carbonic anhydrase activity in matrix vesicle mineralization.
Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts.
Bone resorption induced by parathyroid hormone and dibutyryl cyclic AMP: role of carbonic anhydrase.
Bone resorptive activity of human peripheral blood mononuclear cells after fusion with polyethylene glycol.
Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro.
Carbonic anhydrase activity in fetal rat bone resorbing cells: inhibition by acetazolamide infusion.
Carbonic anhydrase and bone remodeling: sulfonamide inhibition of bone resorption in organ culture.
Carbonic anhydrase and bone resorption.
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency.
Carbonic anhydrase II gene transcript in cultured osteoclasts from neonatal rats: effect of calcitonin.
Carbonic anhydrase II is induced in HL-60 cells by 1,25-dihydroxyvitamin D3: a model for osteoclast gene regulation.
Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+.
Carbonic anhydrase inhibition by flurbiprofen and related agents.
Carbonic anhydrase inhibitors are antiarthritic in the rat.
Cholera toxin-stimulated bone resorption in cultured mouse calvarial bones not inhibited by calcitonin: a possible interaction at the stimulatory G protein.
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts.
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Effects of a potent carbonic anhydrase inhibitor on bone resorption in organ culture.
Effects of heterocyclic sulfonamides on bone metabolism.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Forskolin-induced bone resorption in neonatal mouse calvaria in vitro.
High active isoenzyme of carbonic anhydrase in rat calvaria osteoclasts. Immunohistochemical study.
Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro.
In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation.
In vitro resorptive activity of isolated chick osteoclasts: effects of carbonic anhydrase inhibition.
Increased expression of fibroblast growth factor 23 is the signature of a deteriorated Ca/P balance in ageing laying hens.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
Inhibitory mechanisms of H(+)-ATPase inhibitor bafilomycin A1 and carbonic anhydrase II inhibitor acetazolamide on experimental bone resorption.
miR-506-3p alleviates uncontrolled osteoclastogenesis via repression of RANKL/NFATc1 signaling pathway.
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Potential anti-osteoporotic activity of low-molecular weight hyaluronan by attenuation of osteoclast cell differentiation and function in vitro.
Proton channel part of vacuolar H(+)-ATPase and carbonic anhydrase II expression is stimulated in resorbing osteoclasts.
Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase.
Role of carbonic anhydrase in bone resorption induced by 1,25 dihydroxyvitamin D3 in vitro.
Role of carbonic anhydrase in bone resorption induced by prostaglandin E2 in vitro.
Role of carbonic anhydrase in bone resorption: effect of acetazolamide on basal and parathyroid hormone-induced bone metabolism.
Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice.
The cellular physiology of carbonic anhydrases.
The effect of carbonic anhydrase inhibition on calcium and bone homeostasis in healthy postmenopausal women.
The expression of carbonic anhydrase in canine mammary gland and mammary gland tumor.
The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors.
Treat ankylosing spondylitis with methazolamide.
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Vitamin D and genomic stability.
Bradycardia
Cardiorespiratory effects induced by acetazolamide on the ventromedullary surface of the cat.
New glaucoma medications in the geriatric population: efficacy and safety.
Brain Diseases
Brain carbonic anhydrase activity in rats in experimental hepatogenic encephalopathy.
Carbonic anhydrase VA deficiency: a very rare case of hyperammonemic encephalopathy.
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl.
Small-molecule suppression of misfolding of mutated human carbonic anhydrase II linked to marble brain disease.
Thermodynamic interrogation of a folding disease. Mutant mapping of position 107 in human carbonic anhydrase II linked to marble brain disease.
Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.
Brain Edema
[Treatment of increase of the cerebral volume with electrolyte substitution and inhibition of carbonic anhydrase. With a contribution to the genesis of cerebral edema.]
Brain Infarction
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Brain Injuries
Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage.
Brain Ischemia
Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors.
Extracellular pH changes during spreading depression and cerebral ischemia: mechanisms of brain pH regulation.
Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia.
Role of Carbonic Anhydrase in Cerebral Ischemia and Carbonic Anhydrase Inhibitors as Putative Protective Agents.
Brain Neoplasms
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase IX in oligodendroglial brain tumors.
Carbonic anhydrase XII functions in health and disease.
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Expression of Myoglobin in Normal and Cancer Brain Tissues: Correlation With Hypoxia Markers.
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Intrinsic thermodynamics of trifluoromethanesulfonamide and ethoxzolamide binding to human carbonic anhydrase VII.
Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer.
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Substituted (E)-2-(2-benzylidenehydrazinyl)-4-methylthiazole-5-carboxylates as dual inhibitors of 15-lipoxygenase & carbonic anhydrase II: synthesis, biochemical evaluation and docking studies.
The Expression of Carbonic Anhydrases II, IX and XII in Brain Tumors.
Topiramate induces acute intracellular acidification in glioblastoma.
Breast Neoplasms
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells.
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies.
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts.
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer.
Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells.
Blood Oxygenation Level-dependent Magnetic Resonance Imaging of Breast Cancer: Correlation with Carbonic Anhydrase IX and Vascular Endothelial Growth Factor.
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
CA IX is upregulated in CoCl2-induced hypoxia and associated with cell invasive potential and a poor prognosis of breast cancer.
CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer.
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
Carbonic Anhydrase IX Promotes Myeloid-Derived Suppressor Cell Mobilization and Establishment of a Metastatic Niche by Stimulating G-CSF Production.
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling.
Carbonic anhydrase XII functions in health and disease.
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma.
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology.
Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly.
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Chemometric modeling of breast cancer associated carbonic anhydrase IX inhibitors belonging to the ureido-substituted benzene sulfonamide class.
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.
Correction: Signaling Pathways of ESE-16, an Antimitotic and Anticarbonic Anhydrase Estradiol Analog, in Breast Cancer Cells.
Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2? (HIF-2?) in breast cancer.
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition.
Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging.
Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
Expression and Activity of Carbonic Anhydrase IX Is Associated With Metabolic Dysfunction in MDA-MB-231 Breast Cancer Cells.
Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2.
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.
Germinal center hypoxia in tumor-draining lymph nodes negatively regulates tumor-induced humoral immune responses in mouse models of breast cancer.
GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.
Glycoprotein profiles of human breast cells demonstrate a clear clustering of normal/benign versus malignant cell lines and basal versus luminal cell lines.
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints.
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
High expression of carbonic anhydrase 12 (CA12) is associated with good prognosis in breast cancer.
Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX.
Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients.
Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
Identification of potential breast cancer markers in nipple discharge by protein profile analysis using two-dimensional nano-liquid chromatography/nanoelectrospray ionization-mass spectrometry.
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration.
Interaction of HIF-1? and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells.
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Investigation of acetylcholinesterase and mammalian DNA topoisomerases, carbonic anhydrase inhibition profiles, and cytotoxic activity of novel bis(?-aminoalkyl)phosphinic acid derivatives against human breast cancer.
Metabolic Effect of Estrogen Receptor Agonists on Breast Cancer Cells in the Presence or Absence of Carbonic Anhydrase Inhibitors.
Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry.
Modulation of markers associated with aggressive phenotype in MDA-MB-231 breast carcinoma cells by sulforaphane.
Necrosis and hypoxia in invasive breast carcinoma.
New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.
New strategies for targeting the hypoxic tumour microenvironment in breast cancer.
Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.
Overexpression of CA1 mRNA and the CA I Protein in Tumor Cells Does Not Change the Gene Expression of the ECM Proteins.
Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.
p300 and p53 levels determine activation of HIF-1 downstream targets in invasive breast cancer.
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Peroxisome proliferator activated receptor-?/hypoxia inducible factor-1? interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
PPAR? and RXR Ligands Disrupt the Inflammatory Cross-talk in the Hypoxic Breast Cancer Stem Cells Niche.
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in Breast Cancer Patients.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity.
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Renewed interests in carbonic anhydrase IX in relevance to breast cancer treatment.
Repression of protocadherin 17 is correlated with elevated angiogenesis and hypoxia markers in female patients with breast cancer.
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells.
Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog, in breast cancer cells.
Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1? expression.
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
Synthesis of novel tellurides bearing benzensulfonamide moiety as carbonic anhydrase inhibitors with antitumor activity.
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
Tellurides bearing benzensulfonamide as carbonic anhydrase inhibitors with potent antitumor activity.
TFAP2C regulates carbonic anhydrase XII in human breast cancer.
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1? and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis.
Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.
[Expression of carbonic anhydrase IX in the breast carcinomas].
[Hypoxia induces down-regulation of estrogen receptor alpha in human breast cancer.]
[Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
Breast Neoplasms, Male
Fibrotic focus and hypoxia in male breast cancer.
Brucellosis
Brucella suis carbonic anhydrases and their inhibitors: Towards alternative antibiotics?
Design and development of novel therapeutics for brucellosis treatment based on carbonic anhydrase inhibition.
Calcinosis
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
carbonic anhydrase deficiency
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement.
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
A unique mutation underlying carbonic anhydrase II deficiency syndrome in patients of Arab descent.
Altered gene expression in the lower respiratory tract of Car6 (-/-) mice.
Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome.
Bone marrow transplantation demonstrates that carbonic anhydrase II deficiency limited to bone marrow-derived cells affects ammonium chloride tolerance in mice.
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
Brain phenotype of carbonic anhydrase IX-deficient mice.
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Carbonic anhydrase deficiency with persistence of foetal haemoglobin: a new syndrome.
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Carbonic anhydrase II deficiency a novel mutation.
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency in a Japanese patient produced by a nonsense mutation (TAT-->TAG) at Tyr-40 in exon 2, (Y40X).
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Carbonic anhydrase II deficiency in three unrelated Japanese patients.
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene.
Carbonic anhydrase II deficiency syndrome--clinico-pathological, biochemical and molecular studies.
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency.
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Carbonic anhydrase II deficiency: report of a novel mutation.
Carbonic anhydrase II deficiency: single-base deletion in exon 7 is the predominant mutation in Caribbean Hispanic patients.
Carbonic anhydrase II in the developing and adult human brain.
Carbonic anhydrase isozyme-II-deficient mice lack the duodenal bicarbonate secretory response to prostaglandin E2.
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Carbonic anhydrase VA deficiency: a very rare case of hyperammonemic encephalopathy.
Carbonic anhydrase XIV deficiency produces a functional defect in the retinal light response.
Carbonic Anhydrase-Deficient Mutant of Chlamydomonas reinhardii Requires Elevated Carbon Dioxide Concentration for Photoautotrophic Growth.
Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice.
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Case report 718. Osteopetrosis with carbonic anhydrase II deficiency.
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Clinical quiz. Osteopetrosis with carbonic anhydrase II deficiency.
Combined inherited protein S and heparin co-factor II deficiency in a patient with upper limb thrombosis: a family study.
Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis.
Developmental changes in seizure susceptibility in carbonic anhydrase II-deficient mice and normal littermates.
Disturbances of growth hormone-insulin-like growth factor axis and response to growth hormone in acidosis.
Effect of disease-linked mutations on the structure, function, stability and aggregation of human carbonic anhydrase II.
Effect of metabolic acidosis on hydrogen ion excretion in a pigtail macaque with erythrocyte carbonic anhydrase I deficiency.
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
Elimination of CO2 in patients with carbonic anhydrase II deficiency, with studies of respiratory function at rest.
ERRATUM: Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Expression of carbonic anhydrase IX in mouse tissues.
Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency.
Fatal metabolic decompensation in carbonic anhydrase VA deficiency despite early treatment and control of hyperammonemia.
Gastric carbonic anhydrase IX deficiency: At base, it is all about acid.
Gene therapy for renal diseases.
Global transcriptional response to carbonic anhydrase IX deficiency in the mouse stomach.
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Heparin cofactor II, antithrombin and protein C in plasma from term and preterm infants.
Hereditary heparin cofactor II deficiency and coronary artery disease.
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds.
Herpes simplex virus as a model vector system for gene therapy in renal disease.
Human carbonic anhydrases and carbonic anhydrase deficiencies.
Intracranial calcification in children with osteopetrosis caused by carbonic anhydrase II deficiency.
Kinetic analysis of a mutant (His107-->Tyr) responsible for human carbonic anhydrase II deficiency syndrome.
Liposome-mediated gene therapy in the kidney.
Long-term follow up of carbonic anhydrase II deficiency syndrome.
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
Molecular basis of human carbonic anhydrase II deficiency.
Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima.
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome.
Natural History and Clinical Manifestations of Hyponatremia and Hyperchlorhidrosis due to Carbonic Anhydrase XII Deficiency.
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
Oligodendrocytes express a normal phenotype in carbonic anhydrase II-deficient mice.
Osteoclastic acid transport: mechanism and implications for physiological and pharmacological regulation.
Osteopetrosis, renal tubular acidosis without urinary concentration abnormality, cerebral calcification and severe mental retardation in three Turkish brothers.
Osteopetrosis: some unusual radiological features with a short review.
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Positive renal response to intravenous acetazolamide in patients with carbonic anhydrase II deficiency.
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
Purification and characterization of human salivary carbonic anhydrase.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Report of Another Mutation Proven Case of Carbonic Anhydrase II Deficiency.
Respiratory acidosis in carbonic anhydrase II-deficient mice.
Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis.
Siblings with renal tubular acidosis and nerve deafness. The first family in Japan.
Small-molecule suppression of misfolding of mutated human carbonic anhydrase II linked to marble brain disease.
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
Time course of the response to recombinant growth hormone in acidotic mice.
Transfusion of carbonic anhydrase-replete erythrocytes fails to correct the acidification defect in the syndrome of osteopetrosis, renal tubular acidosis, and cerebral calcification (carbonic anhydrase-II deficiency).
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
Unfolding a folding disease: folding, misfolding and aggregation of the marble brain syndrome-associated mutant H107Y of human carbonic anhydrase II.
Up-regulation of carbonic anhydrase isozyme IV in CNS myelin of mice genetically deficient in carbonic anhydrase II.
Variable clinical presentation of carbonic anhydrase deficiency: evidence for heterogeneity?
[Carbonic anhydrase II deficiency and Fanconi syndrome]
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
[Carbonic anhydrase II deficiency]
[Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis]
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
[Kidney tubular transport disorders. Carbonic anhydrase II deficiency]
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
[Recessive osteopetrosis. Identification of a form of medium severity]
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Carcinogenesis
A class of carbonic anhydrase IX/XII - selective carboxylate inhibitors.
An update on anticancer drug development and delivery targeting carbonic anhydrase IX.
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
Carbonic anhydrase IX: a regulator of pH and participant in carcinogenesis.
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents.
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Development of 3-(4-aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma.
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Dickkopf-1 (DKK-1) interrupts FAK/PI3K/mTOR pathway by interaction of carbonic anhydrase IX (CA9) in tumorigenesis.
Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer.
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2.
Expression of carbonic anhydrases IX and XII during mouse embryonic development.
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
G250: a carbonic anhydrase IX monoclonal antibody.
High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumorigenesis markers BMI1, MCM4 and MCM7.
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity.
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
Serendipitous fragment-based drug discovery: ketogenic diet metabolites and statins effectively inhibit several carbonic anhydrases.
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
The cellular physiology of carbonic anhydrases.
Carcinoid Tumor
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.
Hypoxia stimulates CXCR4 signalling in ileal carcinoids.
Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II.
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
Carcinoma
'Image and treat': an individualized approach to urological tumors.
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX((R))) and interferon-alpha-2a in metastatic renal cell carcinoma patients.
A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV).
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Agreement between carcinoma experiments in vivo and low-energy x-ray irradiation of the metalloprotein carbonic anhydrase.
An evaluation of cytosolic erythrocyte carbonic anhydrase and catalase in carcinoma patients: an elevation of carbonic anhydrase activity.
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma.
Association between carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma.
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Calcifying epithelioma of Malherbe with ossification. Special reference to lectin binding and immunohistochemistry of ossified sites.
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment.
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma.
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Carbonic anhydrase IX expression is associated with favorable prognostic factors in small intestinal carcinoma.
Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses.
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy.
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
CAXII Is a sero-diagnostic marker for lung cancer.
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma.
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients.
COILED COIL PEPTIDES AS UNIVERSAL LINKERS FOR THE ATTACHMENT OF RECOMBINANT PROTEINS TO POLYMER THERAPEUTICS.
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings.
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Computational discovery of plant-based inhibitors against human carbonic anhydrase IX and molecular dynamics simulation.
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Current status and future directions of molecular markers in renal cell carcinoma.
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR.
Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.
Diagnostic and prognostic molecular markers in renal cell carcinoma.
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Expression of MaTu-MN protein in human tumor cultures and in clinical specimens.
Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines.
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro.
Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.
Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer.
Glycolysis-related protein expression in thyroid cancer.
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
HIF-1? and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays.
HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3.
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p53.
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells.
Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells.
Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Immunostimulatory Activity of Dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A.
Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients.
Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan.
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Indium-111-labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma.
Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Intercalated cells as a probable source for the development of renal oncocytoma.
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Intracellular distribution of hepatic carbonic anhydrase in mice bearing Ehrlich ascites carcinoma or with spontaneous mammary carcinoma.
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Metabolic correlates of tumour hypoxia in malignant canine mammary carcinoma.
Metastatic instability of murine tumor metastases: dependence on tumor type.
Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.
Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1.
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model.
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Paxillin and Carbonic Anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas.
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha.
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
Prognostic value of CAIX expression in oral squamous cell carcinoma: a systematic review and meta-analysis.
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin.
Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII.
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Quantitative image analysis of immunohistochemical stains using a CMYK color model.
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Radionuclide and fluorescence imaging of clear cell renal cell carcinoma using dual-labeled anti-Carbonic Anhydrase IX antibody G250.
Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies.
Renal cell carcinoma: new prognostic factors?
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Serum carbonic anhydrase I and II autoantibodies in patients with chronic lymphocytic leukaemia.
Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract.
Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate.
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Subnormal level of carbonic anhydrase in blood of carcinoma patients?
Substituted (E)-2-(2-benzylidenehydrazinyl)-4-methylthiazole-5-carboxylates as dual inhibitors of 15-lipoxygenase & carbonic anhydrase II: synthesis, biochemical evaluation and docking studies.
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations.
The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct.
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma.
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
The role of carbonic anhydrase IX overexpression in kidney cancer.
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.
Transcriptional regulation of carbonic anhydrase II by retinoic acid in the human pancreatic tumor cell line DANG.
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015.
Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
[A preliminary study on the relationship between GLUT-1?MCT-4 and CA? in laryngeal squamous cell carcinoma].
[Clinical significance for detection of circulating cancer cells in renal cell carcinoma]
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
[Detection of carbonic anhydrase IX gene expression in renal cell carcinoma with reverse transcription-PCR]
[Evaluation of genotyping of human papilomavirus by a new DNA liquid chip based on Luminex XMAP]
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
[Hypoxia induces down-regulation of estrogen receptor alpha in human breast cancer.]
[Progress in the study of carbonic anhydrase inhibitors as potential anticancer drugs].
Carcinoma in Situ
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Carcinoma, Acinar Cell
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Carcinoma, Adenosquamous
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Carcinoma, Basal Cell
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Carcinoma, Ductal
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
Necrosis and hypoxia in invasive breast carcinoma.
[Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
Carcinoma, Embryonal
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Carcinoma, Hepatocellular
3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.
Analyses of polypeptides in the liver of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma by two-dimensional gel electrophoresis: identification of P29/6.8 as carbonic anhydrase III and triosephosphate isomerase.
Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway.
Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.
Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice.
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
Expression of carbonic anhydrase IX is associated with poor prognosis through regulation of the epithelial?mesenchymal transition in hepatocellular carcinoma.
Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma.
Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma.
Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro.
Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.
Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma.
Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma.
Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma.
Synthesis, biological activity and multiscale molecular modeling studies of bis-coumarins as selective carbonic anhydrase IX and XII inhibitors with effective cytotoxicity against hepatocellular carcinoma.
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1.
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Carcinoma, Intraductal, Noninfiltrating
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.
Carcinoma, Lobular
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Carcinoma, Medullary
Glycolysis-related protein expression in thyroid cancer.
Carcinoma, Non-Small-Cell Lung
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma.
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment.
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
Postoperative recurrence of epithelial ovarian cancer patients and chemoresistance related protein analyses.
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
Carcinoma, Papillary
Expression of glycolysis-related proteins in solid papillary carcinoma of the breast according to basement membrane status.
Carcinoma, Renal Cell
'Image and treat': an individualized approach to urological tumors.
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX((R))) and interferon-alpha-2a in metastatic renal cell carcinoma patients.
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
A potential for tissue restrictive gene therapy in renal cell carcinoma using MN/CA IX promoter.
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Acetazolamide-based [
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma.
Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma.
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment.
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.
Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.
Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses.
Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management.
Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy.
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses.
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Current status and future directions of molecular markers in renal cell carcinoma.
Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Diagnostic and prognostic molecular markers in renal cell carcinoma.
Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma.
Evaluation of morphologically unclassified renal cell carcinoma with electron microscopy and novel renal markers: implications for tumor reclassification.
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Fabrication of mAb G250-SPIO molecular magnetic resonance imaging nanoprobe for the specific detection of renal cell carcinoma in vitro.
Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with 111In-girentuximab.
Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
hERG1 and CA IX expression are associated with disease recurrence in surgically resected clear cell renal carcinoma.
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity Assays.
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor.
Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells.
Immunoaffinity Enrichment and Liquid Chromatography-Selected Reaction Monitoring Mass Spectrometry for Quantitation of Carbonic Anhydrase 12 in Cultured Renal Carcinoma Cells.
Immunohistochemical distinction of metastases of renal cell carcinoma to the adrenal from primary adrenal nodules, including oncocytic tumor.
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma.
Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression.
Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
Immunostimulatory Activity of Dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A.
Indium-111-labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma.
Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.
Intercalated cells as a probable source for the development of renal oncocytoma.
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Molecular imaging of urogenital diseases.
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model.
Pairwise comparison of (89)Zr- and (124)I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
Pazopanib-associated posterior reversible encephalopathy syndrome with intracerebral haemorrhage.
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Radionuclide and fluorescence imaging of clear cell renal cell carcinoma using dual-labeled anti-Carbonic Anhydrase IX antibody G250.
Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Recent advances in preoperative imaging of renal tumors.
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies.
Renal cell carcinoma: new prognostic factors?
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients.
Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate.
STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker.
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study.
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy.
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015.
Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
[Clinical significance for detection of circulating cancer cells in renal cell carcinoma]
[Detection of carbonic anhydrase IX gene expression in renal cell carcinoma with reverse transcription-PCR]
[Future perspectives for diagnostic imaging in urology: from anatomic and functional to molecular imaging.]
Carcinoma, Squamous Cell
A new PCR-based assay amplifies the E6-E7 genes of most mucosal human papillomaviruses (HPV).
A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression.
Association between carbonic anhydrase 9 expression and poor prognosis in sinonasal squamous cell carcinoma.
Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
CAXII Is a sero-diagnostic marker for lung cancer.
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review.
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma.
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Carcinoma, Transitional Cell
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract.
The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
Cardiomegaly
Discovery of arjunolic acid as a novel non-zinc binding carbonic anhydrase II inhibitor.
Cardiomyopathies
Carbonic anhydrase II/sodium-proton exchanger 1 metabolon complex in cardiomyopathy of ob-/- type 2 diabetic mice.
Cardiovascular Diseases
The hypoxia-sensor carbonic anhydrase IX affects macrophage metabolism, but is not a suitable biomarker for human cardiovascular disease.
Cataract
A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery.
Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery.
The effect of carbonic anhydrase inhibition on central corneal thickness after cataract extraction.
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes.
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Central Nervous System Infections
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Central Serous Chorioretinopathy
Efficacy of Topical Carbonic Anhydrase Inhibitors in Reducing Duration of Chronic Central Serous Chorioretinopathy.
RECURRENT CENTRAL SEROUS CHORIORETINOPATHY ASSOCIATED WITH RETINITIS PIGMENTOSA TREATED WITH CARBONIC ANHYDRASE INHIBITORS.
Cerebellar Ataxia
Neurochondrin Antibody Serum Positivity in Three Cases of Autoimmune Cerebellar Ataxia.
Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3.
Phenotypical spectrum of cerebellar ataxia associated with a novel mutation in the CA8 gene, encoding carbonic anhydrase (CA) VIII.
Cerebral Hemorrhage
Inhibition of carbonic anhydrase reduces brain injury after intracerebral hemorrhage.
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
Cerebral Infarction
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Cerebrovascular Disorders
Acetazolamide improves cerebral hemodynamics in CADASIL.
The influence of acetazolamide on cerebral low-flow regions in migraine--an interictal 99mTc-HMPAO SPECT study.
Cervical Intraepithelial Neoplasia
Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples.
Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy.
Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Chagas Disease
A Class of Sulfonamides with Strong Inhibitory Action against the ?-Carbonic Anhydrase from Trypanosoma cruzi.
A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors.
Anion inhibition studies of the ?-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an ?-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease.
Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity.
N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis.
Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi.
Cherubism
Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts.
Cheyne-Stokes Respiration
[Influencing of Cheyne-Stokes respiration through carbonic anhydrase inhibitors]
Cholangiocarcinoma
CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Cholangitis
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Autoimmune liver disease.
Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II.
Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds.
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model.
Cholangitis, Sclerosing
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Cholera
Anion inhibition profiles of ?-, ?- and ?-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.
Cholera toxin-stimulated bone resorption in cultured mouse calvarial bones not inhibited by calcitonin: a possible interaction at the stimulatory G protein.
Novel Indole-Based Hydrazones as Potent Inhibitors of the ?-class Carbonic Anhydrase from Pathogenic Bacterium Vibrio cholerae.
The effect of cholera toxin on choroid plexus carbonic anhydrase activity in vitro.
Chondroblastoma
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Chorea
Zonisamide ameliorates symptoms of secondary paroxysmal dystonia.
Choriocarcinoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Choroid Plexus Neoplasms
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Choroidal Effusions
Determinants of Corneal Endothelial Cell Loss After Trabeculectomy With Mitomycin C.
Dorzolamide-induced choroidal detachment in a surgically untreated eye.
Choroideremia
TOPICAL DORZOLAMIDE FOR TREATMENT OF CYSTOID MACULAR EDEMA IN PATIENTS WITH CHOROIDEREMIA.
Colitis
Colonic epithelial functional phenotype varies with type and phase of experimental colitis.
Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression.
Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3-CD4+CD25- T cells.
Regulatory Dendritic Cells Pulsed with Carbonic Anhydrase I Protect Mice from Colitis Induced by CD4+CD25- T Cells.
Uncoupling of Carbonic Anhydrase from Na-H exchanger-1 in Experimental Colitis: A Possible Mechanistic Link with Na-H Exchanger.
Colitis, Ulcerative
Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis.
Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis.
In vivo effects of curcumin on the paraoxonase, carbonic anhydrase, glucose-6-phosphate dehydrogenase and ?-glucosidase enzyme activities in dextran sulphate sodium-induced ulcerative colitis mice.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Colonic Neoplasms
Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis.
Carbonic anhydrase-related protein VIII promotes colon cancer cell growth.
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Differential proteomics mass spectrometry of melanosis coli.
Discovery of New Sulfonamide Carbonic Anhydrase IX Inhibitors Incorporating Nitrogenous Bases.
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
Genetic disruption of the pHi-regulating proteins Na+/H+ exchanger 1 (SLC9A1) and carbonic anhydrase 9 severely reduces growth of colon cancer cells.
Immunohistochemical localization of sodium-potassium-stimulated adenosine triphosphatase and carbonic anhydrase in human colon and colonic neoplasms.
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer.
Colorectal Neoplasms
A new approach to the validation of tissue microarrays.
A novel 111Indium-labeled dual carbonic anhydrase 9-targeted probe as a potential SPECT imaging radiotracer for detection of hypoxic colorectal cancer cells.
Binding of the Phage Display Derived Peptide CaIX-P1 on Human Colorectal Carcinoma Cells Correlates with the Expression of Carbonic Anhydrase IX.
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells.
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Carbonic anhydrase enzymes II, VII, IX and XII in colorectal carcinomas.
Carbonic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle.
Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis.
Carbonic anhydrase IX expression in prostate cancer.
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Carbonic anhydrase-related protein VIII promotes colon cancer cell growth.
Cloning and chromosome assignment of the human CDX2 gene.
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors.
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Expression and association of carbonic anhydrase IX and cyclooxygenase-2 in colorectal cancer.
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Fecal protein markers of colorectal cancer.
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation.
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.
Inhibition of cell proliferation, migration and colony formation of LS174T Cells by carbonic anhydrase inhibitor.
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer.
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.
Prognostic value of carbonic anhydrase VII expression in colorectal carcinoma.
Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by 61Cu and 64Cu and its biological testing.
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.
Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo.
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells.
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
The significance of carbonic anhydrase expression in human colorectal cancer.
[Proteome study of colorectal cancer genesis and hepatic metastasis]
Colorectal Neoplasms, Hereditary Nonpolyposis
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Cone-Rod Dystrophies
Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal photoreceptor degeneration.
Congenital Abnormalities
Carbonic anhydrase distribution in rodent embryos and its relationship to acetazolamide teratogenesis.
Congenital Hypothyroidism
Carbonic anhydrase content in the brain of rats with thiouracil induced cretinism.
Connective Tissue Diseases
Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement.
Corneal Diseases
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Corneal Dystrophies, Hereditary
Use of carbonic anhydrase inhibitor acetazoleamide (diamox) for endothelial corneal dystrophy and diseased corneal grafts.
Corneal Edema
Retinoschisis associated with Kearns-Sayre syndrome.
[The role of Brinzolamide 1% ophtalmic suspension in corneal edema]
Corneal Ulcer
Suspected Spontaneous Aqueous Humor Misdirection Syndrome in a Boston Terrier.
Coronavirus Infections
A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
Cough
Effect of acetazolamide on cough induced by low-chloride-ion solutions in normal subjects: comparison with furosemide.
COVID-19
Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?
Craniopharyngioma
Expression of carbonic anhydrase IX in craniopharyngiomas.
Cryptorchidism
Malondialdehyde and CA II autoantibody levels are elevated in children with undescended testes.
Cystadenocarcinoma, Mucinous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenocarcinoma, Serous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenoma, Mucinous
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Cystadenoma, Papillary
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Cystic Fibrosis
Altered expression of Na(+)/K(+)-ATPase and other osmoregulatory genes in the gills of euryhaline animals in response to salinity transfer: A meta-analysis of 59 quantitative PCR studies over 10years.
cAMP stimulation of HCO3- secretion across airway epithelia.
Cigarette smoke-induced differential expression of the genes involved in exocrine function of the rat pancreas.
Expression of carbonic anhydrase, cystic fibrosis transmembrane regulator (CFTR) and V-H(+)-ATPase in the lancelet Branchiostoma lanceolatum (Pallas, 1774).
Expression of ion transport-associated proteins in human efferent and epididymal ducts.
Expressional Changes of Water Transport-related Molecules in the Efferent Ductules and Initial Segment of Mouse Treated with Bisphenol A-Containing Drinking Water for Two Generations.
Immortalization of bovine pancreatic duct epithelial cells.
Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras.
Immunohistochemical analysis of the distribution of molecules involved in ionic and pH regulation in the lancelet Branchiostoma floridae (Hubbs, 1922).
Immunohistochemical and electron microscopic characterization of brush cells of the rat cecum.
Immunohistochemical localization of carbonic anhydrase I and II in eccrine sweat glands from control subjects and patients with cystic fibrosis.
Immunolocalization of ion-transport proteins to branchial epithelium mitochondria-rich cells in the mudskipper (Periophthalmodon schlosseri).
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
In vitro validation of duct differentiation in developing embryonic mouse pancreas.
In-vivo functional study on the involvement of CFTR, SLC26A6, NHE-1 and CA isoenzymes II and XII in uterine fluid pH, volume and electrolyte regulation in rats under different sex-steroid influence.
Molecular Basis and Differentiation-Associated Alterations of Anion Secretion in Human Duodenal Enteroid Monolayers.
Mouse pancreatic acinar/ductular tissue gives rise to epithelial cultures that are morphologically, biochemically, and functionally indistinguishable from interlobular duct cell cultures.
New pancreas cancers cell lines that represent distinct stages of ductal differentiation.
Physiological and molecular mechanisms of osmoregulatory plasticity in killifish after seawater transfer.
Putative interaction of brush cells with bicarbonate secreting cells in the proximal corpus mucosa.
Rapid screening of genetic polymorphisms using buccal cell DNA with detection by matrix-assisted laser desorption/ionization mass spectrometry.
Regulatory mechanism underlying cyclic changes in mouse uterine bicarbonate secretion: role of estrogen.
Tandem mass tag-based quantitative proteomic analysis of the liver reveals potential protein targets of Xiaochaihutang in CUMS model of depression.
Cysts
CA9 level in renal cyst fluid: a possible molecular diagnosis of malignant tumours.
Cytopathologic features of clear cell papillary renal cell carcinoma: A recently described variant to be considered in the differential diagnosis of clear cell renal epithelial neoplasms.
Expression of carbonic anhydrase IX in craniopharyngiomas.
Iron regulatory protein 2 in ovarian endometrial cysts.
Kidney intercalated cells and the transcription factor FOXi1 drive cystogenesis in tuberous sclerosis complex.
Macular cysts in retinal dystrophy.
Ophthalmic manifestations of Heimler syndrome due to PEX6 mutations.
Pathologic spectrum of cysts in end-stage kidneys: possible precursors to renal neoplasia.
Polycystic disease of the kidney. Evaluation and classification based on nephron segment and cell-type specific markers.
Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.
Renal carbonic anhydrase activity in DBA/2FG-pcy/pcy mice with inherited polycystic kidney disease.
Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature.
The Acetazolamide Challenge: A Tool for Surgical Decision Making and Predicting Surgical Outcome in Patients with Arachnoid Cysts.
The Prevalence of Macular Cysts in Patients with Clinical Cone-Rod Dystrophy Determined by Spectral-Domain Optical Coherence Tomography.
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Topical dorzolamide treatment of macular cysts in the enhanced S-cone syndrome patient.
USE OF A CARBONIC ANHYDRASE INHIBITOR IN X-LINKED RETINOSCHISIS: Effect on Cystic-Appearing Macular Lesions and Visual Acuity.
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease.
X-linked juvenile retinoschisis in females and response to carbonic anhydrase inhibitors: case report and review of the literature.
Dandruff
A new procedure for the cloning, expression and purification of the ?-carbonic anhydrase from the pathogenic yeast Malassezia globosa, an anti-dandruff drug target.
Anion Inhibition Profile of the ?-Carbonic Anhydrase from the Opportunist Pathogenic Fungus Malassezia Restricta Involved in Dandruff and Seborrheic Dermatitis.
Anion inhibition studies of the dandruff-producing fungus Malassezia globosa ?-carbonic anhydrase MgCA.
Carbonic anhydrase activators: Activation of the ?-carbonic anhydrase from Malassezia globosa with amines and amino acids.
Cloning, Purification, and Characterization of a ?-Carbonic Anhydrase from Malassezia restricta, an Opportunistic Pathogen Involved in Dandruff and Seborrheic Dermatitis.
Phenols from Origanum dictamnus L. and Thymus vulgaris L. and their activity against Malassezia globosa carbonic anhydrase.
Deafness
New insights into the pathogenesis of renal tubular acidosis--from functional to molecular studies.
Deficiency Diseases
Induction of carbonic anhydrase in SaOS-2 cells, exposed to bicarbonate and consequences for calcium phosphate crystal formation.
Dehydration
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
Acetazolamide inhibits the recovery from triethyl tin intoxication: putative role of carbonic anhydrase in dehydration of central myelin.
Activation of mammalian skeletal-muscle carbonic anhydrase III by arginine modification.
Active CO(2) Transport by the Green Alga Chlamydomonas reinhardtii.
Apparent diffusion limitations for CO(2) excretion in rainbow trout are relieved by injections of carbonic anhydrase.
Ascorbic Acid Induces the Increase of Secondary Metabolites, Antioxidant Activity, Growth, and Productivity of the Common Bean under Water Stress Conditions.
Bicarbonate uptake via an anion exchange protein is the main mechanism of inorganic carbon acquisition by the giant kelp Macrocystis pyrifera (Laminariales, Phaeophyceae) under variable pH
Bicarbonate uptake via an anion exchange protein is the main mechanism of inorganic carbon acquisition by the giant kelp Macrocystis pyrifera (Laminariales, Phaeophyceae) under variable pH.
Bromine catalysis for carbon dioxide hydration and dehydration and some observations concerning the mechanism of carbonic anhydrase.
Buffer enhancement of proton transfer in catalysis by human carbonic anhydrase III.
Buffering limits plasma HCO3- dehydration when red blood cell anion exchange is inhibited.
Bulky guanidinato and amidinato zinc complexes and their comparative stabilities.
Carbon isotope effect on dehydration of bicarbonate ion catalyzed by carbonic anhydrase.
Carbon-concentrating mechanism in a green alga, Chlamydomonas reinhardtii, revealed by transcriptome analyses.
Carbonic anhydrase activity in intact red blood cells measured with 18O exchange.
Carbonic anhydrase II and IV mRNA in rabbit nephron segments: stimulation during metabolic acidosis.
Carbonic anhydrase inhibitor in trout plasma.
CARBONIC ANHYDRASE INJECTION PROVIDES EVIDENCE FOR THE ROLE OF BLOOD ACID-BASE STATUS IN STIMULATING VENTILATION AFTER EXHAUSTIVE EXERCISE IN RAINBOW TROUT
Carbonic anhydrase IV is expressed in H(+)-secreting cells of rabbit kidney.
Carboxysomal carbonic anhydrases: Structure and role in microbial CO(2) fixation.
Catalysis and inhibition of human carbonic anhydrase IV.
Catalytic Mechanism of ?-Class Carbonic Anhydrases: CO2 Hydration and Proton Transfer.
Characterization of the carboxysomal carbonic anhydrase CsoSCA from Halothiobacillus neapolitanus.
Chemical rescue of proton transfer in catalysis by carbonic anhydrases in the beta- and gamma-class.
CO2 exchange characteristics during dark-light transitions in wild-type and mutant Chlamydomonas reinhardii cells.
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status and ion transporter gene expression.
Differential modification of specificity in carbonic anhydrase catalysis.
Discovery and microassay of a nitrite-dependent carbonic anhydrase activity by stable-isotope dilution gas chromatography-mass spectrometry.
Disequilibrium pH and ammonia transport in isolated perfused cortical collecting ducts.
Effect of CO2-induced seawater acidification on growth, photosynthesis and inorganic carbon acquisition of the harmful bloom-forming marine microalga, Karenia mikimotoi.
Exertional rhabdomyolysis in carbonic anhydrase 12 deficiency.
Extracellular carbonic anhydrase and an acid-base disequilibrium in the blood of the dogfish Squalus acanthias
Flow-through sol-gel optical biosensor for the colorimetric determination of acetazolamide.
Gas transfer in dogfish: a unique model of CO2 excretion.
H 2 CO 3 as substrate for carbonic anhydrase in the dehydration of HCO 3 .
Hagfish (Myxine glutinosa) red cell membrane exhibits no bicarbonate permeability as detected by (18)O exchange.
HCO3- absorption in rabbit outer medullary collecting duct: role of luminal carbonic anhydrase.
Hydrogen Sulfide-Mediated Activation of O-Acetylserine (Thiol) Lyase and l/d-Cysteine Desulfhydrase Enhance Dehydration Tolerance in Eruca sativa Mill.
Identification and characterization of a carboxysomal ?-carbonic anhydrase from the cyanobacterium Nostoc sp. PCC 7120.
Immobilized carbonic anhydrase: preparation, characteristics and biotechnological applications.
Inactivation and adsorption of human carbonic anhydrase II by nanoparticles.
Influence of carbon dioxide kinetics on pulmonary carbon dioxide exchange.
Inhibition of Carbonic Anhydrase by Anions in the Carbon Dioxide-Bicarbonate System.
Inhibitory effects of nitrite on the reactions of bovine carbonic anhydrase II with CO2 and bicarbonate consistent with zinc-bound nitrite.
Isotope and pH effects on the dehydration of acetaldehyde hydrate by carbonic anhydrase.
Kinetic and crystallographic studies of the role of tyrosine 7 in the active site of human carbonic anhydrase II.
Kinetics of carbonic anhydrase catalysis in solvents of increased viscosity: a partially diffusion-controlled reaction.
Kinetics of inhibition by acetazolamide and sulfanilamide of bicarbonate dehydration catalyzed by bovine carbonic anhydrase.
Localization of carbonic anhydrase on pulmonary artery endothelial cells in culture.
Maturation of carbonic anhydrase IV expression in rabbit kidney.
Membrane Associated Carbonic Anhydrase IV (CA IV): A Personal and Historical Perspective.
Microalgal bacterial flocs treating paper mill effluent: A sunlight-based approach for removing carbon, nitrogen, phosphorus, and calcium.
Microalgal carbon-dioxide-concentrating mechanisms: Chlamydomonas inorganic carbon transporters.
Microsensor studies on Padina from a natural CO2 seep: implications of morphology on acclimation to low pH
Microsensor studies on Padina from a natural CO2 seep: implications of morphology on acclimation to low pH.
Modification of carbonic anhydrase activity by antisense and over-expression constructs in transgenic tobacco.
Molecular basis of ionic strength effects: interaction of enzyme and sulfate ion in CO2 hydration and HCO3- dehydration reactions catalyzed by carbonic anhydrase II.
Na+-H+ exchange and pH regulation in red blood cells: role of uncatalyzed H2CO3 dehydration.
Natural protein engineering: a uniquely salt-tolerant, but not halophilic, alpha-type carbonic anhydrase from algae proliferating in low- to hyper-saline environments.
On the lack of specificity of the cobalt-bicarbonate method for carbonic anhydrase.
Origin of viscosity effects in carbonic anhydrase catalysis. Kinetic studies with bulky buffers at limiting concentrations.
Origins of enhanced proton transport in the Y7F mutant of human carbonic anhydrase II.
PGE2 stimulates gastric chloride transport: possible key to cytoprotection.
Photosynthetic carbon acquisition in Sargassum henslowianum (Fucales, Phaeophyta), with special reference to the comparison between the vegetative and reproductive tissues.
Photosynthetic use of inorganic carbon in deep-water kelps from the Strait of Gibraltar.
Physiology and molecular biology of renal carbonic anhydrase.
Plant carbonic anhydrase. Properties and bicarbonate dehydration kinetics.
Possible CO2 concentrating mechanism in chloroplasts of C3 plants. Role of carbonic anhydrase.
Postnatal development of carbonic anhydrase IV expression in rabbit kidney.
Potential role for microbial ureolysis in the rapid formation of carbonate tufa mounds.
Potential role of endothelial carbonic anhydrase in dehydration of plasma bicarbonate.
Preferred orientations of His64 in human carbonic anhydrase II.
Production and X-ray crystallographic analysis of fully deuterated human carbonic anhydrase II.
Proton transfer in a Thr200His mutant of human carbonic anhydrase II.
Pyropia yezoensis genome reveals diverse mechanisms of carbon acquisition in the intertidal environment.
Rate of CO2 diffusion in the human red blood cell measured with pH-sensitive fluorescence.
Rate-equilibria relationships in intramolecular proton transfer in human carbonic anhydrase III.
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Regulation of photosynthesis and stomatal and mesophyll conductance under water stress and recovery in olive trees: correlation with gene expression of carbonic anhydrase and aquaporins.
Relationship of urinary and blood carbon dioxide tension during hypercapnia in the rat. Its significance in the evaluation of collecting duct hydrogen ion secretion.
Role of anions and carbonic anhydrase in epithelia.
Role of C4 carbon fixation in Ulva prolifera, the macroalga responsible for the world's largest green tides.
Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II.
Structural and kinetic characterization of active-site histidine as a proton shuttle in catalysis by human carbonic anhydrase II.
Symbiosis-dependent gene expression in coral-dinoflagellate association: cloning and characterization of a P-type H+-ATPase gene.
Taste buds and nerve fibers in the rat larynx: an ultrastructural and immunohistochemical study.
The effects of exogenous extracellular carbonic anhydrase on CO2 excretion in rainbow trout (Oncorhynchus mykiss): role of plasma buffering capacity.
Thermodynamics of carbonic anhydrase catalysis. A comparison between human isoenzymes B and C.
Thylakoid lumen carbonic anhydrase (CAH3) mutation suppresses air-Dier phenotype of LCIB mutant in Chlamydomonas reinhardtii.
Type IV carbonic anhydrase is present in the gills of spiny dogfish (Squalus acanthias).
Ultrastructural localization of carbonic anhydrase in gastric parietal cells with the immunoglobulin-enzyme bridge method.
Dementia
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Demyelinating Diseases
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Atypical localization of the oligodendrocytic isoform (PI) of glutathione-S-transferase in astrocytes during cuprizone intoxication.
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Changes in glial cell markers in recent and old demyelinated lesions in central pontine myelinolysis.
Class switching of carbonic anhydrase isoforms mediates remyelination in CA3 hippocampal neurons during chronic hypoxia.
Decrease in oligodendrocyte carbonic anhydrase activity preceding myelin degeneration in cuprizone induced demyelination.
Expression of carbonic anhydrase II mRNA and protein in oligodendrocytes during toxic demyelination in the young adult mouse.
Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model.
Dent Disease
A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction.
Dental Calculus
Effect of Genetic Polymorphisms in CA6 Gene on the Expression and Catalytic Activity of Human Salivary Carbonic Anhydrase VI.
Dental Caries
Children with a Higher Activity of Carbonic Anhydrase VI in Saliva Are More Likely to Develop Dental Caries.
Cloning, characterization and anion inhibition study of a ?-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
Effects of the carbonic anhydrase VI gene polymorphisms on dental caries: A meta-analysis.
Engineered Carbonic Anhydrase VI-Mimic Enzyme Switched the Structure and Affinities of Inhibitors.
Genetic polymorphisms in the carbonic anhydrase VI gene and dental caries susceptibility.
Polymorphism in the CAVI gene, salivary properties and dental caries.
Salivary protein polymorphisms and risk of dental caries: a systematic review.
Sulfonamide inhibition study of the ?-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.
[Carbonic anhydrase activity in human saliva and dental caries]
Dental Plaque
A role of salivary carbonic anhydrase VI in dental plaque.
Association of polymorphisms in the carbonic anhydrase 6 gene with salivary buffer capacity, dental plaque pH, and caries index in children aged 7-9 years.
Dentigerous Cyst
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Dermatitis, Atopic
Importance of tryptophan nitration of carbonic anhydrase III for the morbidity of atopic dermatitis.
Increased expression of carbonic anhydrase II (CA II) in lesional skin of atopic dermatitis: regulation by Th2 cytokines.
Toll-like Receptor 3 Agonist, Polyinosinic-polycytidylic Acid, Upregulates Carbonic Anhydrase II in Human Keratinocytes.
Dermatitis, Seborrheic
Anion Inhibition Profile of the ?-Carbonic Anhydrase from the Opportunist Pathogenic Fungus Malassezia Restricta Involved in Dandruff and Seborrheic Dermatitis.
Cloning, Purification, and Characterization of a ?-Carbonic Anhydrase from Malassezia restricta, an Opportunistic Pathogen Involved in Dandruff and Seborrheic Dermatitis.
Dermatomyositis
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Diabetes Mellitus
Acetazolamide-insensitive carbonic anhydrase activities in liver and tonic skeletal muscle of adult male rats with streptozotocin-induced diabetes mellitus.
Cholinesterases, ?-glycosidase, and carbonic anhydrase inhibition properties of 1H-pyrazolo[1,2-b]phthalazine-5,10-dione derivatives: Synthetic analogues for the treatment of Alzheimer's disease and diabetes mellitus.
Decreased total carbonic anhydrase esterase activity and decreased levels of carbonic anhydrase 1 isozyme in erythrocytes of type II diabetic patients.
Determination of carbonic anhydrase-III by enzyme-immunoassay in liver, muscle and serum of male rats with streptozotocin-induced diabetes mellitus.
Erythrocyte carbonic anhydrase activity in smokers and in diabetic patients.
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Estimation and characterization of glycosylated carbonic anhydrase I in erythrocytes from patients with diabetes mellitus.
No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
The L-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus.
The Role of Carbonic Anhydrase in Hepatic Glucose Production.
[Changes in carbohydrate metabolism in diabetes mellitus under treatment with the carbonic anhydrase inhibitor 6063; preliminary report.]
Diabetes Mellitus, Experimental
Determination of carbonic anhydrase-III by enzyme-immunoassay in liver, muscle and serum of male rats with streptozotocin-induced diabetes mellitus.
Diabetes Mellitus, Type 1
High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Prevalence of autoantibodies to carbonic anhydrase II and lactoferrin in patients with type 1 diabetes.
Regional cerebral blood flow and cerebrovascular reactivity in IDDM.
The L-arginine/NO pathway, homoarginine, and nitrite-dependent renal carbonic anhydrase activity in young people with type 1 diabetes mellitus.
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
Diabetes Mellitus, Type 2
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ?50 kg/m2 Prior to Bariatric Surgery.
No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study.
Oxygen-18 isotope of breath CO2 linking to carbonic anhydrase activity: A biomarker for type 2 diabetes.
Oxygen-18 isotope of breath CO2 linking to erythrocytes carbonic anhydrase activity: a biomarker for pre-diabetes and type 2 diabetes.
Targeting erythrocyte carbonic anhydrase and (18)O-isotope of breath CO2 for sorting out type 1 and type 2 diabetes.
The Role of Carbonic Anhydrase in Hepatic Glucose Production.
Diabetic Cardiomyopathies
Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy.
Diabetic Nephropathies
Effect of carbonic anhydrase inhibitors on glomerular filtration rate in diabetic nephropathy.
Diabetic Retinopathy
Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms.
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Inhibition of Apoptosis and Reduction of Intracellular pH Decrease in Retinal Neural Cell Cultures by a Blocker of Carbonic Anhydrase.
Müller's cell involvement in proliferative diabetic retinopathy.
Optic nerve oxygenation.
Proteomics as a research tool in clinical and experimental ophthalmology.
Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results.
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
Utilization of the common functional groups in bioactive molecules: Exploring dual inhibitory potential and computational analysis of keto esters against ?-glucosidase and carbonic anhydrase-II enzymes.
Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
Diphtheria
Naturally-occurring anti-thymocyte autoantibody which identifies a restricted CD4+CD8+CD3-/lo/int thymocyte subpopulation exhibits extensive polyspecificity.
Disseminated Intravascular Coagulation
Consumption of heparin cofactor II (dermatan sulfate cofactor) and antithrombin during coagulation.
Heparin cofactor II in adults and infants with thrombosis and DIC.
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Down Syndrome
Increased levels of carbonic anhydrase II in the developing Down syndrome brain.
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
The levels of superoxide dismutase, catalase, and carbonic anhydrase in erythrocytes of patients with Down's syndrome.
Drug Resistant Epilepsy
Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.
Drug-Related Side Effects and Adverse Reactions
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Dry Eye Syndromes
A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome.
Association between Glaucoma Medication Usage and Dry Eye in Taiwan.
Clinical Correlations of Novel Autoantibodies in Patients with Dry Eye.
Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
Utility of Novel Autoantibodies in the Diagnosis of Sjögren's Syndrome Among Patients With Dry Eye.
Duodenal Ulcer
"Ulcosilvanil"--an inhibitor of carbonic anhydrase--associated with adrenergic beta-blockers in the treatment of duodenal ulcers.
Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model.
Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase.
Effects of the synthetic PGE1 derivative misoprostol on basal, stimulated and nocturnal acid secretion in duodenal ulcer cases. Mechanism of action.
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Red cell carbonic anhydrase activity in duodenal ulcer.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Treatment of duodenal ulcers with ethoxzolamide, an inhibitor of gastric mucosa carbonic anhydrase.
[Carbonic anhydrase inhibitors in the treatment of gastric and duodenal ulcers (author's transl)]
[Treatment of duodenal ulcer with carbonic anhydrase inhibitors in combination with adrenergic beta blockaders]
Duodenogastric Reflux
Effect of bile salts on carbonic anhydrase from rat and human gastric mucosa.
Dysgeusia
Acetazolamide promotes decreased consumption of carbonated drinks and weight loss.
Efficacy of exogenous oral zinc in treatment of patients with carbonic anhydrase VI deficiency.
Recovery of a patient with a recurrent dysgeusia monitored by salivary variables and serum zinc content.
Dyspnea
Activity of carbon anhydrase in the blood; study of patients with dyspnea consequent to chronic cardiac and pulmonary disease.
Eczema
Molecular Diagnostics of Psoriasis, Atopic Dermatitis, Allergic Contact Dermatitis and Irritant Contact Dermatitis.
[Activity of carbonic anhydrase in the blood and skin of patients with disseminated forms of eczema.]
Edema, Cardiac
[Diamox, a carbonic anhydrase inhibitor, in therapy of cardiac edema.]
Encephalomyelitis, Autoimmune, Experimental
Gliosis in the spinal cords of rats with experimental allergic encephalomyelitis: immunostaining of carbonic anhydrase and vimentin in reactive astrocytes.
Endemic Diseases
Sulfonamide inhibition profile of the ?-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.
Endocarditis
[Blood carbonic anhydrase and certain blood and urinary indicators in infective and rheumatic endocarditis.]
Endocarditis, Bacterial
[Clinical importance of determining the blood carbonic anhydrase activity in congenital heart defects complicated by bacterial endocarditis]
Endodermal Sinus Tumor
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Endolymphatic Hydrops
Activities of carbonic anhydrase in the cochleae of guinea pigs with early experimental endolymphatic hydrops.
Changes in immunostaining of cochleas with experimentally induced endolymphatic hydrops.
[Effect of furosemide on the carbonic anhydrase activity in vestibule]
Endometrial Neoplasms
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Correlation between Expression of Biological Markers and [F]Fluorodeoxyglucose Uptake in Endometrial Cancer.
Hypoxia contributes to development of recurrent endometrial carcinoma.
The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators.
The role of Hypoxia-inducible factor-1 ? , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients.
Endometriosis
Antibodies to carbonic anhydrase in endometriosis: prevalence, specificity, and relationship to clinical and laboratory parameters.
Autoantibody responses to carbohydrate epitopes in endometriosis.
Carbonic anhydrase antibody in sera from patients with endometriosis.
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Dapsone hydroxylamine-mediated alterations in human red blood cells from endometriotic patients.
Endometriosis: identification by carbonic anhydrase autoantibodies and clinical features.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Enteritis
Bacteria grown on natural gas prevent soybean meal-induced enteritis in Atlantic salmon.
Eosinophilia
Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy.
Ependymoma
Primary glial tumor of the retina with features of myxopapillary ependymoma.
Prognostic marker analysis in pediatric intracranial ependymomas.
Epilepsies, Partial
Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons.
Zonisamide: new drug. No advantage in refractory partial epilepsy.
Epilepsy
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
Acetazolamide in bipolar affective disorders.
Acetazolamide in the treatment of seizures.
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review.
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines.
Carbonic anhydrase enzymes: Likely targets for inhalational anesthetics.
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Carbonic anhydrase inhibitors as anticonvulsant agents.
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Determination of acetazolamide in human serum by enzymatic assay.
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Diamox; a carbonic anhydrase inhibitor; its use in epilepsy.
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Evaluating off-label uses of acetazolamide.
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Heterocyclic compounds as carbonic anhydrase inhibitor.
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds.
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Intrinsic thermodynamics of trifluoromethanesulfonamide and ethoxzolamide binding to human carbonic anhydrase VII.
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug.
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides.
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
The effects of acetazolamide on arterial pressure variability during REM sleep in the rat.
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
The structural comparison between membrane-associated human carbonic anhydrases provides insights into drug design of selective inhibitors.
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
[Carbonic anhydrase in the blood in epilepsy.]
[Effect of carbonic anhydrase inhibitors on electroencephalograms in epilepsy in children.]
Epilepsy, Reflex
Neuron-glia relationships in human and experimental epilepsy: a biochemical point of view.
[Activity of blood and brain carbonic anhydrase in white rats resistant to sound and rats predisposed to audiogenic epilepsy]
Epiretinal Membrane
Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: example with epiretinal membrane.
Erectile Dysfunction
Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma.
Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV.
Esophageal Achalasia
Triosephosphate isomerase, carbonic anhydrase, and creatinine kinase-brain isoform are possible antigen targets in patients with achalasia.
Esophageal Neoplasms
Carbonic Anhydrase IX Overexpression is Associated with Diminished Prognosis in Esophageal Cancer and Correlates with Her-2 Expression.
Catalase, carbonic anhydrase and other biochemical parameters in esophageal cancers in Turkey.
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.
Stromal expression of carbonic anhydrase IX in esophageal cancer.
Esophageal Squamous Cell Carcinoma
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Esophagitis
Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.
Cell biology of laryngeal epithelial defenses in health and disease: preliminary studies.
Essential Hypertension
Renal circulatory effects of acetazolamide in patients with essential hypertension.
[Study on mechanism for anti-hypertension efficacy of Eucommiae Cortex through assistant analysis systems for acting mechanisms of traditional Chinese medicine].
Essential Tremor
Double-blind controlled study of methazolamide in the treatment of essential tremor.
Medical treatment of essential tremor and Parkinson's disease.
New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.
The effect of acetazolamide on essential tremor: an open-label trial.
Exanthema
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
Eye Diseases
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Discovery of curcumin inspired sulfonamide derivatives as a new class of carbonic anhydrase isoforms I, II, IX, and XII inhibitors.
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Purification of carbonic anhydrase from dog erythrocytes and investigation of in vitro inhibition by various compounds.
Familial Primary Pulmonary Hypertension
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.
Fanconi Syndrome
Drug-induced acid-base disorders.
Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies.
[Carbonic anhydrase II deficiency and Fanconi syndrome]
Fatty Liver
Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Correction: Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Fibroadenoma
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Fibrocystic Breast Disease
Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology.
Salivary gland-type mammary carcinoma arising in microglandular adenosis: A case report and clinicopathological review of the literature.
Fibrosarcoma
A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes.
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines.
Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells.
Gallstones
High-activity carbonic anhydrase isoenzyme (CA II) in human gallbladder epithelium.
Ganglioneuroma
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Gastritis
Carbonic Anhydrase Inhibitors: DNA Cloning and Inhibition Studies of the alpha-Carbonic Anhydrase from Helicobacter pylori, A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs.
[Role of carbonic anhydrase in the mechanism of action of "Dilizhan" mineral water in chronic gastritis]
Gastroesophageal Reflux
Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis.
Gastrointestinal Diseases
Salivary carbonic anhydrase protects gastroesophageal mucosa from acid injury.
Gastrointestinal Stromal Tumors
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors.
Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors.
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Giant Cell Tumor of Bone
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Giant Cell Tumors
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Immunohistochemical localization of carbonic anhydrase isoenzymes I and II in human bone, cartilage and giant cell tumor.
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Glaucoma
13C saturation transfer effect of carbon dioxide-bicarbonate exchange catalyzed by carbonic anhydrase in vivo.
4-Substituted benzenesulfonamides featuring cyclic imides moieties exhibit potent and isoform-selective carbonic anhydrase II/IX inhibition.
A class of carbonic anhydrase IX/XII - selective carboxylate inhibitors.
A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
A long term study of low concentration guanethidine and adrenaline therapy in glaucoma.
A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology.
A new synthesis of difluoromethanesulfonamides--a novel pharmacophore for carbonic anhydrase inhibition.
A review of the pharmacology of carbonic anhydrase inhibitors for the treatment of glaucoma in dogs and cats.
A topical carbonic anhydrase inhibitor for glaucoma.
Acetazolamide blood concentrations are excessive in the elderly: propensity for acidosis and relationship to renal function.
Acetazolamide impairs fear memory consolidation in rodents.
Acetazolamide-like carbonic anhydrase inhibitors with topical ocular hypotensive activity.
Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.
Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
Adult cytomegalic inclusion retinitis.
Advances in Bile Acid Medicinal Chemistry.
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers.
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Antiglaucoma medications: a review of safety and tolerability issues related to their use.
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Argon laser trabecular surgery as an alternative to carbonic anhydrase therapy.
Association between Glaucoma Medication Usage and Dry Eye in Taiwan.
Asymmetric bioreduction of a ketosulfone to the corresponding trans-hydroxysulfone by the yeast Rhodotorula rubra MY 2169.
Basic pharmacology of some glaucoma drugs with emphasis on new information and new developments.
Blood dyscrasias in patients using methazolamide (neptazane) for glaucoma.
Brinzolamide loaded chitosan-pectin mucoadhesive nanocapsules for management of glaucoma: Formulation, characterization and pharmacodynamic study.
Brinzolamide--a new topical carbonic anhydrase inhibitor for glaucoma.
Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate.
Canine glaucoma: medical and surgical treatment options.
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019.
Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?
Carbonic anhydrase inhibitor acetazoleamide (diamox); a new approach to the therapy of glaucoma.
Carbonic anhydrase inhibitor side effects. Serum chemical analysis.
Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors.
Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
Carbonic Anhydrase Inhibitors in Corneal Endothelial Transport.
Carbonic anhydrase inhibitors induce elevations in human whole-blood zinc levels.
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Carbonic anhydrase inhibitors with strong topical antiglaucoma properties incorporating a 4-(2-aminopyrimidin-4-yl-amino)-benzenesulfonamide scaffold.
Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties.
Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.
Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide.
Changes in glaucoma medication numbers after cataract and glaucoma surgery: A nationwide population-based study.
Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
Comparative effects of intraocular pressure between systemic and topical carbonic anhydrase inhibitors: a clinical masked, cross-over study.
Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prostaglandin analog in the treatment of glaucoma.
Complexes with biologically active ligands. Part 11. Synthesis and carbonic anhydrase inhibitory activity of metal complexes of 4,5-disubstituted-3-mercapto-1,2,4-triazole derivatives.
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database.
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension.
Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review.
Daily cost of ophthalmic solutions for treating glaucoma in Japan.
Decreased libido--a side effect of carbonic anhydrase inhibitor.
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors.
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Determinants of Corneal Endothelial Cell Loss After Trabeculectomy With Mitomycin C.
Determination of acetazolamide in human serum by enzymatic assay.
Determination of methazolamide concentrations in human biological fluids using high performance liquid chromatography.
Development of 3-(4-aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma.
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Development of inclusion complex of brinzolamide with hydroxypropyl-?-cyclodextrin
Development of inclusion complex of brinzolamide with hydroxypropyl-?-cyclodextrin.
Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors.
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Discovery of ?-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.
Discovery of New 1,1'-Biphenyl-4-sulfonamides as Selective Subnanomolar Human Carbonic Anhydrase II Inhibitors.
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action.
Disturbance of CO2 elimination in the lungs by carbonic anhydrase inhibition.
Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.
Docking of sulfonamides to carbonic anhydrase II and IV.
Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.
Dorzolamide, A Topical Carbonic Anhydrase Inhibitor: A Two-Week Dose-Response Study in Patients with Glaucoma or Ocular Hypertension.
Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma.
Dorzolamide-Induced Relaxation of Intraocular Porcine Ciliary Arteries In Vitro Depends on Nitric Oxide and The Vascular Endothelium.
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses.
Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-4(isobutylamino)thieno(2,3-B)thiopyran-2-sulfonamide-7,7 -dioxide , a potent carbonic anhydrase inhibitor, in rats.
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Effect of dorzolamide/timolol combination on the visual field in glaucoma.
Effect of topical dorzolamide on optic nerve head blood flow.
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
Effects of acetazolamide on choroidal blood flow.
Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells.
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or ?-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
Emerging drugs for ocular hypertension.
Evaluating off-label uses of acetazolamide.
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: overexpression of CA12 (CAXII) in glaucoma.
Eye Conditions in Older Adults: Open-Angle Glaucoma.
Fabrication of Transgelosomes for Enhancing the Ocular Delivery of Acetazolamide: Statistical Optimization, In Vitro Characterization, and In Vivo Study.
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Gamma sterilization and in vivo evaluation of cationic nanostructured lipid carriers as potential ocular delivery systems for antiglaucoma drugs.
Glaucoma and the applications of carbonic anhydrase inhibitors.
Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.
Glaucoma medications, glaucoma therapy, and the evolving paradigm.
Heterocyclic compounds as carbonic anhydrase inhibitor.
High Correlation between Glaucoma Treatment with Topical Prostaglandin Analogs and BDNF Immunoreactivity in Human Retina.
Hybrid dendrimer hydrogel/poly(lactic-co-glycolic Acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management.
Hydrophilic acrylic hydrogels with built-in or pendant cyclodextrins for delivery of anti-glaucoma drugs
Hyperkalaemia induced by carbonic anhydrase inhibitor.
Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes.
Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Influence of Anti-Glaucoma Drugs on Uptake of Extracellular Vesicles by Trabecular Meshwork Cells.
Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility.
Inhibition of bovine carbonic anhydrase by new sulfonamide compounds.
Inhibition of carbonic anhydrase in the treatment of glaucoma.
Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds.
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma.
Long-term Glaucoma Treatment with MK-507, Dorzolamide, a Topical Carbonic Anhydrase Inhibitor.
Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma.
Management of glaucoma: focus on pharmacological therapy.
Medical therapy of pediatric glaucoma and glaucoma in pregnancy.
Medical treatment of normal tension glaucoma.
Medical versus surgical interventions for open angle glaucoma.
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function.
Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
MicroPulse® transscleral laser therapy in the management of glaucoma patients.
Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration.
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug.
New developments in the drug treatment of glaucoma.
New medical therapies in glaucoma management.
Newer therapeutic vistas for antiglaucoma medicines.
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
Novel Polymeric Nanoparticles Intended for Ophthalmic Administration of Acetazolamide.
Novel therapies for glaucoma: a patent review 2007 - 2011.
Ocular hypertension. II. A carbonic anhydrase inhibitor test for early detection of glaucoma.
Ocular microemulsion of brinzolamide: Formulation, physicochemical characterization, and in vitro irritation studies based on EpiOcular™ eye irritation assay.
Ocular pharmacology of methazolamide analogs: distribution in the eye and effects on pressure after topical application.
Ocular pharmacology of sulfonamides: the cornea as barrier and depot.
Ocular Surface Disease and Quality of Life in Patients With Glaucoma.
Oculohypotensive effects of various acetozolamide nanopreparations for topical treatment of animal model-induced glaucoma and their impact on optic nerve.
Oleuropein and Verbascoside - Their Inhibition Effects on Carbonic Anhydrase and Molecular Docking Studies.
Optic nerve oxygenation.
Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma.
Papillomacular retinoschisis associated with glaucoma: Response to topical carbonic anhydrase inhibitor.
Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors.
Persisent ocular hypertension following intravitreal ranibizumab.
Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
Pharmacological advances in the treatment of glaucoma.
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Pharmacological therapy for glaucoma: a review.
Poly(amidoamine) Dendrimers with Carbonic Anhydrase Inhibitory Activity and Antiglaucoma Action.
Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses
Poly-(cyclo)dextrins as ethoxzolamide carriers in ophthalmic solutions and in contact lenses.
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Preclinical overview of brinzolamide.
Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Problems With Large Joints: Knee Conditions.
Prophylactic anti-glaucoma therapy in dogs with primary glaucoma: A practitioner survey of current medical protocols.
Prostaglandin analogues in the treatment of glaucoma.
Purification of carbonic anhydrase from dog erythrocytes and investigation of in vitro inhibition by various compounds.
Quantitative structure activity relationship studies of sulfamide derivatives as carbonic anhydrase inhibitor: as antiglaucoma agents.
Quinazolinones as Competitive Inhibitors of Carbonic Anhydrase-II (Human and Bovine): Synthesis, in-vitro, in-silico, Selectivity, and Kinetics Studies.
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment.
Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat model.
Relationship of patient age and tolerance to carbonic anhydrase inhibitors.
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
Secondary glaucoma in patients with juvenile rheumatoid arthritis-associated iridocyclitis.
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy.
Structural analysis of inhibitor binding to human carbonic anhydrase II.
Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV.
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents.
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.
Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits.
Sulfamates of methyl triterpenoates are effective and competitive inhibitors of carbonic anhydrase II.
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Sulfonamides and secretion of aqueous humor.
Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
Syntesis of thio- and seleno-acetamides bearing benzenesulfonamide as potent inhibitors of human carbonic anhydrase II and XII.
Synthesis 4-[2-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulfonamides with subnanomolar carbonic anhydrase II and XII inhibitory properties.
Synthesis and biological evaluation of benzenesulphonamide-bearing 1,4,5-trisubstituted-1,2,3-triazoles possessing human carbonic anhydrase I, II, IV, and IX inhibitory activity.
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors.
Synthesis of benzamide derivatives with thiourea-substituted benzenesulfonamides as carbonic anhydrase inhibitors.
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Synthesis of novel sulfonamides under mild conditions with effective inhibitory activity against the carbonic anhydrase isoforms I and II.
Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes.
Synthesis of sulfanilamide derivatives and investigation of in vitro inhibitory activities and antimicrobial and physical properties.
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors.
Systemic carbonic anhydrase inhibitors have been used to reduce intraocular pressure in glaucoma patients unresponsive to other anti glaucomatous medical treatments.
Systemic side effects of glaucoma medications.
The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma.
The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents.
The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents.
The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications.
The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys.
The rates of movement of Na+, Cl-, and HCO-3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma.
The safety and efficacy of glaucoma medication in the pediatric population.
The study of ocular hypotensive effect of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor.
The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion.
The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases.
Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma.
Timolol activates the enzyme activities of human carbonic anhydrase I and II.
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Topical carbonic anhydrase inhibitors in the treatment of glaucoma.
Topical carbonic anhydrase inhibitors.
Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy.
Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future.
Topical drug delivery to the eye: dorzolamide.
Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits.
Topical therapies for glaucoma: what family physicians need to know.
Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
Topically active carbonic anhydrase inhibitors for glaucoma.
Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin.
Transient renal tubular acidosis in a neonate following transplacental acetazolamide.
Treatment of glaucoma among elderly patients in Sofia.
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Treatment of glaucoma in children with Sturge-Weber syndrome.
Trends in licence approvals for ophthalmic medicines in the United Kingdom.
Two flavonoid-based compounds from Murraya paniculata as novel human carbonic anhydrase isozyme II inhibitors detected by a resazurin yeast-based assay.
Ultratrace analysis of drugs in biological fluids using affinity probe capillary electrophoresis: analysis of dorzolamide with fluorescently labeled carbonic anhydrase.
Update and critical appraisal of combined timolol and carbonic anhydrase inhibitors and the effect on ocular blood flow in glaucoma patients.
Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
Update on the management of glaucoma.
Update on topical carbonic anhydrase inhibitors.
Use of a new carbonic anhydrase inhibitor (cardrase) in glaucoma.
Variable involvement of the perivascular retinal tissue in carbonic anhydrase inhibitor induced relaxation of porcine retinal arterioles in vitro.
Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.
[Changes in corneal thickness in glaucoma].
[Clinical experiences with timolol eye drops]
[Clinical tests on the use of ethoxzolamide in glaucoma therapy (author's transl)]
[Corneal descompensation in patients with endothelial compromise treated with topical dorzolamide]
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
[Diuretics; their characteristics and future development]
[Early adherence to anti-glaucoma therapy: An observational study].
[Effect of methazolamide on the intraocular pressure of patients with open-angle glaucoma (author's transl)]
[Effects of carbonic anhydrase inhibitors on pseudophakic corneal edema].
[Experiences with timolol in treatment of glaucoma (author's transl)]
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost]
[Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors]
[Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
[New carbonic anhydrase inhibitors in the treatment of glaucoma.]
[Ocular hemodynamics and visual field in glaucoma treated with dorzolamide]
[Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma]
[ON UROLITHIASIS FOLLOWING LONG-TERM ADMINISTRATION OF CARBONIC ANHYDRASE INHIBITORS IN THE THERAPY OF GLAUCOMA.]
[Pharmacology aspects of glaucoma]
[Renal lithiasis, a logical complication of long-term treatment of glaucoma with a carbonic anhydrase inhibitor]
[Sport and Glaucoma].
[The background of therapeutic use of carbonic anhydrase inhibitors in glaucoma.]
[Tolerance to fixed combinations]
[Topical carbonic anhydrase inhibitors for glaucoma]
[Topical carbonic anhydrase inhibitors in the treatment of glaucoma]
[Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide]
[Treatment of glaucoma].
[Trusopt, a local carboanhydrase inhibitor, in the treatment of glaucoma in children (preliminary report)]
[Trusopt--a new form of drug for treating glaucoma]
Glaucoma, Angle-Closure
The effect of prophylactic topical carbonic anhydrase inhibitors in canine primary closed-angle glaucoma.
Timolol therapy in secondary angle-closure glaucoma post penetrating keratoplasty.
[Clinical experiences with timolol eye drops]
Glaucoma, Open-Angle
A long term study of low concentration guanethidine and adrenaline therapy in glaucoma.
Acetazolamide Intoxication in an Elderly Patient with Diabetes and Chronic Renal Failure after Cataract Surgery.
Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide.
Argon laser trabecular surgery as an alternative to carbonic anhydrase therapy.
Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma.
Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Dilatation of Retinal Arterioles Induced by Topical Dorzolamide for One Week Is Impaired in Patients with Type 1 Diabetes and Mild Retinopathy.
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Effect of dorzolamide/timolol combination on the visual field in glaucoma.
Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma.
Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma.
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
Medical versus surgical interventions for open angle glaucoma.
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
New topical drugs for open-angle glaucoma.
Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma.
Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.
Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.
Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment.
The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
Timolol activates the enzyme activities of human carbonic anhydrase I and II.
Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma.
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
[Ocular pulse amplitude and local carbonic anhydrase inhibition]
[Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma]
Glioblastoma
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1? in human glioma stem cells.
Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells.
Function of carbonic anhydrase IX in glioblastoma multiforme.
Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1.
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma.
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo.
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.
The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.
Topiramate induces acute intracellular acidification in glioblastoma.
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Glioma
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma.
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor.
Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.
Enzymatic and morphological properties of primary rat brain astrocyte cultures, and enzyme development in vivo.
Evaluation of
Fully Automated Production and Characterization of 64 Cu and Proof-of-Principle Small-Animal PET Imaging Using 64 Cu-Labelled CA XII Targeting 6A10 Fab.
Hypoxia-related molecules HIF-1?, CA9, and osteopontin : predictors of survival in patients with high-grade glioma.
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.
Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Targeting CAIX with [64Cu]XYIMSR-06 small molecular radio-tracer enables noninvasive PET imaging of malignant glioma in U87 MG tumor cell xenograft mice.
Trace elements, heavy metals and other biochemical parameters in malignant glioma patients.
[3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.
Glomerulonephritis
Gene therapy for renal diseases.
Herpes simplex virus as a model vector system for gene therapy in renal disease.
Glycogen Storage Disease Type IIb
Cystoid macular edema in a patient with Danon disease.
Granuloma
Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.
Graves Disease
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Gyrate Atrophy
Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy.
Head and Neck Neoplasms
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models.
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Heart Defects, Congenital
Carbonic anhydrase in congenital heart disease.
[Blood carbonic anhydrase activity in young children with different forms of congenital heart defects]
[Clinical importance of determining the blood carbonic anhydrase activity in congenital heart defects complicated by bacterial endocarditis]
Heart Diseases
The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes.
Heart Failure
Acetazolamide protects against posthypoxic unstable breathing in the C57BL/6J mouse.
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Discovery of arjunolic acid as a novel non-zinc binding carbonic anhydrase II inhibitor.
Diuretic therapy in fluid-overloaded and heart failure patients.
Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors.
Effect of Acetazolamide on Chemosensitivity, Cheyne-Stokes Respiration, and Response to Effort in Patients With Heart Failure.
Oral administration of a potent carbonic anhydrase inhibitor (Diamox). II. Its use as a diuretic in patients with severe congestive heart failure.
Oral administration of a potent carbonic anhydrase inhibitor (diamox). III. Its use as a diuretic in patients with severe congestive heart failure due to cor pulmonale.
Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
The effect of intravenously administered 6063, the carbonic anhydrase inhibitor, 2-acetylamino-1, 3, 4-thiadiazole-5-sulfonamide, on fluid and electrolytes in normal subjects and patients with congestive heart failure.
The use of carbonic anhydrase inhibitor (diamox) in congestive heart failure.
The use of diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure.
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
[Effect of carbonic anhydrase inhibitor (diamox A) and of mercurial diuretics on electrolyte and water elimination in congestive heart failure.]
HELLP Syndrome
Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome.
Hemangioblastoma
Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas.
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Soft-tissue Hemangioblastoma of the Retroperitoneum: A Case Study and Review of the Literature.
Specific immunohistochemical pattern of carbonic anhydrase IX is helpful for the diagnosis of CNS hemangioblastoma.
Hemangioma
Carbonic anhydrase is abundant in fenestrated capillaries of cherry hemangioma.
Hematologic Neoplasms
The expression of carbonic anhydrase II in hematological malignancies.
Hemorrhagic Fever, Crimean
Carbonic anhydrase I-II autoantibodies and oxidative status in long-term follow-up of patients with Crimean-Congo haemorrhagic fever.
Hepatic Encephalopathy
Production of impending hepatic coma by a carbonic anhydrase inhibitor, diamox.
Hepatitis
Analyses of polypeptides in the liver of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma by two-dimensional gel electrophoresis: identification of P29/6.8 as carbonic anhydrase III and triosephosphate isomerase.
Identification of the zinc-binding protein specifically present in male rat liver as carbonic anhydrase III.
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Sexual dimorphism in LEC rat liver: suppression of carbonic anhydrase III by copper accumulation during hepatocarcinogenesis.
Hepatitis A
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
Hepatitis, Autoimmune
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Hepatolenticular Degeneration
Identification of the zinc-binding protein specifically present in male rat liver as carbonic anhydrase III.
Herpes Zoster
Carbonic anhydrase isoenzymes II and I are present in the zona glomerulosa cells of the human adrenal gland.
Carbonic anhydrases in the human adrenal gland and its disorders: Immunohistochemical and biochemical studies of the enzymes.
Histiocytoma, Malignant Fibrous
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Hodgkin Disease
Hypoxia related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin's lymphoma.
Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes.
Huntington Disease
The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
Hydrocephalus
Acetazolamide Attenuates Thrombin-Induced Hydrocephalus.
Acetazolamide treatment of progressive hydrocephalus secondary to intraventricular hemorrhage in a preterm infant.
Carbonic anhydrase inhibitors in chronic infantile hydrocephalus.
Risk Factors for Intraoperative Hypocapnia in Pediatric Neurosurgical Patients: A Retrospective Cohort Study.
Hyperaldosteronism
A novel low-activity form of carbonic anhydrase I in erythrocytes of patients with primary aldosteronism. Evidence for the presence of a mixed disulfide with glutathione.
Inactive form of carbonic anhydrase I in erythrocytes from primary aldosteronism.
Hyperalgesia
Acetazolamide, a carbonic anhydrase inhibitor, reverses inflammation-induced thermal hyperalgesia in rats.
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors.
Trigeminal antihyperalgesic effect of intranasal carbon dioxide.
Hypercalcemia
Drug-induced acid-base disorders.
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Hyperemia
New glaucoma medications in the geriatric population: efficacy and safety.
Hypergammaglobulinemia
Autoimmune chronic pancreatitis.
Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy.
Autoimmune pancreatitis, pancreatic mass, and lower gastrointestinal bleed.
Hyperglycemia
PDX1 in Ducts Is Not Required for Postnatal Formation of ?-Cells but Is Necessary for Their Subsequent Maturation.
Hyperinsulinism
Carbonic anhydrase III in obese Zucker rats.
Hyperkalemia
DSR-71167, a novel mineralocorticoid receptor antagonist with carbonic anhydrase inhibitory activity, separates urinary sodium excretion and serum potassium elevation in rats.
The treatment of hyperpotassemia: some observations on the use of a carbonic anhydrase inhibitor as a therapeutic aid.
Use of diuretics in chronic renal failure.
Hyperlactatemia
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Hyperlipidemias
Use of diuretics in chronic renal failure.
Hyperphosphatemia
The role of vitamin D in chorioallantoic membrane calcium transport.
Hypersensitivity
Evaluation of Adverse Events in Self-Reported Sulfa-Allergic Patients Using Topical Carbonic Anhydrase Inhibitors.
Octreotide: The IIH therapy beyond weight loss, carbonic anhydrase inhibitors, lumbar punctures and surgical/interventional treatments.
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
[Activity of blood carbonic anhydrase in various allergies.]
Hypertension
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
A Taste-intensity Visual Analog Scale: An Improved Zinc Taste-test Protocol.
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma.
Carbonic anhydrase I and II autoantibody levels in primary hypertension: our preliminary results.
Carbonic anhydrase, obstructive sleep apnea and hypertension: Effects of intervention.
Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension.
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition.
Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Lagenaria siceraria and it's bioactive constituents in carbonic anhydrase inhibition: A bioactivity guided LC-MS/MS approach.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
[Study on mechanism for anti-hypertension efficacy of Eucommiae Cortex through assistant analysis systems for acting mechanisms of traditional Chinese medicine].
Hypertension, Pulmonary
CA Dreamin': Carbonic Anhydrase Inhibitors, Macrophages and Pulmonary Hypertension.
Carbonic Anhydrase Inhibition Ameliorates Inflammation and Experimental Pulmonary Hypertension.
Carbonic anhydrase inhibition improves pulmonary artery reactivity and nitric oxide-mediated relaxation in sugen-hypoxia model of pulmonary hypertension.
[Mountain sickness].
Hyperthyroidism
Carbonic anhydrase isoenzyme B in erythrocytes of hyperthyroid, pregnant and oestrogen-treated subjects.
Carbonic anhydrase isozymes of red blood cells in surgically treated hyperthyroidism.
Carbonic anhydrase of the blood in hyperthyroidism.
Changes in red cell carbonic anhydrase B and serum iodothyronines in hyperthyroid subjects following 131-I treatment.
Clinical utility of red blood cell carbonic anhydrase I and zinc concentrations in patients with thyroid diseases.
Effect of thyroid hormone on the levels of erythrocyte carbonic anhydrase isozymes and 2,3-diphosphoglycerate in rabbits.
Effects of thyroid hormone on carbonic anhydrase I concentration in human erythroid burst-forming unit-derived cells.
Effects of thyroid hormone on carbonic anhydrase I gene expression in human erythroid cells.
Effects of thyroid hormone on carbonic anhydrase I levels in human erythroid (YN-1) cells.
Erythrocyte carbonic anhydrase I concentration in patients receiving thyroxine.
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Investigation of red blood cell carbonic anhydrase, glucose 6-phosphate dehydrogenase, hexokinase enzyme activities, and zinc concentration in patients with hyperthyroid diseases.
Regulation of carbonic anhydrase III by thyroid hormone: opposite modulation in slow- and fast-twitch skeletal muscle.
[Erythrocytic carbonic anhydrase in hyperthyroidism]
Hyperventilation
Acetazolamide, metabolic acidosis, and intraocular pressure.
Dorzolamide hydrochloride and visual function in normal eyes.
Drug-induced acid-base disorders.
Elevated erythrocyte carbonic anhydrase activity is a novel clinical marker in hyperventilation syndrome.
Topiramate-induced metabolic acidosis: report of two cases.
Ventilatory response to carbonic anhydrase inhibition in cats: effects of acetazolamide in intact vs peripherally chemodenervated animals.
Hyphema
Reversal of retinal and optic disc ischemia in a patient with sickle cell trait and glaucoma secondary to traumatic hyphema.
Hypocalcemia
Acidosis inhibits the hypocalcemic effect of acetazolamide.
The role of vitamin D in chorioallantoic membrane calcium transport.
Hypoglycemia
Mitochondrial carbonic anhydrase VA deficiency in three Indian infants manifesting early metabolic crisis.
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Hypohidrosis
Clear cell injury associated with reduced expression of carbonic anhydrase II in eccrine glands consistently occurs in patients with acquired idiopathic generalized anhidrosis.
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Hypokalemia
Distal renal tubular acidosis and the potassium enigma.
Diuretic complications.
Hypokalemia and suspected renal tubular acidosis associated with topical carbonic anhydrase inhibitor therapy in a cat.
Renal bicarbonate reabsorption in the rat. I. Effects of hypokalemia and carbonic anhydrase.
Hypokalemic Periodic Paralysis
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.
Channelopathies.
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Treatment of hypokalemic periodic paralysis with topiramate.
Treatment of neuromuscular channelopathies: current concepts and future prospects.
Hyponatremia
Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12.
Natural History and Clinical Manifestations of Hyponatremia and Hyperchlorhidrosis due to Carbonic Anhydrase XII Deficiency.
Hypophosphatemia, Familial
Carbonic anhydrase, cyclic AMP, and the phosphaturia of parathyroid hormone.
Hypotension
Cardiorespiratory effects induced by acetazolamide on the ventromedullary surface of the cat.
The effect of metabolic alkalosis, hypotension and inhibitors of carbonic anhydrase on fluid secretion by rat testes.
[Anaesthesia and intraocular pressure (author's transl)]
Hypothyroidism
Effects of hyper- and hypothyroidism on carbonic anhydrase, Mg2(+)-dependent ATPase and Mg2(+)-dependent, HCO3(-)-stimulated ATPase activities of rat duodenal mucosa and kidney cortex.
Quantitation of red cell carbonic anhydrase B. A diagnostic test for hyper and hypothyroidism.
[Quantity of carbonic anhydrase in hypothyroidism (author's transl)]
Infections
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Carbonic anhydrase enzymes regulate mast cell-mediated inflammation.
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Carbonic Anhydrase IX and Hypoxia Promote Rat Pulmonary Endothelial Cell Survival During Infection.
Carbonic anhydrase, acetazolamide and Helicobacter pylori infection.
CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection.
Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States).
Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status and ion transporter gene expression.
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Comparative study between the Hybrid Capture II test and PCR based assay for the detection of human papillomavirus DNA in oral submucous fibrosis and oral squamous cell carcinoma.
Cyclooxygenase-2/Carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells.
Decreased expression of GRIM-19 and its association with high-risk HPV infection in cervical squamous intraepithelial neoplasias and cancer.
Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA.
Differential expression of resistance to powdery mildew at the early stage of development in wheat line N0308.
Distinct neural stem cell tropism, early immune activation, and choroid plexus pathology following coxsackievirus infection in the neonatal central nervous system.
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study.
Evaluation of the digene hybrid capture II CT-ID test for detection of Chlamydia trachomatis in endocervical specimens.
HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Lymphocyte depletion in ileal Peyer's patch follicles in lambs infected with Eimeria ovinoidalis.
Molecular characterization of a carbon dioxide-dependent Escherichia coli small-colony variant isolated from blood cultures.
New Gene Variants Associated with the Risk of Chronic HBV Infection.
Newcastle disease virus degrades HIF-1? through proteasomal pathways independent of VHL and p53.
Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response.
Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade.
Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection.
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
The effects of bronchodilator drugs and antibiotics used for respiratory infection on human erythrocyte carbonic anhydrase I and II isozymes.
The pivotal role of carbonic anhydrase in malaria infection.
Infertility
Alternation of cytosolic carbonic anhydrase isoenzymes during deciduomatal development in pregnant mice.
Endometriosis: identification by carbonic anhydrase autoantibodies and clinical features.
Infertility, Male
Ectopic expression of mitochondrial gamma carbonic anhydrase 2 causes male sterility by anther indehiscence.
Inflammatory Bowel Diseases
Carbonic Anhydrate I Epitope Peptide Improves Inflammation in a Murine Model of Inflammatory Bowel Disease.
Elevated serum anti-carbonic anhydrase II antibodies in patients with ulcerative colitis.
Influenza, Human
QSAR models based on quantum topological molecular similarity.
Quantum topological QSAR models based on the MOLMAP approach.
Insulin Resistance
Study on the changes of carbonic anhydrase activity in insulin resistance and the effect of methylglyoxal.
Intellectual Disability
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
Carbonic anhydrase gating of attention: memory therapy and enhancement.
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Carbonic anhydrase II deficiency: report of a novel mutation.
Carbonic anhydrase II in the developing and adult human brain.
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Five- and Six-Membered Nitrogen-Containing Compounds as Selective Carbonic Anhydrase Activators.
Genetic diseases of acid-base transporters.
Indazole, Pyrazole, and Oxazole Derivatives Targeting Nitric Oxide Synthases and Carbonic Anhydrases.
Molecular basis of human carbonic anhydrase II deficiency.
Molecular basis of proximal renal tubular acidosis.
Novel homozygous variant of carbonic anhydrase 8 gene expanding the phenotype of cerebellar ataxia, mental retardation, and disequilibrium syndrome subtype 3.
Osteopetrosis, renal tubular acidosis without urinary concentration abnormality, cerebral calcification and severe mental retardation in three Turkish brothers.
Plasma carbonic anhydrase II protein is elevated in Alzheimer's disease.
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Intracranial Hypertension
Topiramate-responsive headache due to idiopathic intracranial hypertension in Behçet syndrome.
Iridocyclitis
The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases.
Iron Deficiencies
Differential expression of carbonic anhydrase isoenzymes in various types of anemia.
Keratitis
Keratitis in six dogs after topical treatment with carbonic anhydrase inhibitors for glaucoma.
Ketosis
Two cases of carbonic anhydrase VA deficiency-An ultrarare metabolic decompensation syndrome presenting with hyperammonemia, lactic acidosis, ketonuria, and good clinical outcome.
Kidney Calculi
Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet.
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Topiramate-Induced Refractory Hypokalemia.
Kidney Diseases
The excretion of carbonic anhydrase isozymes CA I and CA II in the urine of apparently healthy subjects and in patients with kidney disease.
Urinary carbonic anhydrase VI as a biomarker for kidney disease in pigs.
[Carbonic anhydrase activity of the kidneys in various kidney diseases, experimental and in humans.]
[Carbonic anhydrase inhibition in kidney diseases.]
Kidney Failure, Chronic
Anti-carbonic anhydrase II antibodies in end-stage renal disease patients.
Carbonic anhydrase B concentration of erythrocytes in chronic renal failure.
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Isotope-specific breath analysis to track the end-stage renal disease during hemodialysis.
Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis.
The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure.
[Erythrocyte carbonic anhydrase in subjects on periodic hemodialysis]
Kidney Neoplasms
Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma.
Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma.
Biomarker discovery in urogenital cancer.
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer.
Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment.
Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro.
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)?
Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo.
Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma.
In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.
Kidney cancer: Carbonic anhydrase IX in resected clear cell RCC.
Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance.
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
The role of carbonic anhydrase IX overexpression in kidney cancer.
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Laryngopharyngeal Reflux
Biomarkers and laryngopharyngeal reflux.
Expression of CAIII and Hsp70 Is Increased the Mucous Membrane of the Posterior Commissure in Laryngopharyngeal Reflux Disease.
Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin.
Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease.
Leiomyoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia.
Proteomic identification of plasma biomarkers in uterine leiomyoma.
Leiomyosarcoma
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Leishmaniasis
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Cloning, Characterization, and Inhibition Studies of a ?-Carbonic Anhydrase from Leishmania donovani chagasi , the Protozoan Parasite Responsible for Leishmaniasis.
Discovery of new organoselenium compounds as antileishmanial agents.
N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis.
Leukemia
Arsenolipids.
Carbonic anhydrase: a marker for the erythroid phenotype in acute nonlymphocytic leukemia.
Clinical and molecular features of papillary thyroid cancer in adolescents and young adults.
Erythrocyte catalase and carbonic anhydrase activities in acute leukemias.
Implication of sulfonylurea derivatives as prospective inhibitors of human carbonic anhydrase II.
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture.
Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and ?-glycosidase inhibitors.
Synthesis of novel bis-sulfone derivatives and their inhibition properties on some metabolic enzymes including carbonic anhydrase, acetylcholinesterase, and butyrylcholinesterase.
Leukemia, Erythroblastic, Acute
A case of juvenile erythroleukemia with uncoordinated expression of fetal red cell markers.
Carbonic anhydrase is aberrantly and constitutively expressed in both human and murine erythroleukemia cells.
Erythroid cell differentiation.
Increased carbonic anhydrase activity in Friend erythroleukemia cells during DMSO-stimulated erythroid differentiation and its inhibition by BrdU.
Induction of carbonic anhydrase I isozyme precedes the globin synthesis during erythropoiesis in K562 cells.
The carbonic anhydrase I locus contains a c-Myb target promoter and modulates differentiation of murine erythroleukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Erythroid cell differentiation.
[Myelomonocytic leukemia with Philadelphia-positive and Philadelphia-negative cell lines in early childhood (author's transl)]
Leukemia, Myeloid, Acute
Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.
Carbonic anhydrase: a marker for the erythroid phenotype in acute nonlymphocytic leukemia.
Leukemia, Myelomonocytic, Juvenile
[Juvenile chronic myelogenous leukemia in a seven-year-old boy with normal red cell carbonic anhydrase activity--a case report (author's transl)]
Leukemia, Promyelocytic, Acute
Arsenolipids.
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Leukodystrophy, Globoid Cell
Carbonic anhydrase and 2',3' cyclic nucleotide 3'-phosphohydrolase activity in normal human brain and in demyelinating diseases.
Leukoencephalopathies
Identification of membrane-bound carbonic anhydrase in white matter coated vesicles: the fate of carbonic anhydrase and other white matter coated vesicle proteins in triethyl tin-induced leukoencephalopathy.
Leukopenia
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Heparin cofactor II as a predictor of thrombotic microangiopathy after bone marrow transplantation.
Leukoplakia
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
The use of CA-IX as a diagnostic method for oral leukoplakia.
Leukoplakia, Oral
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
The use of CA-IX as a diagnostic method for oral leukoplakia.
Leydig Cell Tumor
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Lichen Planus, Oral
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Liver Cirrhosis
Heparin cofactor II: a simple assay method and results of its clinical application.
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Liver Cirrhosis, Alcoholic
Plasma heparin cofactor II in alcoholic liver disease.
Liver Cirrhosis, Biliary
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?
Autoimmune liver disease.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis.
Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds.
Relation between zinc status and hepatic functional reserve in patients with liver disease.
The ability of anti-carbonic anhydrase II antibody to distinguish autoimmune cholangitis from primary biliary cirrhosis in Japanese patients.
Liver Diseases
Antibodies to carbonic anhydrase in patients with immune cholangiopathies.
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions.
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Relation between zinc status and hepatic functional reserve in patients with liver disease.
Serum antibody to carbonic anhydrase II in patients with chronic viral hepatitis: a review of its prevalence in liver diseases.
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Liver Diseases, Alcoholic
Expression of testosterone-dependent enzyme, carbonic anhydrase III, and oxidative stress in experimental alcoholic liver disease.
Relation between zinc status and hepatic functional reserve in patients with liver disease.
Liver Failure
Plasma heparin cofactor II in alcoholic liver disease.
Liver Neoplasms
Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway.
Expression of liver cancer associated gene HCCA3.
Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.
Low Tension Glaucoma
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
Lung Diseases
Activity of carbon anhydrase in the blood; study of patients with dyspnea consequent to chronic cardiac and pulmonary disease.
Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with pulmonary diseases.
DICHLORPHENAMIDE, A POTENT CARBONIC ANHYDRASE INHIBITOR. EFFECT ON ALVEOLAR VENTILATION, VENTILATION-PERFUSION RELATIONSHIPS AND DIFFUSION IN PATIENTS WITH CHRONIC LUNG DISEASE.
Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?
[Determination of carbonic anhydrase in the blood in chronic pulmonary diseases.]
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Lung Diseases, Obstructive
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Lung Injury
Carbonic anhydrase inhibitor attenuates ischemia-reperfusion induced acute lung injury.
Lung Neoplasms
A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis.
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients.
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer.
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma.
CAXII Is a sero-diagnostic marker for lung cancer.
Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions.
Diverging prognostic impacts of hypoxic markers according to NSCLC histology.
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Erythrocyte catalase and carbonic anhydrase activities in lung cancer.
Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer.
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression.
Inhibition of carbonic anhydrase II by sulfonamide derivatives.
Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.
Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I-II Non-Small-Cell Lung Cancer.
Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment.
Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma.
Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy.
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer.
[Value of Detection of CAIX in the Pleural Effusion and Its Sediment in the Diagnosis of Lung Cancer].
Lupus Erythematosus, Systemic
A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren's syndrome.
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases.
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure.
Lymphadenitis
Immunohistochemical observations on carbonic anhydrase I and II in human salivary glands and submandibular obstructive adenitis.
Lymphatic Metastasis
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Lymphocytic Choriomeningitis
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Lymphocytic choriomeningitis virus mx strain does not induce the expression of tumor-associated carbonic anhydrase IX in persistently infected HeLa cells.
Lymphoma
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Lymphoma, B-Cell
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Carbonic Anhydrase Inhibitor Acetazolamide Enhances CHOP Treatment Response and Stimulates Effector T-Cell Infiltration in A20/BalbC Murine B-Cell Lymphoma.
Cytokeratin and protein expression patterns in squamous cell carcinoma of the oral cavity provide evidence for two distinct pathogenetic pathways.
Lymphoma, Non-Hodgkin
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
Sjögren's syndrome--study of autoantigens and autoantibodies.
Lymphoma, T-Cell
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Machado-Joseph Disease
Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Macular Degeneration
Oral acetazolamide as a medical adjuvant to retinal surgery in optic disc pit maculopathy in a pediatric patient.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Macular Edema
Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema.
Carbonic anhydrase inhibitor with topical NSAID therapy to manage cystoid macular edema in a case of gyrate atrophy.
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, Muller cells, and astrocytes.
Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.
Efficacy of topical brinzolamide in children with retinal dystrophies.
Graft failure: III. Glaucoma escalation after penetrating keratoplasty.
Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: example with epiretinal membrane.
Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume.
Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study.
Macular cysts in retinal dystrophy.
Membrane-bound carbonic anhydrase in human retinal pigment epithelium.
Regression of macular edema with topical brinzolamide and nepafenac alone and identification of a novel gyrate atrophy mutation.
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Simplex Crumbs Homologue 1 Maculopathy Masquerading as Juvenile X-Linked Retinoschisis in Male Patients.
Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema.
STRUCTURAL AND FUNCTIONAL MONITORING OF EXTRAMACULAR CYSTOID SPACES IN A CASE OF X-LINKED RETINOSCHISIS TREATED WITH ACETAZOLAMIDE.
The Relationship between Serum Carbonic Anhydrase I-II Autoantibody Levels and Diabetic Retinopathy in Type 1 Diabetes Patients.
The role of carbonic anhydrase inhibitors in the management of macular edema.
Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.
Topical carbonic anhydrase inhibitors in macular edema associated with Alström syndrome.
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY.
Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal.
TOPICAL DORZOLAMIDE FOR TREATMENT OF CYSTOID MACULAR EDEMA IN PATIENTS WITH CHOROIDEREMIA.
Topical steroidal and nonsteroidal antiinflammatory drugs for the treatment of cystoid macular edema in retinitis pigmentosa.
Treatment of chronic macular edema with acetazolamide.
Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy.
Vitreoretinal toxicity of acetazolamide following intravitreal administration in the rabbit eye.
[Efficacy of dorzolamide in reducing retinal thickness after photocoagulation in diabetic macular oedema].
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Malaria
Anion inhibition studies of a beta carbonic anhydrase from the malaria mosquito Anopheles gambiae.
Are Carbonic Anhydrases Suitable Targets to Fight Protozoan Parasitic Diseases?
Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides-in vitro and in vivo studies.
Carbonic anhydrases and anion transport in mosquito midgut pH regulation.
Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the ?-carbonic anhydrases.
Inhibition survey with phenolic compounds against the ?- and ?-class carbonic anhydrases from the marine diatom thalassiosira weissflogii and protozoan Plasmodium falciparum.
Malaria parasite carbonic anhydrase: inhibition of aromatic/heterocyclic sulfonamides and its therapeutic potential.
Mild Plasmodium falciparum Malaria following an Episode of Severe Malaria Is Associated with Induction of the Interferon Pathway in Malawian Children.
Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.
Quantitative Proteomics Analysis of Plasmodium vivax Induced Alterations in Human Serum during the Acute and Convalescent Phases of Infection.
Sulfonamide inhibition studies of the ?-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.
The ?-carbonic anhydrase from the malaria mosquito Anopheles gambiae is highly inhibited by sulfonamides.
The alpha-carbonic anhydrase from the malaria parasite and its inhibition.
The first activation studies of the ?-carbonic anhydrase from the malaria parasite Plasmodium falciparum with amines and amino acids.
The pivotal role of carbonic anhydrase in malaria infection.
Malaria, Cerebral
Mild Plasmodium falciparum Malaria following an Episode of Severe Malaria Is Associated with Induction of the Interferon Pathway in Malawian Children.
Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.
Malnutrition
Effects of abnormal thyroid state and undernutrition on carbonic anhydrase and oligodendroglia development in the rat cerebellum.
Heparin cofactor II deficiency in the elderly: comparison with antithrombin III.
[Studies on acid-balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. 3. Variation of carbonic anhydrase content in blood]
[Studies on the acid-balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. II. Effect of various endocrine organ preparations on CO2 and O2 content in blood]
[Studies on the acid-base balance and the concentration of carbonic dioxide, oxygen and carbonic anhydrase in the blood of patients with malnutrition. I. Observation on the acid-base balance in the blood]
Mammary Analogue Secretory Carcinoma
Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland.
Mastocytosis
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Measles
Microwave antigen retrieval for immunocytochemistry on formalin-fixed, paraffin-embedded post-mortem CNS tissue.
Medulloblastoma
The choroid plexus carcinomas of childhood: histopathology, immunocytochemistry and clinicopathological correlations.
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Meibomian Gland Dysfunction
The Carbonic Anhydrase Inhibitor Dorzolamide Stimulates the Differentiation of Human Meibomian Gland Epithelial Cells.
Melanoma
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma.
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carbonic Anhydrase-Related Protein VIII antibodies and paraneoplastic cerebellar degeneration.
Cell division cycle-associated protein 1 as a new melanoma-associated antigen.
Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8+ T-cell Responses.
Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII.
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Melanoma tumors exhibit a variable but distinct metabolic signature.
Plasma Proteomics of Renal Function: A Trans-ethnic Meta-analysis and Mendelian Randomization Study.
Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.
The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells.
The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells.
Umbelliferone decreases intracellular pH and sensitizes melanoma cell line A375 to dacarbazin. Comparison with acetazolamide.
Melioidosis
Anion inhibition profiles of the ?-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei responsible of melioidosis and highly drug resistant to common antibiotics.
Comparison of the amine/amino acid activation profiles of the ?- and ?-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei.
Comparison of the anion inhibition profiles of the ?- and ?-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei.
Comparison of the Sulfonamide Inhibition Profiles of the ?- and ?-Carbonic Anhydrases from the Pathogenic Bacterium Burkholderia pseudomallei.
Sulfonamide inhibition profile of the ?-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.
Meningioma
Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.
Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
Distinct Expression Patterns of Carbonic Anhydrase IX in Clear Cell, Microcystic, and Angiomatous Meningiomas.
Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
Meningomyelocele
Relationship of antioxidant enzyme activities with myelomeningocele.
MERRF Syndrome
Promoter analysis and transcriptional regulation of human carbonic anhydrase VIII gene in a MERRF disease cell model.
Mesothelioma
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma.
Mesothelioma, Malignant
Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia.
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Role of carbonic anhydrases in ferroptosis-resistance.
Metabolic Diseases
Erythrocyte carbonic anhydrase: a major intracellular enzyme to regulate cellular sodium metabolism in chronic renal failure patients with diabetes and hypertension.
Metabolic Syndrome
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
Microphthalmos
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Migraine Disorders
Efficacy of zonisamide in migraineurs with nonresponse to topiramate.
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Monoclonal Gammopathy of Undetermined Significance
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Mouth Neoplasms
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis.
Mucopolysaccharidosis III
Characterization of a Case of Pigmentary Retinopathy in Sanfilippo Syndrome Type IIIA Associated with Compound Heterozygous Mutations in the SGSH Gene.
Multiple Endocrine Neoplasia
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Endocrine Neoplasia Type 1
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Multiple Myeloma
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Multiple Sclerosis
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Muscle Weakness
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Treatment of hypokalemic periodic paralysis with topiramate.
Muscular Atrophy
Effect of immobilization on carbonic anhydrase III and myoglobin content in human leg muscle.
[Carbonic anhydrase III and mRNA expression levels in quadriceps femoris muscle of chronic obstructive pulmonary disease patients].
Muscular Atrophy, Spinal
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Muscular Diseases
Carbonic anhydrase III in neuromuscular disorders.
Carbonic Anhydrase III Is Expressed in Mouse Skeletal Muscles Independent of Fiber Type-Specific Myofilament Protein Isoforms and Plays a Role in Fatigue Resistance.
Detection of the phosphatase activity of carbonic anhydrase III on a nitrocellulose membrane following 2D gel electrophoresis.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Plasma biomarker identification in S-adenosylhomocysteine hydrolase deficiency.
Muscular Disorders, Atrophic
Effect of immobilization on carbonic anhydrase III and myoglobin content in human leg muscle.
Role of carbonic anhydrase in bone: partial inhibition of disuse atrophy of bone by parenteral acetazolamide.
Muscular Dystrophies
Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Distribution of immunoreactive carbonic anhydrase III in various human tissues determined by a sensitive enzyme immunoassay method.
Early postnatal muscle contractile activity regulates the carbonic anhydrase phenotype of proprioceptive neurons in young and mature mice: evidence for a critical period in development.
Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Serum carbonic anhydrase III in progressive muscular dystrophy.
[Serum carbonic anhydrase III in patients with muscular dystrophy]
Muscular Dystrophy, Duchenne
Carbonic anhydrase III in Duchenne muscular dystrophy.
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Evaluation of carrier detection of Duchenne muscular dystrophy using carbonic anhydrase III and creatine kinase.
Fetal plasma carbonic anhydrase III in prenatal diagnosis of Duchenne muscular dystrophy.
Radioimmunoassay of human muscle carbonic anhydrase III in dystrophic states.
Serum carbonic anhydrase III in progressive muscular dystrophy.
Myalgia
Warm underwater water-jet massage improves recovery from intense physical exercise.
Myasthenia Gravis
Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients.
Detection of the phosphatase activity of carbonic anhydrase III on a nitrocellulose membrane following 2D gel electrophoresis.
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis.
Mycoses
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Mycosis Fungoides
Catalase, carbonic anhydrase and xanthine oxidase activities in patients with mycosis fungoides.
Mydriasis
Pseudophakic pupillary-block glaucoma.
Myocardial Infarction
Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats.
Carbonic anhydrase IX and hypoxia-inducible factor 1 attenuate cardiac dysfunction after myocardial infarction.
Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients.
Distribution of immunoreactive carbonic anhydrase III in various human tissues determined by a sensitive enzyme immunoassay method.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Improved specificity of myoglobin plus carbonic anhydrase assay versus that of creatine kinase-MB for early diagnosis of acute myocardial infarction.
Myoglobin/carbonic anhydrase III ratio: highly specific and sensitive early indicator for myocardial damage in acute myocardial infarction.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction.
Serum myoglobin/carbonic anhydrase III ratio as a marker of reperfusion after myocardial infarction.
Serum myoglobin/carbonic anhydrase III ratio in the diagnosis of perioperative myocardial infarction during coronary bypass surgery.
Myopia
Hypotony following trabeculectomy.
Inhibition of carbonic anhydrase in the lens does not induce myopia in cynomolgus monkeys.
Late Acute Myopia Syndrome Induced by Combination of Sulfonamide Drugs.
Transient myopia during treatment with carbonic anhydrase inhibitors.
Myositis
Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis.
Myotonia
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Myotonic Dystrophy
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Serum carbonic anhydrase III in myotonic dystrophy.
Nasal Polyps
Down-regulation of carbonic anhydrase isoenzymes in nasal polyps.
Effects of pepsin A on heat shock protein 70 response in laryngopharyngeal reflux patients with chronic rhinosinusitis.
[HIF-1alpha and CA IX expression in nasal polyps and study on their correlation].
Nasopharyngeal Carcinoma
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Expression of HIF-1? and CAIX in nasopharyngeal carcinoma and their correlation with patients' prognosis.
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.
SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma.
Neoplasm Metastasis
6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX.
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion.
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Carbonic Anhydrase IX as an Imaging and Therapeutic Target for Tumors and Metastases.
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Carving out its niche: A role for carbonic anhydrase IX in pre-metastatic niche development.
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation.
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Design of a Carbonic Anhydrase IX Active-Site Mimic To Screen Inhibitors for Possible Anticancer Properties (dagger) (double dagger).
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX.
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Expression of carbonic anhydrase IX in human pancreatic cancer.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
Expression of liver cancer associated gene HCCA3.
Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.
Gastric Adenocarcinoma Biomarker Expression Profiles and their Prognostic Value.
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer.
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.
Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody.
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.
Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Inhibition of V-ATPases and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes.
Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds.
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis.
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Metastatic instability of murine tumor metastases: dependence on tumor type.
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Organic Photodynamic Nanoinhibitor for Synergistic Cancer Therapy.
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
Predicting Isoform-Selective Carbonic Anhydrase Inhibitors via Machine Learning and Rationalizing Structural Features Important for Selectivity.
Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry.
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Reproducibility and biological basis of in vivo T(2) * magnetic resonance imaging of liver metastasis of colorectal cancer.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX.
Structural comparison of protiated, H/D-exchanged and deuterated human carbonic anhydrase IX.
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors.
Targeting CAIX with [64Cu]XYIMSR-06 small molecular radio-tracer enables noninvasive PET imaging of malignant glioma in U87 MG tumor cell xenograft mice.
Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs.
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Targeting Hypoxic Tumors with Hybrid Nanobullets for Oxygen-Independent Synergistic Photothermal and Thermodynamic Therapy.
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
TFAP2C regulates carbonic anhydrase XII in human breast cancer.
TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
The Expression of Carbonic Anhydrase (CA) IX/ XII and Lymph Node Metastasis in Early Breast Cancer.
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis.
TSGA10 Over Expression Decreases Metastasic and Metabolic Activity by Inhibiting HIF-1 in Breast Cancer Cells.
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis.
Using neutron crystallography to elucidate the basis of selective inhibition of carbonic anhydrase by saccharin and a derivative.
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
[Proteome study of colorectal cancer genesis and hepatic metastasis]
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
Neoplasm Micrometastasis
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Neoplasm, Residual
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Neoplasms
"Paradoxical" findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab.
"Seriously Sweet": Acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms.
1-Naphthol basic dye (1-NBD). An alternative to diaminobenzidine (DAB) in immunoperoxidase techniques.
18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers.
18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation.
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
3,17?-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity.
4-Functionalized 1,3-diarylpyrazoles bearing 6-aminosulfonylbenzothiazole moiety as potent inhibitors of carbonic anhydrase isoforms hCA I, II, IX and XII.
4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII.
4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.
4-Hydroxy-7-oxo-5-heptenoic acid lactone is a potent inducer of brain cancer cell invasiveness that may contribute to the failure of anti-angiogenic therapies.
5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations.
6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.
7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors.
A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
A carbonic anhydrase inhibitor as a potential modulator of cancer therapies.
A combined theoretical and spectroscopic study of 4,6-di-O-acetyl-2,3-dideoxy-D-erythro-hex-2-enopyranosyl sulfamide: a novel glycosyl carbonic anhydrase IX inhibitor.
A comparative study of the binding modes of SLC-0111 and its analogues in the hCA II and hCA IX active sites using QM/MM, molecular docking, MM-GBSA and MD approaches.
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
A Multifunctional Graphene Oxide Platform for Targeting Cancer.
A multivariate approach for the determination of isoelectric point of human carbonic anhydrase isoforms by capillary isoelectric focusing.
A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.
A Nonsense Mitochondrial DNA Mutation Associates with Dysfunction of HIF1? in a Von Hippel-Lindau Renal Oncocytoma.
A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".
A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.
A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity.
A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis
A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis.
A pair of long intergenic non-coding RNA LINC00887 variants act antagonistically to control Carbonic Anhydrase IX transcription upon hypoxia in tongue squamous carcinoma progression.
A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
A prodrug approach toward cancer-related carbonic anhydrase inhibition.
A Rare Case of Renal Cell Carcinoma With Leiomyomatous Stroma and Concomitant Ruptured Adrenal Aneurysm.
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
A Review on Anti-Tumor Mechanisms of Coumarins.
A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors.
A study of pancreatic secretory and intracellular enzymes in pancreatic cancer tissue, other gastrointestinal cancers, normal pancreas and serum.
A sucrose-binding site provides a lead towards an isoform-specific inhibitor of the cancer-associated enzyme carbonic anhydrase IX.
A surface proton antenna in carbonic anhydrase II supports lactate transport in cancer cells.
A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors.
A Versatile Carbonic Anhydrase IX Targeting Ligand-Functionalized Porous Silicon Nanoplatform for Dual Hypoxia Cancer Therapy and Imaging.
Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma.
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Acetazolamide-based [
Acetazolamide-Loaded pH-Responsive Nanoparticles Alleviating Tumor Acidosis to Enhance Chemotherapy Effects.
Acinar-ductal-carcinoma sequence in transforming growth factor-alpha transgenic mice.
Activation of carbonic anhydrase IX by alternatively spliced tissue factor under late-stage tumor conditions.
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Adenoviral targeting of gene expression to tumors.
Adiponectin Attenuates the Inflammation in Atopic Dermatitis-Like Reconstructed Human Epidermis.
Adult-onset renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: 3 case reports and review of literature.
Affinity Selections of DNA-Encoded Chemical Libraries on Carbonic Anhydrase IX-Expressing Tumor Cells Reveal a Dependence on Ligand Valence.
Agents described in the Molecular Imaging and Contrast Agent Database for imaging carbonic anhydrase IX expression.
Albumin/sulfonamide stabilized iron porphyrin metal organic framework nanocomposites: targeting tumor hypoxia by carbonic anhydrase IX inhibition and T1-T2 dual mode MRI guided photodynamic/photothermal therapy.
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype.
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.
Amine coupling versus biotin capture for the assessment of sulfonamide as ligands of hCA isoforms.
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
An evaluation of cytosolic erythrocyte carbonic anhydrase and catalase in carcinoma patients: an elevation of carbonic anhydrase activity.
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
An Immunohistochemical Study of the Expression of the Hypoxia Markers Glut-1 and Ca-IX in Canine Sarcomas.
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
An Intrarenal Adrenocortical Carcinoma Arising in an Adrenal Rest.
An update on anticancer drug development and delivery targeting carbonic anhydrase IX.
Analysis of evolution of carbonic anhydrases IV and XV reveals a rich history of gene duplications and a new group of isozymes.
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Analysis of Modification of Liver Proteome in Diabetic Rats by 2D Electrophoresis and MALDI-TOF-MS.
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies.
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response.
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Antibody-specific detection of CAIX in breast and prostate cancers.
Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013).
Anticancer Effect of Biodegradable Magnesium on Hepatobiliary Carcinoma: An In Vitro and In Vivo Study.
Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems.
Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII.
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy.
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Arsenolipids.
Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
Assessment of the antiproliferative and apoptotic roles of sulfonamide carbonic anhydrase IX inhibitors in HeLa cancer cell line.
Assessment of tumor hypoxia for prediction of response to therapy and cancer prognosis.
Assessment of tumor response to radiation and vascular targeting therapy in mice using quantitative ultrasound spectroscopy.
Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.
Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy.
Autoimmune phenomena and spontaneous tumour regression. The role of carbonic anhydrase I.
Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy.
Benzenesulfonamide bearing 1,2,4-triazole scaffolds as potent inhibitors of tumor associated carbonic anhydrase isoforms hCA IX and hCA XII.
Benzenesulfonamide bearing imidazothiadiazole and thiazolotriazole scaffolds as potent tumor associated human carbonic anhydrase IX and XII inhibitors.
Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors.
Benzoxepinones: A new isoform-selective class of tumor associated carbonic anhydrase inhibitors.
Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells.
Bile Acid Conjugated DNA Chimera that Conditionally Inhibits Carbonic Anhydrase-II in the Presence of MicroRNA-21.
Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.
Biochemical, biophysical and molecular dynamics studies on the proteoglycan-like domain of carbonic anhydrase IX.
Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
Biologic instability of pancreatic cancer xenografts in the nude mouse.
Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors.
Biomarkers in clear cell renal cell carcinoma.
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Biophysical Characterization of Cancer-Related Carbonic Anhydrase IX.
Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers.
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.
CA II, a potential biomarker by proteomic analysis, exerts significant inhibitory effect on the growth of colorectal cancer cells.
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
CA IX stratification based on cancer treatment: a patent evaluation of US2016/0002350.
CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.
Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography.
CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors.
CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells.
CAIX-Mediated Control of LIN28/let-7 Axis Contributes to Metabolic Adaptation of Breast Cancer Cells to Hypoxia.
CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma.
Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.
Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues.
Carbamoylphosphonates Control Tumor Cell Proliferation and Dissemination by Simultaneously Inhibiting Carbonic Anhydrase IX and Matrix Metalloproteinase-2. Toward Nontoxic Chemotherapy Targeting Tumor Microenvironment (1).
Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment.
Carbonic anhydrase 2 inhibits epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas.
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
Carbonic Anhydrase Activity Monitored In Vivo by Hyperpolarized 13C-Magnetic Resonance Spectroscopy Demonstrates Its Importance for pH Regulation in Tumors.
Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series.
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Carbonic anhydrase III is a new target of HIF1? in prostate cancer model.
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors.
Carbonic anhydrase inhibition as a cancer therapy: a review of patent literature, 2007 - 2009.
Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II.
Carbonic anhydrase inhibitors and the management of cancer.
Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors.
Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment.
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.
Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides.
Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors.
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates.
Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides.
Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors.
Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.
Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).
Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors.
Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
Carbonic anhydrase inhibitors: design of membrane-impermeant copper(II) complexes of DTPA-, DOTA-, and TETA-tailed sulfonamides targeting the tumor-associated transmembrane isoform IX.
Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.
Carbonic Anhydrase Inhibitors: DNA Cloning and Inhibition Studies of the alpha-Carbonic Anhydrase from Helicobacter pylori, A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs.
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides.
Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates.
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties.
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds.
Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX.
Carbonic anhydrase inhibitors: Transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters.
Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX.
Carbonic anhydrase inhibitors; fluorinated phenyl sulfamates show strong inhibitory activity and selectivity for the inhibition of the tumor-associated isozymes IX and XII over the cytosolic ones I and II.
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Carbonic anhydrase isozymes IX and XII in gastric tumors.
Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment.
Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes.
Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion.
Carbonic Anhydrase IX (CAIX) as a Mediator of Hypoxia-Induced Stress Response in Cancer Cells.
Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness.
Carbonic anhydrase IX and acid transport in cancer.
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials.
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Carbonic anhydrase IX as a novel candidate in liquid biopsy.
Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs.
Carbonic anhydrase IX as a target for metastatic disease.
Carbonic Anhydrase IX as an Anticancer therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain.
Carbonic Anhydrase IX as an Imaging and Therapeutic Target for Tumors and Metastases.
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma.
Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer.
Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix.
Carbonic anhydrase IX expression correlates with FDG uptake by primary non-small cell lung cancer.
Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.
Carbonic anhydrase IX expression in prostate cancer.
Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade.
Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma.
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas.
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant.
Carbonic anhydrase IX in early-stage non-small cell lung cancer.
Carbonic anhydrase IX in malignant pleural mesotheliomas: A potential target for anti-cancer therapy.
Carbonic anhydrase IX in oligodendroglial brain tumors.
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition.
Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.
Carbonic anhydrase IX inhibitors in cancer therapy: an update.
Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain.
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma.
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo.
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking.
Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer.
Carbonic Anhydrase IX is Not a Predictor of Outcomes in Non-Metastatic Clear Cell Renal Cell Carcinoma - A Digital Analysis of Tissue Microarray.
Carbonic Anhydrase IX Overexpression is Associated with Diminished Prognosis in Esophageal Cancer and Correlates with Her-2 Expression.
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.
Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin.
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts.
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro.
Carbonic Anhydrase IX-Mouse versus Human.
Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence Imaging of Hypoxic Tumors.
Carbonic anhydrase IX: A hypoxia-controlled "catalyst" of cell migration.
Carbonic anhydrase IX: a new druggable target for the design of antitumor agents.
Carbonic anhydrase IX: A promising diagnostic and prognostic biomarker in breast carcinoma.
Carbonic anhydrase IX: a regulator of pH and participant in carcinogenesis.
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target.
Carbonic Anhydrase IX: Regulation and Role in Cancer.
Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction.
Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
Carbonic Anhydrase Related Protein VIII and its Role in Neurodegeneration and Cancer.
Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix.
Carbonic Anhydrase XII as an Independent Prognostic Factor in Advanced Esophageal Squamous Cell Carcinoma.
Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome.
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Carbonic anhydrase XII functions in health and disease.
Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma.
Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells.
Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway.
Carbonic Anhydrases and Metabolism.
Carbonic anhydrases as disease markers.
Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts.
Catalase, carbonic anhydrase and xanthine oxidase activities in patients with mycosis fungoides.
Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cells.
Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly.
Cell division cycle associated 1 as a novel prognostic biomarker and therapeutic target for oral cancer.
CellectSeq: In silico discovery of antibodies targeting integral membrane proteins combining in situ selections and next-generation sequencing.
Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells.
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells.
Characterization of carbonic anhydrase IX interactome reveals proteins assisting its nuclear localization in hypoxic cells.
Characterization of CD147, CA9, and CD70 as Tumor-Specific Markers on Extracellular Vesicles in Clear Cell Renal Cell Carcinoma.
Characterization of human carbonic anhydrase XII stability and inhibitor binding.
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Chemokine-Dependent pH Elevation at the Cell Front Sustains Polarity in Directionally Migrating Zebrafish Germ Cells.
Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice.
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Chromene-Containing Aromatic Sulfonamides with Carbonic Anhydrase Inhibitory Properties.
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity.
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Clinical Molecular Imaging with Radiotracers: Current Status.
Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging.
Clinical value of significance of Hypoxia Inducible Factor-1?, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer.
Cobalt Bis(dicarbollide) Alkylsulfonamides: Potent and Highly Selective Inhibitors of Tumor Specific Carbonic Anhydrase IX.
Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.
Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
COILED COIL PEPTIDES AS UNIVERSAL LINKERS FOR THE ATTACHMENT OF RECOMBINANT PROTEINS TO POLYMER THERAPEUTICS.
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.
Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity.
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Comparative evaluation of Affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX.
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor.
Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines.
Comparison of human papillomavirus detection and typing by hybrid capture 2, linear array, DNA chip, and cycle sequencing in cervical swab samples.
Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer.
Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy.
Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma.
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.
Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs.
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Continued exploration of 1,2,4-oxadiazole periphery for carbonic anhydrase-targeting primary arene sulfonamides: Discovery of subnanomolar inhibitors of membrane-bound hCA IX isoform that selectively kill cancer cells in hypoxic environment.
Coordinated Regulation of Metabolic Transporters and Migration/Invasion by Carbonic Anhydrase IX.
Correction to Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX.
Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2? (HIF-2?) in breast cancer.
Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma.
Correlation of a priori DCE-MRI and (1)H-MRS data with molecular markers in neck nodal metastases: Initial analysis.
Correlation of carbonic anhydrase IX expression with clinico-morphological parameters, hormonal receptor status and HER-2 expression in breast cancer.
Corrigendum to "Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent" [J. Med. Chem. 222 (2021) 113589].
Coumarin-Thiourea Hybrids Show Potent Carbonic Anhydrase IX and XIII Inhibitory Action.
Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity.
Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells.
Cryptophane Nanoscale Assemblies Expand 129Xe NMR Biosensing.
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.
Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells.
Current status and future directions of molecular markers in renal cell carcinoma.
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
CuZnSOD and MnSOD inhibit metabolic stress-induced necrosis and multicellular tumour spheroid growth.
Cyclic Secondary Sulfonamides: Unusually Good Inhibitors of Cancer-Related Carbonic Anhydrase Enzymes.
Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives.
Cystic clear cell papillary renal cell carcinoma: is it related to multilocular clear cell cystic neoplasm of low malignant potential?
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces.
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
Design and synthesis of a novel class of carbonic anhydrase-IX inhibitor 1-(3-(phenyl/4-fluorophenyl)-7-imino-3H-[1,2,3]triazolo[4,5d]pyrimidin 6(7H)yl)urea.
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Design and synthesis of novel benzenesulfonamide containing 1,2,3-triazoles as potent human carbonic anhydrase isoforms I, II, IV and IX inhibitors.
Design of a Carbonic Anhydrase IX Active-Site Mimic To Screen Inhibitors for Possible Anticancer Properties (dagger) (double dagger).
Design of zinc binding functions for carbonic anhydrase inhibitors.
Design, synthesis & biological evaluation of ferulic acid-based small molecule inhibitors against tumor-associated carbonic anhydrase IX.
Design, synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors.
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Design, synthesis and evaluation of (18)F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging.
Design, synthesis and molecular docking of novel N,N-dimethylbenzenesulfonamide derivatives as potential antiproliferative agents.
Designing carbonic anhydrase inhibitors for the treatment of breast cancer.
Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole.
Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry.
Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR.
Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Development and biological evaluation of ??mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers.
Development and characterization of new monoclonal antibodies against human recombinant CA XII.
Development and initial clinical testing of a multi-plexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
Development of a 68 Ga-labelled PET tracer for carbonic anhydrase IX-overexpressed tumors using the artificial sweetener saccharin.
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors.
Development of the 99mTc-Hydroxamamide Complex as a Probe Targeting Carbonic Anhydrase IX.
Dexamethasone downregulates expression of carbonic anhydrase IX via HIF-1? and NF-?B-dependent mechanisms.
Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.
Different expression patterns of carbonic anhydrase IX in oral lichen planus and leukoplakia.
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors.
Differential in vitro inhibition effects of some antibiotics on tumor associated carbonic anhydrase isozymes of hCA-IX and hCA-XII.
Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII.
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.
Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
Differentially expressed genes in a flock of Chinese local-breed chickens infected with a subgroup J avian leukosis virus using suppression subtractive hybridization.
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors.
Direct Introduction of an Alkylsulfonamido Group on C-sites of Isomeric Carboranes; the Influence of Stereochemistry on Inhibitory Activity Against Cancer-associated Carbonic Anhydrase IX Isoenzyme.
Disclosing the Interaction of Carbonic Anhydrase IX with Cullin-Associated NEDD8-Dissociated Protein 1 by Molecular Modeling and Integrated Binding Measurements.
Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis.
Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX.
Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.
Discovery of novel artemisinin-sulfonamidehybrids as potential carbonicanhydraseIX inhibitors with improved antiproliferative activities.
Discovery of novel isatin-based sulfonamides with potent and selective inhibition of the tumor-associated carbonic anhydrase isoforms IX and XII.
Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy.
Disrupting Hypoxia-Induced Bicarbonate Transport Acidifies Tumor Cells and Suppresses Tumor Growth.
Disruption of pH Dynamics Suppresses Proliferation and Potentiates Doxorubicin Cytotoxicity in Breast Cancer Cells.
Dissecting the Inhibition Mechanism of Cytosolic versus Transmembrane Carbonic Anhydrases by ESR.
Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor.
Distinctive renal cell tumor simulating atrophic kidney with 2 types of microcalcifications. Report of 3 cases.
Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.
DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.
Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes.
Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.
Downregulation of carbonic anhydrase IV contributes to promotion of cell proliferation and is associated with poor prognosis in non-small cell lung cancer.
Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck.
Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII.
Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Dual carbonic anhydrase--cyclooxygenase-2 inhibitors.
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.
Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
Dual Human Carbonic Anhydrase/Cyclooxygenase-2 Inhibitors: A Promising Approach for Cancer Treatment.
Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.
Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice.
Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site.
Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.
Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17.
Effect of an Imidazole-Containing Schiff Base of an Aromatic Sulfonamide on the Cytotoxic Efficacy of N,N-Coordinated Half-Sandwich Ruthenium(II) p-Cymene Complexes.
Effect of Carbonic Anhydrase IX inhibitors on human endothelial cell survival.
Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth.
Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX.
Effect of low-dose irradiation on induction of an apoptotic adaptive response in the murine system.
Effect of pazopanib on tumor microenvironment and liposome delivery.
Effect of Treatment Sequencing on the Tumor Response to Combined Treatment With Ultrasound-Stimulated Microbubbles and Radiotherapy.
Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Efficacy of a Three Drug-Based Therapy for Neuroblastoma in Mice.
Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX.
Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX.
Emerging drugs for renal cell carcinoma.
Encapsulation of anti-carbonic anhydrase IX antibody in hydrogel microspheres for tumor targeting.
Endogenous Hypoxia Markers in Locally Advanced Cancers of the Uterine Cervix: Reality or Wishful Thinking?
Endogenous hypoxia markers: case not proven!
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.
Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.
Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III.
Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.
Eosinophilic Solid and Cystic Renal Cell Carcinoma With Melanin Pigment-Expanding the Morphological Spectrum.
Erythrocyte catalase and carbonic anhydrase activities in lung cancer.
Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer.
Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity.
Estimation of thermodynamic stability of human carbonic anhydrase IX from urea-induced denaturation and MD simulation studies.
Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer.
Evaluation of
Evaluation of 99mTc-sulfonamide and sulfocoumarin derivatives for imaging carbonic anhydrase IX expression.
Evaluation of a Carbonic Anhydrase IX-Targeted Near-Infrared Dye for Fluorescence-Guided Surgery of Hypoxic Tumors.
Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening.
Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
Evaluation of Nonpeptidic Ligand Conjugates for the Treatment of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.
Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells.
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases.
Experimental Approaches to Identify Selective Picomolar Inhibitors for Carbonic Anhydrase IX.
Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors.
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors.
Expression and Activity of Carbonic Anhydrase IX Is Associated With Metabolic Dysfunction in MDA-MB-231 Breast Cancer Cells.
Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology.
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa.
Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors.
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Expression of cancer-related carbonic anhydrases IX and XII in normal skin and skin neoplasms.
Expression of carbonic anhydrase 9 at the invasion front of gastric cancers.
Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas.
Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.
Expression of carbonic anhydrase IX in craniopharyngiomas.
Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.
Expression of carbonic anhydrase IX in human pancreatic cancer.
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
Expression of hypoxia-induced proteins in ductal carcinoma in situ and invasive cancer of the male breast.
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.
Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas.
Expression of hypoxia-inducible, membrane-bound carbonic anhydrase isozyme XII in mouse tissues.
Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.
Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma.
Expression of liver cancer associated gene HCCA3.
Expression of Myoglobin in Normal and Cancer Brain Tissues: Correlation With Hypoxia Markers.
Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma.
Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma.
Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas.
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Expression of the interleukin-4 receptor alpha in human conjunctival epithelial cells.
Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors.
Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours.
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development.
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.
Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Extraskeletal Myxoid Chondrosarcoma of the Vulva With PLAG1 Gene Activation: Molecular Genetic Characterization of 2 Cases.
Familial occurrence of polymorphous oligodendroglioma.
Feasibility and constraints of particle targeting using the antigen-antibody interaction.
Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells.
Ferrier sulfamidoglycosylation of glycals catalyzed by nitrosonium tetrafluoroborate: towards new carbonic anhydrase glycoinhibitors.
Fibrotic focus and hypoxia in male breast cancer.
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Fluorescence- and spin-labeled carbonic anhydrase inhibitors.
Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.
Fluorinated benzenesulfonamide anticancer inhibitors of carbonic anhydrase IX exhibit lower toxic effects on zebrafish embryonic development than ethoxzolamide.
Fluorine-18 click radiosynthesis and microPET/CT evaluation of a small peptide-a potential PET probe for carbonic anhydrase IX.
Functionalized hydrogel microparticles prepared by microfluidics and their interaction with tumour marker carbonic anhydrase IX.
G250: a carbonic anhydrase IX monoclonal antibody.
Galectin-1: a link between tumor hypoxia and tumor immune privilege.
Gallbladder metastasis of renal cell carcinoma presenting as a hypervascular polypoid lesion: case report of two cases with immunohistochemical analysis.
Gastric Adenocarcinoma Biomarker Expression Profiles and their Prognostic Value.
Gastric pit cell hyperplasia and glandular atrophy in carbonic anhydrase IX knockout mice: studies on two strains C57/BL6 and BALB/C.
GdmCl-induced unfolding studies of human carbonic anhydrase IX: a combined spectroscopic and MD simulation approach.
Gene expression in the mammary gland tissue of female Fischer 344 and Lewis rats after magnetic field exposure (50 Hz, 100 ?T) for 2 weeks.
Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII.
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors.
Glucose Uptake and Intracellular pH in a Mouse Model of Ductal Carcinoma In situ (DCIS) Suggests Metabolic Heterogeneity.
Glycolysis-related protein expression in thyroid cancer.
Glycomimetic Based Approach toward Selective Carbonic Anhydrase Inhibitors.
Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer.
Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors.
Handling drug-target selectivity: A study on ureido containing Carbonic Anhydrase inhibitors.
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.
Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
HIF-mediated hypoxic response is missing in severely hypoxic uterine leiomyomas.
High Expression of Solute Carrier Family 2 Member 1 (SLC2A1) in Cancer Cells Is an Independent Unfavorable Prognostic Factor in Pediatric Malignant Peripheral Nerve Sheath Tumor.
High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
High monocarboxylate transporter 4 protein expression in stromal cells predicts adverse survival in gastric cancer.
High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
High Stromal Carbonic Anhydrase IX Expression Is Associated with Decreased Survival in p16-Negative Head-and-Neck Tumors.
Hippocampal and Cerebellar Changes in Acute Restraint Stress and the Impact of Pretreatment with Ceftriaxone.
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Histopathological Determinants of Tumor Resistance: a Special Look to The Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers.
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Homology modeling and receptor-based 3D-QSAR study of carbonic anhydrase IX.
How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH.
Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers.
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.
Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.
Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.
Hypoxia and energetic tumour metabolism.
Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
Hypoxia contributes to development of recurrent endometrial carcinoma.
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia.
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer.
Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target.
Hypoxia inducible factor (HIF1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer.
Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy.
Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.
Hypoxia-inducible carbonic anhydrase IX expression is insufficient to alleviate intracellular metabolic acidosis in the muscle of zebrafish, Danio rerio.
Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies.
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.
Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways.
Hypoxia-inducible factors in OSCC.
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
Hypoxia-related molecules HIF-1?, CA9, and osteopontin : predictors of survival in patients with high-grade glioma.
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Hypoxia-targeted gold nanorods for cancer photothermal therapy.
Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.
Hypoxic regulation of cytoglobin and neuroglobin expression in human normal and tumor tissues.
Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.
Identification of carbonic anhydrase I immunodominant epitopes recognized by specific autoantibodies which indicate an improved prognosis in patients with malignancy after autologous stem cell transplantation.
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients.
Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.
Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies.
Identification of proteins that regulate radiation-induced apoptosis in murine tumors with wild type p53.
Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging.
Identifying potential selective fluorescent probes for cancer-associated protein carbonic anhydrase IX using a computational approach.
Identifying the stromal cell type that contributes to tumor aggressiveness associated with carbonic anhydrase IX.
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients.
Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model.
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Immunohistochemical demonstration of carbonic anhydrase in human kidney, bone and giant cell tumor of bone.
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumours.
Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Immunohistochemical localization of carbonic anhydrase isoenzymes I and II in human bone, cartilage and giant cell tumor.
Immunohistochemical localization of transport mediators in Wilms' tumor: comparison with fetal and mature human kidney.
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features.
Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues.
Immunohistochemical study of carbonic anhydrase in mixed tumours and adenomas of sweat and sebaceous glands.
Immunohistochemical study of carbonic anhydrase in mixed tumours from major salivary glands and skin.
Immunohistochemical study of carbonic anhydrase in normal salivary gland and salivary gland tumor.
Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity.
Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Impact of Acetazolamide, a Carbonic Anhydrase Inhibitor, on the Development of Intestinal Polyps in Min Mice.
Impacts of CA9 gene polymorphisms and environmental factors on oral-cancer susceptibility and clinicopathologic characteristics in Taiwan.
Impacts of CA9 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
Impairment of carbonic anhydrase IX ectodomain cleavage reinforces tumorigenic and metastatic phenotype of cancer cells.
Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells.
In Search of Advanced Tumor Diagnostics and Treatment: Achievements and Perspectives of Carbonic Anhydrase IX Targeted Delivery.
In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells.
In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia.
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors.
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
In-Vitro Anticancer Evaluation and Docking Study of Novel benzo[g] quinazoline-sulfonamide Derivatives.
Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells.
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.
Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX.
Indisulam: an anticancer sulfonamide in clinical development.
Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells.
Induction of carbonic anhydrase IX by hypoxia and chemical disruption of oxygen sensing in rat fibroblasts and cardiomyocytes.
Influence of hypoxia-dependent factors on the progression of neuroblastoma.
Influence of Paclitaxel and Doxorubicin Therapy of ßIII-Tubulin, Carbonic Anhydrase IX, and Survivin in Chemically Induced Breast Cancer in Female Rat.
Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Inhibition of Carbonic Anhydrase IX Promotes Apoptosis through Intracellular pH Level Alterations in Cervical Cancer Cells.
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.
Inhibition of carbonic anhydrase IX: a new strategy against cancer.
Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.
Inhibition of Melanoma Cell Migration and Invasion Targeting the Hypoxic Tumor Associated CAXII.
Inhibition of smoothened in breast cancer cells reduces CAXII expression and cell migration.
Inhibition of tumor-associated human carbonic anhydrase isozymes IX and XII by a new class of substituted-phenylacetamido aromatic sulfonamides.
Inhibition of V-ATPases and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes.
Inhibition on angiotensin-converting enzyme exerts beneficial effects on trabecular bone in orchidectomized mice.
Inhibitors of CA IX Enzyme Based on Polyhedral Boron Compounds.
Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents.
Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.
Insights towards sulfonamide drug specificity in ?-carbonic anhydrases.
Interaction of HIF-1? and Notch3 Is Required for the Expression of Carbonic Anhydrase 9 in Breast Carcinoma Cells.
Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer.
Interfering with pH regulation in tumours as a therapeutic strategy.
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
Interplay of Carbonic Anhydrase IX With Amino Acid and Acid/Base Transporters in the Hypoxic Tumor Microenvironment.
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Intracellular carbonic anhydrase activity sensitizes cancer cell pH signaling to dynamic changes in CO2 partial pressure.
Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis.
Intrinsic binding of 4-substituted-2,3,5,6-tetrafluorobenezenesulfonamides to native and recombinant human carbonic anhydrase VI.
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX.
Intrinsic thermodynamics of sulfonamide inhibitor binding to human carbonic anhydrases I and II.
Intrinsically disordered features of carbonic anhydrase IX proteoglycan-like domain.
Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent.
Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT.
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Investigation of possible endogenous hypoxia markers in colorectal cancer.
Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX.
Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?
Ischemia dysregulates DNA methyltransferases and p16(INK4a) methylation in human colorectal cancer cells.
Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells.
Kinetically labile ruthenium(II) complexes of terpyridines and saccharin: effect of substituents on photoactivity, solvation kinetics, and photocytotoxicity.
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen.
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Lactate stimulates CA IX expression in normoxic cancer cells.
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.
Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.
LDH-A influences hypoxia-inducible factor 1? (HIF1 ?) and is critical for growth of HT29 colon carcinoma cells in vivo.
Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action.
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas.
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase.
Lymphocytic choriomeningitis virus mx strain does not induce the expression of tumor-associated carbonic anhydrase IX in persistently infected HeLa cells.
Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1?/VEGF signaling pathway in human bladder cancer cells.
Mapping Selective Inhibition of the Cancer-Related Carbonic Anhydrase IX Using Structure-Activity Relationships of Glucosyl-Based Sulfamates.
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment.
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions.
Mesenchymal stem cell transplantation attenuates growth of chemotherapy treated oral squamous cell carcinoma in an animal model.
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
Metallacarborane Sulfamides: Unconventional, Specific, and Highly Selective Inhibitors of Carbonic Anhydrase IX.
Metastatic instability of murine tumor metastases: dependence on tumor type.
Methanethiol Binding Strengths and Deprotonation Energies in Zn(II)-Imidazole Complexes from M05-2X and MP2 Theories: Coordination Number and Geometry Influences Relevant to Zinc Enzymes.
Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors.
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Microfluidic Encapsulation of Prickly Zinc-Doped Copper Oxide Nanoparticles with VD1142 Modified Spermine Acetalated Dextran for Efficient Cancer Therapy.
Microsecond Simulation of the Proteoglycan-like Region of Carbonic Anhydrase IX and Design of Chemical Inhibitors Targeting pH Homeostasis in Cancer Cells.
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Mitochondrial proteomic profiling reveals increased carbonic anhydrase II in aging and neurodegeneration.
Modeling of pH regulation in tumor cells: Direct interaction between proton-coupled lactate transporters and cancer-associated carbonic anhydrase.
Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer.
Modulation of cell surface density of carbonic anhydrase IX by shedding of the ectodomain and endocytosis.
Modulation of the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX with Albumin-Binding Moieties.
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX.
Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Molecular imaging of urogenital diseases.
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Molecular targeting of bioconjugated graphene oxide nanocarriers revealed at a cellular level using label-free Raman imaging.
Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.
Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model.
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.
Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX.
Monoclonal antibody G250 targeting CA ?: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.
Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
Myoglobin variants are expressed in human glioblastoma cells?hypoxia effect?
N-?-Glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII.
N-Acylbenzenesulfonamide Dihydro-1,3,4-oxadiazole Hybrids: Seeking Selectivity toward Carbonic Anhydrase Isoforms.
Natural product polyamines that inhibit human carbonic anhydrases.
Near-infrared fluorescence activation probes based on disassembly-induced emission cyanine dye.
Near-Infrared Fluorescence Imaging of Carbonic Anhydrase IX in Athymic Mice Bearing HT-29 Tumor Xenografts.
Neoplastic transformation of propagable cultured rat pancreatic duct epithelial cells by azaserine and streptozotocin.
Neuroendocrine regulation of carbonic anhydrase expression in the gills of the euryhaline green crab, Carcinus maenas.
New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation.
New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation.
New Monoclonal Antibodies for a Selective Detection of Membrane-Associated and Soluble Forms of Carbonic Anhydrase IX in Human Cell Lines and Biological Samples.
New power of self-assembling carbonic anhydrase inhibitor: Short peptide-constructed nanofibers inspire hypoxic cancer therapy.
New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides.
Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes.
Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.
Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1.
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells.
Novel insights on saccharin- and acesulfame-based carbonic anhydrase inhibitors: design, synthesis, modelling investigations and biological activity evaluation.
Novel predictive biomarkers for cervical cancer prognosis.
Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII.
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.
Oleuropein and Verbascoside - Their Inhibition Effects on Carbonic Anhydrase and Molecular Docking Studies.
Oncogenic roles of carbonic anhydrase IX in human nasopharyngeal carcinoma.
Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.
Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.
Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Organic Photodynamic Nanoinhibitor for Synergistic Cancer Therapy.
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment.
Overcoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach.
Overexpressed CA12 has prognostic value in pancreatic cancer and promotes tumor cell apoptosis via NF-?B signaling.
Overexpression of CA1 mRNA and the CA I Protein in Tumor Cells Does Not Change the Gene Expression of the ECM Proteins.
Overexpression of carbonic anhydrase and HIF-1? in Wilms tumours.
Overexpression of carbonic anhydrase II and Ki-67 proteins in prognosis of gastrointestinal stromal tumors.
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis.
Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors.
Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy.
Overlap of epitopes recognized by anti-carbonic anhydrase I IgG in patients with malignancy-related aplastic anemia-like syndrome and in patients with aplastic anemia.
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors.
Oxygen and glucose consumption in gastrointestinal adenocarcinomas: Correlation with markers of hypoxia, acidity and anaerobic glycolysis.
Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.
P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells.
p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres.
Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX.
Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II.
PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX.
PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas.
Personalized Treatment Response Assessment for Rare Childhood Tumors Using Microcalorimetry-Exemplified by Use of Carbonic Anhydrase IX and Aquaporin 1 Inhibitors.
Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors.
PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide.
PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides.
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
pH control mechanisms of tumor survival and growth.
pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance.
Pharmacological Inhibition of CA-IX Impairs Tumor Cell Proliferation, Migration and Invasiveness.
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors.
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer.
Picomolar inhibitors of carbonic anhydrase: Importance of inhibition and binding assays.
Plasma Osteopontin Is a Useful Diagnostic Biomarker for Advanced Non-Small Cell Lung Cancer.
Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma.
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Podoplanin-positive cancer associated fibroblast could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: Utility of combining analysis of both cancer cell phenotype and cancer associated fibroblast phenotype.
Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.
Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Post-translational modifications in tumor-associated carbonic anhydrases.
Potential anticancer activities of Rhus coriaria (sumac) extract against human cancer cell lines.
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
PPAR? and RXR Ligands Disrupt the Inflammatory Cross-talk in the Hypoxic Breast Cancer Stem Cells Niche.
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers.
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Prediction of activity and selectivity profiles of human Carbonic Anhydrase inhibitors using machine learning classification models.
Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas.
Preliminary biological evaluation of ¹²?I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors.
Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
Primary endocervical gastric-type adenocarcinoma: a clinicopathologic and immunohistochemical analysis of 23 cases.
Primary glial tumor of the retina with features of myxopapillary ependymoma.
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [111 In]In-XYIMSR-01 for phase I regulatory approval.
Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry.
Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Prognostic impact of LY6K and CDCA1 expression for patients with esophageal squamous cell carcinoma.
Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Prognostic impacts of hypoxic markers in soft tissue sarcoma.
Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells.
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Prognostic Relevance of the Expression of CA IX, GLUT-1, and VEGF in Ovarian Epithelial Cancers.
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
Prognostic Significance of Carbonic Anhydrase IX (CA-IX), Endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in Breast Cancer Patients.
Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma.
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.
Prognostic Significance of Osteopontin and Carbonic Anhydrase 9 in Human Brain Tumors: A Meta-Analysis.
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue.
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma.
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.
Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.
Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers.
Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.
Proton Transport in Cancer Cells: The Role of Carbonic Anhydrases.
Protons make tumor cells move like clockwork.
Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers.
Purification, enzymatic activity and inhibitor discovery for recombinant human carbonic anhydrase XIV.
Pyrazolylbenzo[d]imidazoles as new potent and selective inhibitors of carbonic anhydrase isoforms hCA IX and XII.
Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.
Pyruvate dehydrogenase kinase 1 and carbonic anhydrase IX targeting in hypoxic tumors.
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes.
Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays.
Quercetin-Modified Metal-Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX.
Quinoline-sulfamoyl carbamates/sulfamide derivatives: Synthesis, cytotoxicity, carbonic anhydrase activity, and molecular modelling studies.
Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by 61Cu and 64Cu and its biological testing.
Radiosynthesis of three [11C]ureido-substituted benzenesulfonamides as PET probes for carbonic anhydrase IX in tumors.
Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms.
Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
Recent advances in autoimmune pancreatitis: concept, diagnosis, and pathogenesis.
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics.
Recent Developments on Thiourea Based Anticancer Chemotherapeutics.
Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system.
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.
Redox state and carbonic anhydrase isozyme IX expression in human renal cell carcinoma: biochemical and morphological investigations.
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Regulation of intracellular pH in neuronal and glial tumour cells, studied by multinuclear NMR spectroscopy.
Regulation of tumor pH and the role of carbonic anhydrase 9.
Relationship between Hypoxia and Carcinoembryonic Antigen and Upregulated Carcinoembryonic Antigen is Associated with Poor Prognosis in Breast Cancer Patients.
Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.
Renal cell carcinoma in tuberous sclerosis complex.
Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile.
RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.
Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors.
Reproducibility and biological basis of in vivo T(2) * magnetic resonance imaging of liver metastasis of colorectal cancer.
Reproducibility of functional volume and activity concentration in (18)F-FDG PET/CT of liver metastases in colorectal cancer.
Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients.
Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo(-/-) mice.
Retinoblastoma in a dog.
Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines.
Revealing membrane alteration in cellsoverexpressing CA IX and EGFR by Surface-Enhanced Raman Scattering.
RNAi-mediated knockdown of CAIX enhances the radiosensitivity of nasopharyngeal carcinoma cell line, CNE-2.
Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance.
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Role of carbonic anhydrase IX, ?-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis.
Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
Role of the HBx oncoprotein in carbonic anhydrase 9 induction.
Role of zinc in catalytic activity of carbonic anhydrase IX.
Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence.
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
RT-PCR detection of fibronectin EDA+ and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma.
Ruthenium(II) complexes of saccharin with dipyridoquinoxaline and dipyridophenazine: Structures, biological interactions and photoinduced DNA damage activity.
Saccharin: A lead compound for structure-based drug design of carbonic anhydrase IX inhibitors.
Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.
Sarcomatoid Renal Cell Carcinoma With Unusual Metastasis to the Small Intestine Manifesting as Perforated Appendicitis.
Sclerosing Sertoli cell tumor without expression of typical sex cord stromal tumor markers: case report and literature review.
Selective carbonic anhydrase IX inhibitors based on coumarin scaffold as promising antimetastatic agents: WO2012070024.
Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells.
Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition.
Selective inhibition of carbonic anhydrase-IX by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells.
Selective inhibition of human carbonic anhydrase IX in Xenopus oocytes and MDA-MB-231 breast cancer cells.
Sense-and-Release Logic-Gated Molecular Network Responding to Dimeric Cell Surface Proteins.
Sera of patients with spontaneous tumour regression and elevated anti-CA I autoantibodies change the gene expression of ECM proteins.
Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma.
Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Sexual dimorphism in LEC rat liver: suppression of carbonic anhydrase III by copper accumulation during hepatocarcinogenesis.
Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Silencing of carbonic anhydrase I enhances the malignant potential of exosomes secreted by prostatic tumour cells.
Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma.
Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis.
Single nucleotide polymorphisms and haplotypes of carbonic anhydrase 9 can predict invasive squamous cell carcinoma of uterine cervix.
Sinonasal renal cell-like adenocarcinomas: robust carbonic anhydrase expression.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX.
Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines.
Soft-tissue Hemangioblastoma of the Retroperitoneum: A Case Study and Review of the Literature.
Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients.
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation.
Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma.
Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1.
Stromal expression of carbonic anhydrase IX in esophageal cancer.
Structural Basis for the Interaction Between Carbonic Anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides.
Structural comparison of protiated, H/D-exchanged and deuterated human carbonic anhydrase IX.
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates.
Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Structure of the carbonic anhydrase VI (CA6) gene: evidence for two distinct groups within the alpha-CA gene family.
Structure-based drug discovery of carbonic anhydrase inhibitors.
Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors.
Substituted benzene sulfonamides incorporating 1,3,5-triazinyl moieties potently inhibit human carbonic anhydrases II, IX and XII.
Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC.
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.
Sulfamates and their therapeutic potential.
Sulfocoumarins, specific carbonic anhydrase IX and XII inhibitors, interact with cancer multidrug resistant phenotype through pH regulation and reverse P-glycoprotein mediated resistance.
Sulfonamide bearing pyrazolylpyrazolines as potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII.
Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX.
Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells.
Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype.
Sweet Binders: Carbonic Anhydrase IX in Complex with Sucralose.
Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study.
Syntesis of thio- and seleno-acetamides bearing benzenesulfonamide as potent inhibitors of human carbonic anhydrase II and XII.
Synthesis 4-[2-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulfonamides with subnanomolar carbonic anhydrase II and XII inhibitory properties.
Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia.
Synthesis and biological evaluation of benzenesulphonamide-bearing 1,4,5-trisubstituted-1,2,3-triazoles possessing human carbonic anhydrase I, II, IV, and IX inhibitory activity.
Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors.
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors.
Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.
Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.
Synthesis and carbonic anhydrase inhibitory effects of new N-glycosylsulfonamides incorporating the phenol moiety.
Synthesis and evaluation of (18)F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography.
Synthesis and evaluation of (18)F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography.
Synthesis and evaluation of 68Ga-labeled imidazothiadiazole sulfonamide derivatives for PET imaging of carbonic anhydrase-IX.
Synthesis and evaluation of indium-111-labeled imidazothiadiazole sulfonamide derivative for single photon emission computed tomography imaging targeting carbonic anhydrase-IX.
Synthesis and evaluation of near-infrared fluorescent sulfonamide derivatives for imaging of hypoxia-induced carbonic anhydrase IX expression in tumors.
Synthesis and evaluation of novel technetium-99m-hydroxamamide complex based on imidazothiadiazole sulfonamide targeting carbonic anhydrase-IX for tumor imaging.
Synthesis and exploration of 2-morpholino-4-phenylthiazol-5-yl acrylamide derivatives for their effects against carbonic anhydrase I, II, IX and XII isoforms as a non-sulfonamide class of inhibitors.
Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety.
Synthesis and in Vivo Biological Evaluation of (68)Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography.
Synthesis and radiolabeling of (64)Cu-labeled 2-nitroimidazole derivative (64)Cu-BMS2P2 for hypoxia imaging.
Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
Synthesis of 2-[11C]methoxy-3,17?-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers.
Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.
Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors.
Synthesis of an acridine orange sulfonamide derivative with potent carbonic anhydrase IX inhibitory action.
Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects.
Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.
Synthesis of glycoconjugate carbonic anhydrase inhibitors by ruthenium-catalysed azide-alkyne 1,3-dipolar cycloaddition.
Synthesis of N'-phenyl-N-hydroxyureas and investigation of their inhibitory activities on human carbonic anhydrases.
Synthesis of new 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII.
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy.
Synthesis of sulfonamide conjugates of Cu(ii), Ga(iii), In(iii), Re(v) and Zn(ii) complexes: carbonic anhydrase inhibition studies and cellular imaging investigations.
Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors.
Synthesis, carbonic anhydrase inhibition and cytotoxic activity of novel chromone-based sulfonamide derivatives.
Synthesis, characterization, in vitro cytotoxicity and antimicrobial investigation and evaluation of physicochemical properties of novel 4-(2-methylacetamide)benzenesulfonamide derivatives.
Synthesis, cytotoxicity and carbonic anhydrase inhibitory activities of new pyrazolines.
Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
Targeted agents for the treatment of advanced renal cell carcinoma.
Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy.
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Targeting Carbonic Anhydrase IX Activity and Expression.
Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs.
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
Targeting carbonic anhydrase IX with small organic ligands.
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.
Targeting Hypoxic Tumors with Hybrid Nanobullets for Oxygen-Independent Synergistic Photothermal and Thermodynamic Therapy.
Targeting ion transport in cancer.
Targeting of adenovirus to human renal cell carcinoma cells.
Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250.
Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles.
Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.
Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors.
Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
Tellurides bearing benzensulfonamide as carbonic anhydrase inhibitors with potent antitumor activity.
TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells.
The acidic tumor microenvironment drives a stem-like phenotype in melanoma cells.
The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors.
The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
The Anticancer Activity for the Bumetanide-Based Analogs via Targeting the Tumor-Associated Membrane-Bound Human Carbonic Anhydrase-IX Enzyme.
The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression.
The Carbonic Anhydrase Inhibitor E7070 Sensitizes Glioblastoma Cells to Radio- and Chemotherapy and Reduces Tumor Growth.
The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy.
The chemistry, physiology and pathology of pH in cancer.
The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer.
The control of acidity in tumor cells: a biophysical model.
The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.
The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells.
The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma.
The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration.
The effects of CA IX catalysis products within tumor microenvironment.
The effects of some tumor markers on human erythrocyte (HCA-I and HCA-II), bovine erythrocyte (BCA) and bovine lung (CA-IV) carbonic anhydrase enzyme activities in vitro.
The expression of carbonic anhydrase II in hematological malignancies.
The expression of carbonic anhydrase in canine mammary gland and mammary gland tumor.
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
The histological growth pattern of colorectal cancer liver metastases has prognostic value.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct.
The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation.
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours.
The Hypoxic Response Expression as a Survival Biomarkers in Treatment-Naive Advanced Breast Cancer.
The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion.
The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model.
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
The Na(+) /HCO3 (-) Co-Transporter SLC4A4 Plays a Role in Growth and Migration of Colon and Breast Cancer Cells.
The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.
The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors.
The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells.
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas.
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths.
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond.
The role of carbonic anhydrase IX in hypoxia control in OSCC.
The role of carbonic anhydrase IX overexpression in kidney cancer.
The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals.
The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis.
The structural basis for the selectivity of sulfonamido dicarbaboranes toward cancer-associated carbonic anhydrase IX.
The Structure of Carbonic Anhydrase IX Is Adapted for Low-pH Catalysis.
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
The VHL-dependent regulation of microRNAs in renal cancer.
The Warburg Effect, Lactate, and Nearly a Century of Trying to Cure Cancer.
Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung.
Tissue Expression of Carbonic Anhydrase IX Correlates to More Aggressive Phenotype of Basal Cell Carcinoma.
Toll-like receptors 2, 4 and 9 and hypoxia markers HIF-1alpha and CAIX in pancreatic intraepithelial neoplasia.
Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells.
Toward a hierarchical virtual screening and toxicity risk analysis for identifying novel CA XII inhibitors.
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia.
Transcriptional regulation of carbonic anhydrase II by retinoic acid in the human pancreatic tumor cell line DANG.
Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours.
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase.
Treatment selection for patients with metastatic renal cell carcinoma.
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX-Targeted PET Imaging.
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.
Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity.
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model.
Tumor necrosis factor-alpha induces the expression of carbonic anhydrase II in pancreatic adenocarcinoma cells.
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
Tumor-associated carbonic anhydrases and their clinical significance.
Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer.
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Type 1 Sodium Calcium Exchanger Forms a Complex with Carbonic Anhydrase IX and Via Reverse Mode Activity Contributes to pH Control in Hypoxic Tumors.
Ultrastructural immunocytochemical localization of carbonic anhydrase in a benign giant cell tumor of bone.
Umbelliferone decreases intracellular pH and sensitizes melanoma cell line A375 to dacarbazin. Comparison with acetazolamide.
Unconventional amino acids in medicinal chemistry: First report on taurine merged within carbonic anhydrase inhibitors.
Understanding the importance of smart drugs in renal cell carcinoma.
Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
Update on carbonic anhydrase inhibitors: a patent review (2008 - 2011).
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Use of multiple biological markers in radiotherapy-treated head and neck cancer.
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Using neutron crystallography to elucidate the basis of selective inhibition of carbonic anhydrase by saccharin and a derivative.
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.
Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold.
Whole cigarette smoke condensates induce ferroptosis in human bronchial epithelial cells.
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.
[(Cp-R)M(CO)(3) ] (M=Re or (99m) Tc) Arylsulfonamide, Arylsulfamide, and Arylsulfamate Conjugates for Selective Targeting of Human Carbonic Anhydrase IX.
[Activity of blood carbonic anhydrase in cancer of various localizations.]
[Carbonic anhydrase activity and acid-base equilibrium of the blood in patients with tumors and inflammatory diseases of the lungs]
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
[Clinicopathological significance of the expression of carbonic anhydrase II in human pancreatic invasive ductal cancer].
[Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression]
[Expression of carbonic anhydrase IX in the breast carcinomas].
[Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
[Predictive Biomarkers for Bevacizumab in Anti-tumor Therapy].
[Progress in the study of carbonic anhydrase inhibitors as potential anticancer drugs].
[Proteome study of colorectal cancer genesis and hepatic metastasis]
[Proteomic analysis of morphine rabbit myocardium with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry]
[Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
[Significance of carbonic anhydrase IX protein in fibrotic foci of mammary invasive ductal carcinomas].
[Significance of detection of serum carbonic anhydrase IX in the diagnosis of lung cancer].
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
[The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?]
[Value of Detection of CAIX in the Pleural Effusion and Its Sediment in the Diagnosis of Lung Cancer].
Neoplasms, Germ Cell and Embryonal
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.
Neoplasms, Glandular and Epithelial
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Neoplasms, Squamous Cell
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS.
Neoplastic Cells, Circulating
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients.
Development and initial clinical testing of a multi-plexed circulating tumor cell assay in patients with clear cell renal cell carcinoma.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes.
Nephritis
Carbonic anhydrase inhibition. VIII. Lack of renal response to acetazolamide and to meralluride in a dog with chronic nephritis.
Nephritis, Interstitial
Acute Tubulointerstitial Nephritis With an Autoantibody Response Against Carbonic Anhydrase II.
Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis.
Nephrocalcinosis
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
Nephrolithiasis
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Exacerbation of nephrolithiasis by a carbonic anhydrase inhibitor.
Possible Drug-Associated Sialolithiasis From the Bicarbonate Anhydrase Inhibitor Topiramate: A Case Report and Literature Review.
Reduced red blood cell carbonic anhydrase activity in a patient with nephrolithiasis.
[Nephrolithiasis and topiramate.]
[Urinary lithiasis of medical origin]
Nephrotic Syndrome
Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
Nervous System Diseases
A single-step solid phase radioimmunoassay for quantifying human carbonic anhydrase I and II in cerebrospinal fluid.
Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases.
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
Neuralgia
A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects.
Acetazolamide attenuates chemical-stimulated but not thermal-stimulated acute pain in mice.
Analgesic and Antiallodynic Effects of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide in a Murine Model of Pain.
Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms.
Carbonic anhydrase inhibition and the management of neuropathic pain.
Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action.
Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide.
Design, synthesis and X-ray crystallography of selenides bearing benzenesulfonamide moiety with neuropathic pain modulating effects.
Dual Carbonic Anhydrase IX/XII Inhibitors and Carbon Monoxide Releasing Molecules Modulate LPS-Mediated Inflammation in Mouse Macrophages.
Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.
N-aryl-N'-ureido-O-sulfamates: Potent and selective inhibitors of the human Carbonic Anhydrase VII isoform with neuropathic pain relieving properties.
Pharmacological Modulation of Rate-Dependent Depression of the Spinal H-Reflex Predicts Therapeutic Efficacy against Painful Diabetic Neuropathy.
Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy.
Spirocyclic sulfonamides with carbonic anhydrase inhibitory and anti-neuropathic pain activity.
Neuroblastoma
Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.
Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
Chelation of cellular calcium modulates hypoxia-inducible gene expression through activation of hypoxia-inducible factor-1alpha.
Enzymatic and morphological properties of primary rat brain astrocyte cultures, and enzyme development in vivo.
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment.
Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Neuroectodermal Tumors, Primitive
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
Neuroendocrine Tumors
Carbonic Anhydrase II Mediates Malignant Behavior of Pulmonary Neuroendocrine Tumors.
Neurofibromatoses
[Protein expression profiles in a rat cirrhotic model induced by thioacetamide.]
Neurofibromatosis 2
[Protein expression profiles in a rat cirrhotic model induced by thioacetamide.]
Neuroma
Myelinated sensory and alpha motor axon regeneration in peripheral nerve neuromas.
Neuromuscular Diseases
Acetazolamide acts directly on the human skeletal muscle chloride channel.
Carbonic anhydrase-III immunohistochemical localization in human skeletal muscle.
Heterocyclic compounds as carbonic anhydrase inhibitor.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Muscle-specific carbonic anhydrase III is a more sensitive marker of muscle damage than creatine kinase in neuromuscular disorders.
Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction.
Neurosyphilis
Distribution of carbonic anhydrase in the pallium in 19 cases of paretic neurosyphilis.
Nevus
Cell division cycle-associated protein 1 as a new melanoma-associated antigen.
Night Blindness
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Non-alcoholic Fatty Liver Disease
Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.
The Role of Beta-7 Integrin and Carbonic Anhydrase IX in Predicting the Occurrence of de Novo Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients.
non-specific serine/threonine protein kinase deficiency
Kinome siRNA screen identifies SMG-1 as a negative regulator of HIF-1alpha in hypoxia.
Nystagmus, Pathologic
[Treatment options for nystagmus].
Obesity
Active Components of Essential Oils as Anti-Obesity Potential Drugs Investigated by in Silico Techniques.
Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study.
Antiobesity carbonic anhydrase inhibitors.
Carbonic anhydrase III (Car3) is not required for fatty acid synthesis and does not protect against high-fat diet induced obesity in mice.
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
Design and development of 5-(4H)-oxazolones as potential inhibitors of human carbonic anhydrase VA: towards therapeutic management of diabetes and obesity.
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Design of zinc binding functions for carbonic anhydrase inhibitors.
Design, synthesis and biological evaluation of novel ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as potent carbonic anhydrase IX inhibitors.
Developments of small molecules as inhibitors for carbonic anhydrase isoforms.
Effects of leptin and insulin on CA III expression in rat adipose tissue.
Expression of CA III in rodent models of obesity.
Heterocyclic compounds as carbonic anhydrase inhibitor.
Increased oxidation-related glutathionylation and carbonic anhydrase activity in endometriosis.
Intraocular pressure in genetically distinct mice: an update and strain survey.
Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.
Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes.
Lagenaria siceraria and it's bioactive constituents in carbonic anhydrase inhibition: A bioactivity guided LC-MS/MS approach.
Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders.
N-Sulfamoylphenyl- and N-sulfamoylphenyl-N-thiazolyl-?-alanines and their derivatives as inhibitors of human carbonic anhydrases.
Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.
Probing the chemical interaction space governed by 4-aminosubstituted benzenesulfonamides and carbonic anhydrase isoforms.
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.
Synthesis of 1,2,4-triazole-5-on derivatives and determination of carbonic anhydrase II isoenzyme inhibition effects.
The effect of carbonic anhydrase inhibition on leptin secretion by rat adipose tissue.
The green synthesis and molecular docking of novel N-substituted rhodanines as effective inhibitors for carbonic anhydrase and acetylcholinesterase enzymes.
Understanding the role and mechanism of carbonic anhydrase V in obesity and its therapeutic implications.
Obstetric Labor, Premature
[Zinc and carbonic anhydrase content in women with term and premature labor]
Ocular Hypertension
1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads.
3-substituted thieno[2,3-b][1,4]thiazine-6-sulfonamides. A novel class of topically active carbonic anhydrase inhibitors.
A topical or oral carbonic anhydrase inhibitor to control ocular hypertension after cataract surgery.
Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension.
Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers.
Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
Dorzolamide, A Topical Carbonic Anhydrase Inhibitor: A Two-Week Dose-Response Study in Patients with Glaucoma or Ocular Hypertension.
Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor.
Effects of adrenergics, adrenolytics, cholinergics and carbonic anhydrase inhibitors on ibopamine-induced ocular hypertension in POAG.
Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or ?-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
Intraocular pressure reduction with travoprost/timolol fixed combination, with and without adjunctive brinzolamide, in glaucoma.
MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors.
MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action.
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.
Ocular hypertension. II. A carbonic anhydrase inhibitor test for early detection of glaucoma.
Oral versus topical carbonic anhydrase inhibitors in ocular hypertension after scleral tunnel cataract surgery.
Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.
The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
The mechanisms by which latanoprost free acid inhibits human carbonic anhydrase I and II.
Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
[Decrease in intraocular pressure following administration of the local carbonic anhydrase inhibitor (MK-927)--comparison of the effect with pilocarpine]
[Early postoperative intraocular pressure after phacoemulsification: Normal patients versus glaucoma patients].
Ocular Hypotension
Acetazolamide, metabolic acidosis, and intraocular pressure.
Ocular hypotensive effects of carbonic anhydrase inhibitors in normotensive and glaucomatous Beagles.
Odontogenic Cysts
Immunohistochemical expression of GLUT-1, GLUT-3, and carbonic anhydrase IX in benign odontogenic lesions.
Olfaction Disorders
cAMP and cGMP in human parotid saliva: relationships to taste and smell dysfunction, gender, and age.
Carbonic anhydrase I, II, and VI, blood plasma, erythrocyte and saliva zinc and copper increase after repetitive transcranial magnetic stimulation.
Decreased parotid saliva gustin/carbonic anhydrase VI secretion: an enzyme disorder manifested by gustatory and olfactory dysfunction.
Oligodendroglioma
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
Carbonic anhydrase IX in oligodendroglial brain tumors.
High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q-codeletion and Favorable Prognosis in Oligodendroglioma.
Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers.
Immunohistochemical demonstration of human carbonic anhydrase isoenzyme II in brain tumours.
Oliguria
[Renal carbonic anhydrase and oliguria of the burned dog.]
[Research on burns. Aminothiadiazolsulfamide, renal carbonic anhydrase and oliguria of the burned dog.]
Optic Nerve Diseases
The Effect of a Decrease in Intraocular Pressure on Optic Nerve Function in Patients with Optic Nerve Drusen.
Oral Submucous Fibrosis
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Osteoarthritis
A proteomic study of protein variation between osteopenic and age-matched control bone tissue.
Osteoblastoma
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Osteolysis
Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways.
Osteopetrosis
A Case of Carbonic Anhydrase Type 2 Deficiency Syndrome with Autistic Disorder.
A novel homozygous nonsense mutation in the CA2 gene (c.368G>A, p.W123X) linked to carbonic anhydrase II deficiency syndrome in a Chinese family.
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries.
Autosomal dominant osteopetrosis associated with renal tubular acidosis is due to a CLCN7 mutation.
Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome.
Carbonic anhydrase II (CA II) deficiency in Maghrebian patients: evidence for founder effect and genomic recombination at the CA II locus.
Carbonic anhydrase II and H+ -ATPase in osteoclasts of four osteopetrotic mutations in the rat.
Carbonic anhydrase II deficiency a novel mutation.
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic Anhydrase II Deficiency in a Saudi Woman.
Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation.
Carbonic anhydrase II deficiency syndrome: recessive osteopetrosis with renal tubular acidosis and cerebral calcification.
Carbonic anhydrase II deficiency.
Carbonic anhydrase II deficiency: a rare autosomal recessive disorder of osteopetrosis, renal tubular acidosis, and cerebral calcification.
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation.
Carbonic anhydrase II deficiency: report of a novel mutation.
Carbonic anhydrase II in the developing and adult human brain.
Carbonic anhydrase isozymes IV and II in urinary membranes from carbonic anhydrase II-deficient patients.
Carbonic anhydrase isozymes of osteoclasts and erythrocytes of osteopetrotic microphthalmic mice.
Case report 668. Carbonic anhydrase II deficiency syndrome (osteopetrosis associated with renal tubular acidosis and cerebral calcification).
Case report 718. Osteopetrosis with carbonic anhydrase II deficiency.
Cerebral calcification, osteopetrosis and renal tubular acidosis: is it carbonic anhydrase-II deficiency?
Clinical and molecular findings in a family with the carbonic anhydrase II deficiency syndrome.
Clinical and molecular heterogeneity in carbonic anhydrase II deficiency and prenatal diagnosis in an Italian family.
Clinical quiz. Osteopetrosis with carbonic anhydrase II deficiency.
Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.
Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders.
Evaluation of carbonic anhydrase isozymes in disorders involving osteopetrosis and/or renal tubular acidosis.
Genetic causes and mechanisms of distal renal tubular acidosis.
Genetic diseases of acid-base transporters.
Human osteopetrosis and other sclerosing disorders: recent genetic developments.
Identification of a novel mutation in an Indian patient with CAII deficiency syndrome.
Intracranial calcification in children with osteopetrosis caused by carbonic anhydrase II deficiency.
Marble brain disease in two Saudi Arabian siblings.
Molecular basis of human carbonic anhydrase II deficiency.
Molecular basis of proximal renal tubular acidosis.
Molecular Modelling and Dynamics of CA2 Missense Mutations Causative to Carbonic Anhydrase 2 Deficiency Syndrome.
N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome.
New insights into the pathogenesis of renal tubular acidosis--from functional to molecular studies.
Osteoclast biology: lessons from mammalian mutations.
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Phenotypic Characteristics of Bone in Carbonic Anhydrase II-Deficient Mice.
Polymorphic gene for human carbonic anhydrase II: a molecular disease marker located on chromosome 8.
Proteomic Profiling of the First Human Dental Pulp Mesenchymal Stem/Stromal Cells from Carbonic Anhydrase II Deficiency Osteopetrosis Patients.
Recent developments in the understanding of the pathophysiology of osteopetrosis.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency.
Renal tubular acidosis and osteopetrosis with carbonic anhydrase II deficiency: pathogenesis of impaired acidification.
Renal Tubular Acidosis, Osteopetrosis, and Cerebral Calcification: A Rare Syndrome Caused by Carbonic Anhydrase II Deficiency.
Targeted disruption of the Cl-/HCO3- exchanger Ae2 results in osteopetrosis in mice.
The determination of osteopetrotic phenotypes by selective inactivation of red cell carbonic anhydrase isoenzymes.
The neurology of carbonic anhydrase type II deficiency syndrome.
The role of carbonic anhydrase in autosomal dominant osteopetrosis.
Two novel CAII mutations causing carbonic anhydrase II deficiency syndrome in two unrelated Chinese families.
[Carbonic anhydrase II deficiency: osteopetrosis, renal tubular acidosis and intracranial calcifications. Review of the literature and 3 cases]
[Osteopetrosis and renal acidosis: a new case of this rare syndrome]
[Osteopetrosis with carbonic anhydrase II deficiency: report of 24 cases]
[Recessive osteopetrosis. Identification of a form of medium severity]
[Syndrome associating: osteopetrosis, tubular acidosis, mental retardation and cerebral calcifications due to carbonic anhydrase II deficiency. Apropos of 3 cases in the siblings]
Osteoporosis
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors.
Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women.
Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine.
In vitro inhibition of ?-carbonic anhydrase isozymes by some phenolic compounds.
Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.
NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II.
Nucleotide variations in genes encoding carbonic anhydrase 8 and 10 associated with femoral bone mineral density in Japanese female with osteoporosis.
Structural elucidation of the hormonal inhibition mechanism of the bile acid cholate on human carbonic anhydrase II.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols and their derivatives including natural products: Vidalol B.
Synthesis and carbonic anhydrase inhibitory properties of novel bromophenols including natural products.
Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.
Synthesis and characterization of novel substituted thiophene derivatives and discovery of their carbonic anhydrase and acetylcholinesterase inhibition effects.
[Recent progress in molecular biology of inherited tubular transport abnormalities]
Osteoporosis, Postmenopausal
17 beta-estradiol suppresses gene expression of tartrate-resistant acid phosphatase and carbonic anhydrase II in ovariectomized rats.
Osteosarcoma
Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma.
Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.
Detection of mRNA for carbonic anhydrase II in human osteoclast-like cells by in situ hybridization.
Histochemistry of tartrate-resistant acid phosphatase and carbonic anhydrase isoenzyme II in osteoclast-like giant cells in bone tumours.
Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-? axis.
Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells.
Otosclerosis
Spiral ligament and stria vascularis changes in cochlear otosclerosis: effect on hearing level.
Ototoxicity
Use of diuretics in chronic renal failure.
Ovarian Neoplasms
DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours.
Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Pancreatic Fistula
Pharmacological inhibition of digestive secretions in the management of pancreaticoduodenal fistulas.
Pancreatic Neoplasms
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy.
Autoimmune pancreatitis: An underdiagnosed autoimmune disease with clinical, imaging and serological features.
Cell lineage markers in human pancreatic cancer.
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity.
Differentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies.
Expression of carbonic anhydrase IX in human pancreatic cancer.
In vivo and in vitro characterization of human fibroblasts recruited selectively into human cancer stroma.
Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells.
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX).
Potential for differential diagnosis of autoimmune pancreatitis and pancreatic cancer using carbonic anhydrase II antibody.
Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Value of anti-plasminogen binding peptide, anti-carbonic anhydrase II, immunoglobulin G4, and other serological markers for the differentiation of autoimmune pancreatitis and pancreatic cancer.
Pancreatitis
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Experimental immune-mediated pancreatitis in neonatally thymectomized mice immunized with carbonic anhydrase II and lactoferrin.
Inhibition of human pancreatic secretion by diamox (carbonic anhydrase inhibitor; therapeutic implications in pancreatitis.
Use of carbonic anhydrase inhibitor in the treatment of pancreatitis.
Use of diuretics in chronic renal failure.
Pancreatitis, Chronic
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Carbonic anhydrase and primary chronic pancreatitis.
Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.
Diminished cellular immune response to carbonic anhydrase II in patients with Sjögren's syndrome and idiopathic chronic pancreatitis.
Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis.
Low-avidity antibodies to carbonic anhydrase-I and -II in autoimmune chronic pancreatitis.
Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome.
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Utility of serum IgG, IgG4 and carbonic anhydrase II antibodies in distinguishing autoimmune pancreatitis from pancreatic cancer and chronic pancreatitis.
Papilloma
Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women.
Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin.
Papillomavirus Infections
Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States).
Detection of human papillomavirus DNA by the hybrid capture assay.
Establishment of an efficient multiplex real-time PCR assay for human papillomavirus genotyping in cervical cytology specimens: comparison with hybrid capture II.
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Presence of human papillomavirus infection determined by hybrid capture assay in cervical lesions in a Venezuelan population.
Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
Retrospective analysis of cervical cancer and precancerous lesions in patients with atypical squamous cells of undetermined significance in China.
Paralysis
Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats.
Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.
Channelopathies.
Dichlorphenamide: A Review in Primary Periodic Paralyses.
Episodic Muscle Disorders.
Muscle channelopathies: does the predicted channel gating pore offer new treatment options for hypokalaemic periodic paralysis?
Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers.
Paralysis Episodes in Carbonic Anhydrase II Deficiency.
Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis.
Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
Treatment of hypokalemic periodic paralysis with topiramate.
Treatment of neuromuscular channelopathies: current concepts and future prospects.
Use of Acetazolamide in Sulfonamide-Allergic Patients With Neurologic Channelopathies.
[Treatment of familial hypokalemic paralysis with carbon dioxide anhydrase inhibitors]
Paraneoplastic Cerebellar Degeneration
Carbonic Anhydrase-Related Protein VIII antibodies and paraneoplastic cerebellar degeneration.
Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration.
Paraneoplastic cerebellar degeneration in a patient with breast cancer associated with carbonic anhydrase-related protein VIII autoantibodies.
Paraneoplastic Syndromes, Ocular
Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy.
Unique epitopes for carbonic anhydrase II autoantibodies related to autoimmune retinopathy and cancer-associated retinopathy.
Paraproteinemias
Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance.
Parasitic Diseases
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Paresthesia
Efficacy of zonisamide in migraineurs with nonresponse to topiramate.
Penile Neoplasms
Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study.
Peptic Ulcer
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study.
Expression and localization of alpha- and beta-carbonic anhydrase in Helicobacter pylori.
Inhibition of gastric mucosa carbonic anhydrase by pirenzepine in patients with gastroduodenal ulcers.
The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memoriam Ioan Pu?ca? (1932-2015).
Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors.
[Carbonic anhydrase inhibitors in the treatment of gastroduodenal ulcer]
Periodontal Diseases
Effect of Genetic Polymorphisms in CA6 Gene on the Expression and Catalytic Activity of Human Salivary Carbonic Anhydrase VI.
Periodontitis
Sulfonamide inhibition studies of the ?-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
Peripheral Nerve Injuries
Differential effects of distal and proximal nerve lesions on carbonic anhydrase activity in rat primary sensory neurons, ventral and dorsal root axons.
Differential expression of carbonic anhydrase isozymes in microglial cell types.
Persistent Infection
Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA.
Hypoxic marker CA IX and adhesion mediator ?-catenin are downregulated by lymphocytic choriomeningitis virus persistent infection.
Pheochromocytoma
Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study.
Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Phlebitis
[Autoimmune pancreatitis: inflammatory pseudotumor, multifocal fibrosclerosis, portal hypertension, and long-term outcome]
Phyllodes Tumor
The expression of metabolism-related proteins in phyllodes tumors.
Pick Disease of the Brain
Neurochemical enzyme changes in Alzheimer's and Pick's disease.
Pilomatrixoma
Calcifying epithelioma of Malherbe with ossification. Special reference to lectin binding and immunohistochemistry of ossified sites.
Pituitary Neoplasms
Comparison of two isozymes of carbonic anhydrase in the rat anterior pituitary gland and pituitary tumors.
Pleural Effusion
Clinical Impact and Reliability of Carbonic Anhydrase XII in the Differentiation of Malignant and Tuberculous Pleural Effusions.
Pleural Effusion, Malignant
Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry.
Pneumococcal Infections
Selected trace elements and esterase activity of carbonic anhydrase levels in lambs with pneumonia.
Pneumonia
Carbonic Anhydrase IX and Hypoxia Promote Rat Pulmonary Endothelial Cell Survival During Infection.
Selected trace elements and esterase activity of carbonic anhydrase levels in lambs with pneumonia.
[Blood carbonic anhydrase and erythrocyte zinc in cases of acute pneumonia in children]
[Clinical value of determining carbonic anhydrase activity and zinc in children with acute pneumonia]
[Zinc metabolism and carbonic activity anhydrase in patients with acute pneumonia]
Polycystic Kidney Diseases
Molecular mechanisms underlying the reception and transmission of sour taste information.
Renal carbonic anhydrase activity in DBA/2FG-pcy/pcy mice with inherited polycystic kidney disease.
Polycythemia Vera
Blood carbonic anhydrase activity in anemia, with a note on polycythemia vera.
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Polymyositis
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Development of a highly sensitive enzyme-immunoassay for serum carbonic anhydrase-III.
Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease.
Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run.
Pre-Eclampsia
Carbonic anhydrase inhibitors; their effect on water and electrolyte metabolism in toxemia of pregnancy.
Effects of carbonic anhydrase inhibitors in toxemia of pregnancy.
Renal dysfunction and podocyturia in pre-eclampsia may be explained by increased urinary VEGF.
Serum Anti-Carbonic Anhydrase II Antibodies and Oxidant-Antioxidant Balance in Pre-eclampsia.
Spontaneous pregnancy-induced hypertension and intrauterine growth restriction in rats.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.
Primary Myelofibrosis
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Prostatic Diseases
Carbonic anhydrase IX expression in prostate cancer.
Prostatic Neoplasms
Carbonic anhydrase I as a new plasma biomarker for prostate cancer.
Carbonic anhydrase III is a new target of HIF1? in prostate cancer model.
Carbonic anhydrase IX expression in prostate cancer.
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.
Carbonic anhydrase IX is a marker of hypoxia and correlates with higher Gleason scores and ISUP grading in prostate cancer.
Detecting extracellular carbonic anhydrase activity using membrane inlet mass spectrometry.
Genetic polymorphism and carbonic anhydrase 9 expression can predict nodal metastatic prostate cancer risk in patients with prostate-specific antigen levels ?10 ng/ml at initial biopsy.
Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings.
Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
pH low insertion peptide mediated cell division cycle-associated protein 1 -siRNA transportation for prostatic cancer therapy targeted to the tumor microenvironment.
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.
Prostate cancer cells and exosomes in acidic condition show increased carbonic anhydrase IX expression and activity.
Small Molecules for Immunomodulation in Cancer.
Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer.
[Future perspectives for diagnostic imaging in urology: from anatomic and functional to molecular imaging.]
Prostatitis
Serum quantitative proteomic analysis reveals potential zinc-associated biomarkers for nonbacterial prostatitis.
Protein S Deficiency
Heparin cofactor II in adults and infants with thrombosis and DIC.
Pseudomyxoma Peritonei
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei.
Pseudotumor Cerebri
Acetazolamide Mitigates Intracranial Pressure Spikes Without Affecting Functional Outcome After Experimental Hemorrhagic Stroke.
Possible association between acetazolamide administration during pregnancy and multiple congenital malformations.
Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.
Psoriasis
Molecular Diagnostics of Psoriasis, Atopic Dermatitis, Allergic Contact Dermatitis and Irritant Contact Dermatitis.
Pustular psoriasis precipitated by acetazolamide.
[Blood carbonic anhydrase activity in patients with psoriasis]
Pterygium
Overexpression of carbonic anhydrase 1 in pterygium.
Pulmonary Disease, Chronic Obstructive
Acetazolamide and breathing. Does a clinical dose alter peripheral and central CO(2) sensitivity?
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis.
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic obstructive lung disease.
Effect of low-dose acetazolamide on the ventilatory CO2 response during hypoxia in the anaesthetized cat.
Estimations of active and inactive carbonic anhydrase isozyme B in human red cells.
Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of patients with chronic obstructive pulmonary disease.
Human erythrocyte carbonic anhydrase B and C in chronic obstructive lung disease.
Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits.
Oxidized proteins and superoxide anion production in the diaphragm of severe COPD patients.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
Severe mixed acidosis by combined therapy with acetazolamide and timolol eyedrops.
[Acetazolamide in hypercapnic chronic obstructive lung disease--a renaissance?]
[Carbonic anhydrase III and mRNA expression levels in quadriceps femoris muscle of chronic obstructive pulmonary disease patients].
Pulmonary Embolism
Carbonic Anhydrase IX in the Prediction of Right Ventricular Dysfunction in Patients With Hemodynamically Stable Acute Pulmonary Embolism.
Pulmonary Emphysema
The effects of carbonic anhydrase inhibitor on arterial blood gases in chronic pulmonary emphysema: a preliminary report.
[Blood carbonic anhydrase activity in anthracosis (anthracosilicosis) and pulmonary emphysema]
Pulmonary Fibrosis
Investigation of the effects of alpha-tocopherol on the levels of Fe, Cu, Zn, Mn, and carbonic anhydrase in rats with bleomycin-induced pulmonary fibrosis.
Pulmonary Heart Disease
Oral administration of a potent carbonic anhydrase inhibitor (diamox). III. Its use as a diuretic in patients with severe congestive heart failure due to cor pulmonale.
Sensitivity of respiratory center to carbon dioxide in emphysema and cor pulmonale: effects of carbonic anhydrase inhibition.
[Acid-base equilibrium in arterial blood and cerebrospinal fluid in heart insufficiency and cor pulmonale and its control by carbonic anhydrase inhibition.]
Purpura
[Intervention of carbonic anhydrase in the mechanism of perforation of the lamellibranchs valves by Purpura (Thais) lapillus L. (Gastropoda Prosobrancha Muricida) ]
Pyelonephritis
Carbonic anhydrase 2 deficiency leads to increased pyelonephritis susceptibility.
Developmental loss, but not pharmacological suppression, of renal carbonic anhydrase 2 results in pyelonephritis susceptibility.
pyruvate carboxylase deficiency
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
Pyruvate Carboxylase Deficiency Disease
Mitochondrial Carbonic Anhydrase VA Deficiency Resulting from CA5A Alterations Presents with Hyperammonemia in Early Childhood.
Rectal Neoplasms
Carbonic anhydrase IX, hypoxia-inducible factor-1?, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors.
Clinical value of significance of Hypoxia Inducible Factor-1?, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy.
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.
Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.
Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer.
Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy.
Main Effects and Interactions of Carbonic Anhydrase IX, Hypoxia-inducible Factor-1?, Ezrin and Glucose Transporter-1 in Multivariate Analysis for Disease Outcome in Rectal Cancer.
Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.
Reflex, Abnormal
Spinal carbonic anhydrase contributes to nociceptive reflex enhancement by midazolam, pentobarbital, and propofol.
Refractive Errors
Ocular side effects of selected systemic drugs.
Predictors of success in selective laser trabeculoplasty for primary open angle glaucoma in Chinese.
Risk factors of shallow anterior chamber other than hypotony after Ahmed glaucoma valve implant.
Renal Insufficiency
Carbonic anhydrase isoenzyme B in erythrocytes of anemic and non-anemic uremic subjects.
Carbonic anhydrase isoenzyme B in erythrocytes of subjects with chronic acidosis.
Gene therapy for renal diseases.
Hypercarbia and acidosis associated with carbonic anhydrase inhibition: a hazard of topical mafenide acetate use in renal failure.
The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure.
Renal Insufficiency, Chronic
Carbonic anhydrase I and II levels in erythrocytes of chronic renal disease patients.
Erythrocyte zinc and carbonic anhydrase levels in nondialyzed chronic kidney disease patients.
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function.
Reperfusion Injury
Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Cardioprotection of benzolamide in a regional ischemia model: Role of eNOS/NO.
Correction: Carbonic Anhydrase Protects Fatty Liver Grafts against Ischemic Reperfusion Damage.
Role of carbonic anhydrase in acute recovery following renal ischemia reperfusion injury.
Respiratory Distress Syndrome
Carbonic anhydrase isoenzymes in infants with respiratory distress syndrome.
Carbonic anhydrase isoenzymes in the erythrocytes of new-born premature and full-term infants.
Respiratory Insufficiency
Acute respiratory failure precipitated by a carbonic anhydrase inhibitor.
Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials.
Effect of CO2 on carbonic anhydrase activity and isozyme levels in respiratory failure.
Kinetics of CO2 exchange with carbonic anhydrase immobilized on fiber membranes in artificial lungs.
The effect of a new carbonic anhydrase inhibitor (dichlorphenamide) in respiratory insufficiency.
Trial sequential analysis suggested the potential overestimated effect of carbonic anhydrase inhibitor for respiratory failure and metabolic alkalosis.
[A contribution on the treatment of respiratory insufficiency with carbonic anhydrase inhibitors]
[Carbonic anhydrase inhibitors in the treatment of global respiratory insufficiency in patients with chronic bronchopneumathies]
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors in patients with chronic respiratory insufficiency. I. Ventilation, gas exchange, and gas tension in the blood, at rest and during muscular exercise of various intensity]
[Comparison between the effects of metabolic acidosis due to ammonium chloride and carbon anhydrase inhibitors, in patients with chronic respiratory insufficiency. II. Tissue oxygenation and anerobic metabolism during muscular exercise]
[Effects of carbonic anhydrase inhibition and of acidosis due to ammonium chloride on the ventilatory response to CO2 in chronic respiratory insufficiency]
[Effects of carbonic anhydrase inhibition on respiratory function in patients with chronic respiratory insufficiency. During rest]
[Effects of the inhibition of carbonic anhydrase on respiratory function in patients with chronic respiratory insufficiency. During muscular exercise of varying intensity]
[Effects of the inhibition of carbonic anhydrase on respiratory function in patients with chronic respiratory insufficiency. Tissue oxygenation and oxygen debt during muscular exercise of varying intensity]
[Oxygen and carbonic anhydrase inhibitors in the treatment of attacks of respiratory insufficiency.]
Retinal Artery Occlusion
Purulent anterior segment endophthalmitis following paracentesis.
Retinal Degeneration
Efficacy of topical brinzolamide in children with retinal dystrophies.
Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK.
Retinal Dystrophy with Intraretinal Cystoid Spaces Associated with Mutations in the Crumbs Homologue (CRB1) gene.
Retinal Detachment
Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment.
Retinal Diseases
In vivo imaging reveals novel aspects of retinal disease progression in Rs1h(-/Y) mice but no therapeutic effect of carbonic anhydrase inhibition.
Topical Aqueous Suppression and Closure of Idiopathic Full-Thickness Macular Holes.
Retinal Dystrophies
Autoimmune retinopathy associated with monoclonal gammopathy of undetermined significance: a case report.
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Efficacy of topical brinzolamide in children with retinal dystrophies.
Macular cysts in retinal dystrophy.
Paradoxical response to carbonic anhydrase inhibitors in patients with intraretinal cystoid spaces.
Resolution of cystoid macular edema with topical carbonic anhydrase inhibitor in a patient with retinal dystrophy associated with Cohen syndrome.
Topical carbonic anhydrase inhibitors in macular edema associated with Alström syndrome.
TOPICAL DORZOLAMIDE FOR CYSTOID MACULAR EDEMA IN BIETTI CRYSTALLINE RETINAL DYSTROPHY.
Retinal Hemorrhage
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Retinal Perforations
Macular Hole Closure with Topical Carbonic Anhydrase Inhibitor.
Retinitis
Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors.
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Retinitis Pigmentosa
An efficient method for the synthesis of novel derivatives 4-{5-[4-(4-amino-5-mercapto-4H-[1,2,4]triazol-3-yl)-phenyl]-3-trifluoromethyl-pyrazol-1-yl}-benzenesulfonamide and their anti-inflammatory potential.
Apoptosis-inducing signal sequence mutation in carbonic anhydrase IV identified in patients with the RP17 form of retinitis pigmentosa.
Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema.
Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17.
Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa.
Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors.
Discovery of 4-sulfamoyl-phenyl-?-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.
Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa.
Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa.
Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: A meta-analysis.
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa.
Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
First evaluation of organotellurium derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors.
Identification and characterization of a novel mutation in the carbonic anhydrase IV gene that causes retinitis pigmentosa.
Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study.
Intrinsic thermodynamics of high affinity inhibitor binding to recombinant human carbonic anhydrase IV.
Pathogenesis of retinitis pigmentosa associated with apoptosis-inducing mutations in carbonic anhydrase IV.
Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK.
RECURRENT CENTRAL SEROUS CHORIORETINOPATHY ASSOCIATED WITH RETINITIS PIGMENTOSA TREATED WITH CARBONIC ANHYDRASE INHIBITORS.
Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors.
Screening for the carbonic anhydrase IV gene mutations in Chinese retinitis pigmentosa patients.
Short-term outcomes of subtenon triamcinolone acetonide injections in patients with retinitis pigmentosa-associated cystoid macular edema unresponsive to carbonic anhydrase inhibitors.
Synthesis and biological evaluation of cyclic imides incorporating benzenesulfonamide moieties as carbonic anhydrase I, II, IV and IX inhibitors.
Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors.
The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema.
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa.
Topical steroidal and nonsteroidal antiinflammatory drugs for the treatment of cystoid macular edema in retinitis pigmentosa.
Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review.
[Antiretinal antibodies associated with cystoid macular edema]
Retinoschisis
A combination of topical and systemic carbonic anhydrase in the treatment of chromosome X-linked retinoschisis.
Carbonic anhydrase inhibition in X-linked retinoschisis: An eye on the photoreceptors.
Carbonic Anhydrase Inhibitors for the Treatment of Cystic Macular Lesions in Children With X-Linked Juvenile Retinoschisis.
Carbonic anhydrase inhibitors in patients with X-linked retinoschisis: effects on macular morphology and function.
Papillomacular retinoschisis associated with glaucoma: Response to topical carbonic anhydrase inhibitor.
Paradoxical Anatomic Response to Topical Carbonic Anhydrase Inhibitor in X-linked Retinoschisis.
Resolution of optic disc pit-associated macular retinoschisis after topical carbonic anhydrase inhibitor treatment: Report of a case.
STRUCTURAL AND FUNCTIONAL MONITORING OF EXTRAMACULAR CYSTOID SPACES IN A CASE OF X-LINKED RETINOSCHISIS TREATED WITH ACETAZOLAMIDE.
THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS.
Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide.
USE OF A CARBONIC ANHYDRASE INHIBITOR IN X-LINKED RETINOSCHISIS: Effect on Cystic-Appearing Macular Lesions and Visual Acuity.
Use of dorzolamide for patients with x-linked retinoschisis.
X-linked juvenile retinoschisis in females and response to carbonic anhydrase inhibitors: case report and review of the literature.
Rhabdomyolysis
Carbonic anhydrase III as a serum marker for diagnosis of rhabdomyolysis.
Determination of carbonic anhydrase III isoenzyme concentration in sera of racehorses with exertional rhabdomyolysis.
Exertional rhabdomyolysis in carbonic anhydrase 12 deficiency.
Rhabdomyosarcoma
Tumour expressions of hypoxic markers predict the response to neo-adjuvant chemotherapy in children with inoperable rhabdomyosarcoma.
Rheumatic Diseases
Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases.
[Clinical evaluation of blood catalase and carbonic anhydrase activity in rheumatism in children]
Rheumatic Fever
[Carbonic anhydrase of erythrocytes in acute rheumatic fever in children]
Rickets
[Determination of carbonic anhydrase activity, concentration of 2,3-diphosphoglycerate and several erythrocyte indices in rickets]
Salivary Gland Calculi
Possible Drug-Associated Sialolithiasis From the Bicarbonate Anhydrase Inhibitor Topiramate: A Case Report and Literature Review.
Salivary Gland Neoplasms
Intrinsic binding of 4-substituted-2,3,5,6-tetrafluorobenezenesulfonamides to native and recombinant human carbonic anhydrase VI.
Sarcoidosis
Sarcoidosis patient: an unexpected reaction to carbonic anhydrase enzyme inhibitor.
Sarcoma
An Immunohistochemical Study of the Expression of the Hypoxia Markers Glut-1 and Ca-IX in Canine Sarcomas.
Can sparsely and heterogeneously expressed proteins be detected using tissue microarrays? A simulation study of the hypoxia marker carbonic anhydrase IX (CA IX) in human soft tissue sarcoma.
Carbonic anhydrase isozymes II, IX, and XII in uterine tumors.
Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma.
Design, synthesis, and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor (HIF)-1 inhibitors.
Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.
Metastatic instability of murine tumor metastases: dependence on tumor type.
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1?
Prognostic impacts of hypoxic markers in soft tissue sarcoma.
Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin.
Sarcoma, Experimental
[Activity of ceruloplasmin, carbonic anhydrase and saturation of transferrin with iron in blood serum of rats developing experimental sarcoma M-1 against a background of E-avitaminosis]
Schistosomiasis
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
Sulfonamide Inhibition Studies of an ?-Carbonic Anhydrase from Schistosoma mansoni, a Platyhelminth Parasite Responsible for Schistosomiasis.
Schistosomiasis mansoni
Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.
Scleroderma, Diffuse
A study of anti-carbonic anhydrase II antibodies in rheumatic autoimmune diseases.
Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis.
Scleroderma, Systemic
Anti-carbonic anhydrase II antibodies in systemic sclerosis: association with lung involvement.
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.
Serum levels of soluble carbonic anhydrase IX are decreased in patients with diffuse cutaneous systemic sclerosis compared to those with limited cutaneous systemic sclerosis.
Subgroups of Sjögren syndrome patients according to serological profiles.
Seizures
A single dose of sulthiame induces a selective increase in resting motor threshold in human motor cortex: A transcranial magnetic stimulation study.
Acetazolamide impairs fear memory consolidation in rodents.
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action.
Carbonic anhydrase inhibitors as anticonvulsant agents.
Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia.
Carbonic anhydrase IV on brain capillary endothelial cells: a marker associated with the blood-brain barrier.
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ?50 kg/m2 Prior to Bariatric Surgery.
Computer-aided identification of human carbonic anhydrase isoenzyme VII inhibitors as potential antiepileptic agents.
Correlation between effects of acute acetazolamide administration to mice on electroshock seizure threshold and maximal electroshock seizure pattern, and on carbonic anhydrase activity in subcellular fractions of brain.
Development of seizure patterns in newborn animals; significance of brain carbonic anhydrase.
Developmental changes in seizure susceptibility in carbonic anhydrase II-deficient mice and normal littermates.
Discovery of Benzenesulfonamide Derivatives as Carbonic Anhydrase Inhibitors with Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Evaluation.
Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal.
Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus.
Glial contribution to seizure: carbonic anhydrase activity in epileptic mammalian brain.
Increased susceptibility of brain slices from carbonic anhydrase II-deficient mice to low [Mg2+]O-induced seizures.
Induction of new carbonic anhydrase II following treatment with acetazolamide in DBA and C57 mice.
Localization of carbonic anhydrase in the cerebrum and cerebellum of normal and audiogenic seizure mice.
Lucky Switcheroo: Dramatic Potency and Selectivity Improvement of Imidazoline Inhibitors of Human Carbonic Anhydrase VII.
Mechanisms of tolerance to the anticonvulsant effects of acetazolamide in mice: relation to the activity and amount of carbonic anhydrase in brain.
Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.
Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures.
Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of N-((Benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies.
Pharmacological inhibition of brain carbonic anhydrase protects against 4-aminopyridine seizures.
Phenyl(thio)phosphon(amid)ate Benzenesulfonamides as Potent and Selective Inhibitors of Human Carbonic Anhydrases II and VII Counteract Allodynia in a Mouse Model of Oxaliplatin-Induced Neuropathy.
Reduced susceptibility to seizures in carbonic anhydrase II deficient mutant mice.
Resistance of hippocampal synaptic transmission to hypoxia in carbonic anhydrase II-deficient mice.
Role of glial cation and anion transport mechanisms in etiology and arrest of seizures.
Seizure patterns in young animals; significance of brain carbonic anhydrase. II.
Substituted thiadiazolines as inhibitors of central nervous system carbonic anhydrase.
Sulthiame in childhood epilepsy.
The Many Faces of Glut1 Deficiency Syndrome.
The roles of nitric oxide and carbon dioxide gas in the neurotoxic actions of oxygen under pressure.
Up-regulation of carbonic anhydrase isozyme IV in CNS myelin of mice genetically deficient in carbonic anhydrase II.
Zonisamide: chemistry, mechanism of action, and pharmacokinetics.
Seizures, Febrile
Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures.
Seminoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Sepsis
Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with acute promyelocytic leukemia.
Proteome analysis of hemofilter adsorbates to identify novel substances of sepsis: a pilot study.
[The state of carbonic anhydrase in the blood of wounded with sepsis; the role of vitaminotherapy].
Sexually Transmitted Diseases
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Shock, Cardiogenic
Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: an observational cohort study and translational approach.
Sialadenitis
Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II.
Sickle Cell Trait
Carbonic anhydrase activity in sickle cell anemia, sickle cell trait, and pernicious anemia.
Reversal of retinal and optic disc ischemia in a patient with sickle cell trait and glaucoma secondary to traumatic hyphema.
Sinus Thrombosis, Intracranial
Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis.
Sjogren's Syndrome
Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis.
Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome.
Evaluation of Autoantibodies in Patients with Primary and Secondary Sjogren's Syndrome.
Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjogren's syndrome.
Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjogren's syndrome.
Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis.
Sleep Apnea Syndromes
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Effects of acetazolamide on the sleep apnea syndrome and its therapeutic mechanism.
Increased Carbonic Anhydrase Activity is Associated with Sleep Apnea Severity and Related Hypoxemia.
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist: a patent evaluation of CA2958110 and IN6616DEN2012.
Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study.
[Inhibition of renal carbonic anhydrase as a respiratory stimulant-- an obsolete indication?]
Sleep Apnea, Central
Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits.
The effects of acetazolamide on arterial pressure variability during REM sleep in the rat.
Sleep Apnea, Obstructive
Acetazolamide Reduces Blood Pressure and Sleep-Disordered Breathing in Patients With Hypertension and Obstructive Sleep Apnea: A Randomized Controlled Trial.
Carbonic Anhydrase II Deficiency: A Rare Case of Severe Obstructive Sleep Apnea.
Carbonic anhydrase, obstructive sleep apnea and hypertension: Effects of intervention.
Increased Carbonic Anhydrase Activity is Associated with Sleep Apnea Severity and Related Hypoxemia.
Independent associations between arterial bicarbonate, apnea severity and hypertension in obstructive sleep apnea.
Small Cell Lung Carcinoma
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Spinal Muscular Atrophies of Childhood
Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.
Splenosis
Renal Splenosis: Renal Mass Biopsy Diagnosis of a Tumor Clinically Mimicking Renal Cell Carcinoma.
Spondylitis, Ankylosing
Carbonic Anhydrase 1-Mediated Calcification Is Associated With Atherosclerosis, and Methazolamide Alleviates Its Pathogenesis.
Carbonic anhydrase I is involved in the process of bone formation and is susceptible to ankylosing spondylitis.
Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis.
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Squamous Cell Carcinoma of Head and Neck
Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.
Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma.
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma.
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients.
Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma.
Correlation of carbonic anhydrase 9 (CA9) with pathological T-stage and prognosis in patients with oral tongue squamous cell carcinoma.
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.
Expression of CA IX in dysplasia adjacent to surgical resection margins of oral squamous cell carcinoma.
Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients.
Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma.
Expression of carbonic anhydrases I/II and the correlation to clinical aspects of oral squamous cell carcinoma analyzed using tissue microarray.
Galectin-1: a link between tumor hypoxia and tumor immune privilege.
High stromal carbonic anhydrase IX expression is associated with nodal metastasis and decreased survival in patients with surgically-treated oral cavity squamous cell carcinoma.
HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer.
Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients.
Increased expression of carbonic anhydrase IX in oral submucous fibrosis and oral squamous cell carcinoma.
Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma.
Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.
Prognostic value of CAIX expression in oral squamous cell carcinoma: a systematic review and meta-analysis.
Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma.
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis.
[A preliminary study on the relationship between GLUT-1?MCT-4 and CA? in laryngeal squamous cell carcinoma].
[Expression and clinical pathological implications of carbonic anhydrase 9 and P glycoprotein in laryngeal squamous cell carcinoma].
Starvation
Carbonic anhydrases in cytosol, nucleus, and membranes of rat liver.
Stevens-Johnson Syndrome
CD8(+) T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms.
Toxic Epidermal Necrolysis in a Patient with HLA-B*5901 Haplotype Caused by Topical and Oral Carbonic Anhydrase Inhibitors.
Toxic Epidermal Necrolysis Induced by the Topical Carbonic Anhydrase Inhibitors Brinzolamide and Dorzolamide.
Stomach Neoplasms
Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues.
Carbonic anhydrase IV inhibits cell proliferation in gastric cancer by regulating the cell cycle.
CREB is a key negative regulator of carbonic anhydrase IX (CA9) in gastric cancer.
Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer.
Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer.
Expression of carbonic anhydrase 9 at the invasion front of gastric cancers.
Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.
Implications of carbonic anhydrase IX hypermethylation in gastric cancer pathogenesis.
Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
[The clinical significance of E-cadherin and alpha-catenin expression in human gastric cancer]
Stomach Ulcer
Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase.
Measurement of Carbonic Anhydrase I and II Isozymes in Feces as a Marker of Occult Blood in Horses with Intestinal Tract Bleeding.
Successful treatment of intractable gastric ulcers with acetazolamide.
Treatment of gastric ulcer with carbonic anhydrase inhibitors.
Stomatitis, Aphthous
Salivary proteome of aphthous stomatitis reveals the participation of vitamin metabolism, nutrients, and bacteria.
Stroke
Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management.
Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: The Gutenberg Health Study.
The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.
Transgenic Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates A Mechanism to Tolerate Acidosis.
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Taste Disorders
Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.
The role of zinc in the treatment of taste disorders.
Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation.
Telangiectasis
DECREASED MACULAR THICKNESS IN NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2 WITH ORAL CARBONIC ANHYDRASE INHIBITORS.
Teratoma
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Testicular Neoplasms
Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.
Tetany
[Carbonic anhydrase inhibition and spasmophilia.]
Thromboangiitis Obliterans
[Juvenile cerebral infarction associated with heparin cofactor II abnormality. A case report]
Thrombocythemia, Essential
Cytosolic carbonic anhydrase activity in chronic myeloid disorders with different clinical phenotype.
Thromboembolism
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Thrombophilia
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Heparin cofactor II: experimental approach to a new assay and clinical results.
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Thrombosis
Carbonic Anhydrase Inhibitors suppress platelet procoagulant responses and in vivo thrombosis.
Combined inherited protein S and heparin co-factor II deficiency in a patient with upper limb thrombosis: a family study.
Constitutional heparin co-factor II deficiency associated with recurrent thrombosis.
Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis.
Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis.
Heparin cofactor II in adults and infants with thrombosis and DIC.
Heparin cofactor II: experimental approach to a new assay and clinical results.
Hereditary heparin cofactor II deficiency and coronary artery disease.
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Use of single-slice thick slab phase-contrast angiography for the diagnosis of dural venous sinus thrombosis.
[The second cofactor of heparin]
Thymoma
Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas.
Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
The occurrence of hemoglobins Bart's and F associated with carbonic anhydrase deficiency in a patient with alpha-thalassemia and malignant thymoma.
Thyroid Cancer, Papillary
Glycolysis-related protein expression in thyroid cancer.
Thyroid Diseases
Clinical utility of red blood cell carbonic anhydrase I and zinc concentrations in patients with thyroid diseases.
Effects of thyroid hormone on erythrocyte carbonic anhydrase-I and zinc concentrations in vivo and in vitro: clinical usefulness of carbonic anhydrase-I and zinc concentrations in erythrocytes.
Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease.
[Erythrocyte carbonic anhydrase I and zinc concentrations in thyrotoxicosis reflect integrated thyroid hormone levels over the previous few months]
Thyroid Neoplasms
Expression Pattern of Carbonic Anhydrase IX in Medullary Thyroid Carcinoma Supports a Role for RET-Mediated Activation of the HIF Pathway.
Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer.
Thyroid Nodule
Carbonic anhydrase 4 and crystallin ?-B immunoreactivity may distinguish benign from malignant thyroid nodules in patients with indeterminate thyroid cytology.
Thyroiditis
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions.
Thyroiditis, Subacute
Erythrocyte carbonic anhydrase-I concentrations in patients with Graves' disease and subacute thyroiditis reflect integrated thyroid hormone levels over the previous few months.
Thyrotoxicosis
[Erythrocyte carbonic anhydrase I and zinc concentrations in thyrotoxicosis reflect integrated thyroid hormone levels over the previous few months]
Tongue Neoplasms
Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers.
ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Toxemia
Carbonic anhydrase inhibitors; their effect on water and electrolyte metabolism in toxemia of pregnancy.
Effects of carbonic anhydrase inhibitors in toxemia of pregnancy.
Tremor
Essential Tremor: What We Can Learn from Current Pharmacotherapy.
The effect of acetazolamide on essential tremor: an open-label trial.
[Treatment options for nystagmus].
Trichinellosis
Carbonic anhydrase enzyme as a potential therapeutic target for experimental trichinellosis.
Trichomonas Infections
Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis.
Trigeminal Neuralgia
Carbonic anhydrase II in the cerebrospinal fluid: its value as a disease marker.
Triple Negative Breast Neoplasms
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity.
Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Carbonic anhydrase XII expression is linked to suppression of Sonic hedgehog ligand expression in triple negative breast cancer cells.
Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling.
Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.
Harnessing Induced Essentiality: Targeting Carbonic Anhydrase IX and Angiogenesis Reduces Lung Metastasis of Triple Negative Breast Cancer Xenografts.
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
[Clinicopathologic features of mammary microglandular adenosis with carcinoma: a study of 5 cases].
Tuberculosis
3-Phenyl-1H-Indole-5-Sulfonamides: Structure-Based Drug Design of a Promising Class of Carbonic Anhydrase Inhibitors.
3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c ?-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules.
Activation of ?- and ?-carbonic anhydrases from pathogenic bacteria with tripeptides.
Activation studies with amines and amino acids of the ?-carbonic anhydrase encoded by the Rv3273 gene from the pathogenic bacterium Mycobacterium tuberculosis.
Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against Mycobacterium tuberculosis.
Bortezomib inhibits bacterial and fungal ?-carbonic anhydrases.
Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.
Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesulfonamides.
Click-tailed benzenesulfonamides as potent bacterial carbonic anhydrase inhibitors for targeting Mycobacterium tuberculosis and Vibrio cholerae.
Differential chemical and thermal unfolding pattern of Rv3588c and Rv1284 of Mycobacterium tuberculosis - A comparison by fluorescence and circular dichroism spectroscopy.
Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Discovery of Low Nanomolar and Subnanomolar Inhibitors of the Mycobacterial beta-Carbonic Anhydrases Rv1284 and Rv3273.
Dithiocarbamates strongly inhibit the ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis ?-class enzyme Rv3273.
Evaluation of Thio- and Seleno-Acetamides Bearing Benzenesulfonamide as Inhibitor of Carbonic Anhydrases from Different Pathogenic Bacteria.
In vitro inhibition of Mycobacterium tuberculosis ?-carbonic anhydrase 3 with Mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos.
Inhibition of ?-, ?-, ?-, ?-, ?- and ?-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine.
Inhibition of ?-carbonic anhydrases with ureido-substituted benzenesulfonamides.
Inhibition of the ?-carbonic anhydrases from Mycobacterium tuberculosis with C-cinnamoyl glycosides: identification of the first inhibitor with anti-mycobacterial activity.
Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
Mycobacterium tuberculosis?-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs.
Natural Product-Based Phenols as Novel Probes for Mycobacterial and Fungal Carbonic Anhydrases.
Structural Mechanics of the pH-dependent Activity of beta-Carbonic Anhydrase from Mycobacterium tuberculosis.
Structure based drug discovery for designing leads for the non-toxic metabolic targets in multi drug resistant Mycobacterium tuberculosis.
Sulfonamides incorporating fluorine and 1,3,5-triazine moieties are effective inhibitors of three ?-class carbonic anhydrases from Mycobacterium tuberculosis.
Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine.
The beta-Carbonic Anhydrases from Mycobacterium tuberculosis as Drug Targets.
The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits the Mycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence.
[Value of carbonic anhydrase activity in blood in tuberculosis.]
Tuberculosis, Pulmonary
[Effect of oxolamine on respiratory function, carbonic anhydrase and prothrombin level in pulmonary tuberculosis.]
Tuberous Sclerosis
Brain calcification in Kallman's syndrome. Computed tomographic appearance.
Tularemia
Anion inhibitors of the ?-carbonic anhydrase from the pathogenic bacterium responsible of tularemia, Francisella tularensis.
Sulfonamide inhibition profiles of the ?-carbonic anhydrase from the pathogenic bacterium Francisella tularensis responsible of the febrile illness tularemia.
Typhoid Fever
[Carbonic anhydrase in typhoid fever.]
Ureteral Obstruction
Liposome-mediated gene therapy in the kidney.
Urinary Bladder Neoplasms
Analytical validation of ONCURIA™ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection.
Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.
Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer.
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer.
Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer.
Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments.
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer.
Vascular Endothelial Growth Factor, Carbonic Anhydrase 9, and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection.
Urinary Calculi
[Urinary lithiasis of medical origin]
Urogenital Neoplasms
Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers.
Urolithiasis
Immunohistochemical detection of renal carbonic anhydrase of patients with recurrent urolithiasis.
Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome.
The effect of antiepileptic drugs on the kidney function and structure.
Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.
[Detection of carbonic anhydrase in the human kidney from the viewpoint of acid-base regulation (an immunohistochemical study in urolithiasis patients)]
[ON UROLITHIASIS FOLLOWING LONG-TERM ADMINISTRATION OF CARBONIC ANHYDRASE INHIBITORS IN THE THERAPY OF GLAUCOMA.]
[Urinary lithiasis of medical origin]
[Urolithiasis during treatment of carbonic anhydrase inhibitors]
Uterine Cervical Neoplasms
Additional Prognostic Value of SUVmax Measured by F-18 FDG PET/CT over Biological Marker Expressions in Surgically Resected Cervical Cancer Patients.
Assessment of the antiproliferative and apoptotic roles of sulfonamide carbonic anhydrase IX inhibitors in HeLa cancer cell line.
Association between human papillomavirus DNA load and development of cervical intraepithelial neoplasia and cervical cancer.
Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer.
Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression.
Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome.
Comparative assessment of lymph node micrometastasis in cervical, endometrial and vulvar cancer: insights on the real time qRT-PCR approach versus immunohistochemistry, employing dual molecular markers.
Detection of high risk human papillomavirus cervical infections by the hybrid capture in Asunción, Paraguay.
Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.
Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells.
HPV test by Hybrid Capture II for the diagnosis of HR-HPV persistent infection.
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples.
Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.
Inhibition of Carbonic Anhydrase IX Promotes Apoptosis through Intracellular pH Level Alterations in Cervical Cancer Cells.
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Prophylactic irradiation of para-aortic lymph nodes for patients with locally advanced cervical cancers with and without high CA9 expression (KROG 07-01): A randomized, open-label, multicenter, phase 2 trial.
Role of hypoxia-inducible factor-1?, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.
siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis.
Tumor carbonic anhydrase 9 expression is associated with the presence of lymph node metastases in uterine cervical cancer.
[Evaluation of genotyping of human papilomavirus by a new DNA liquid chip based on Luminex XMAP]
Uveal Effusion Syndrome
Medical therapy for uveal effusion syndrome.
Uveitis
Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema.
[Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with the carbonic anhydrase inhibitor acetazolamide (Diamox)]
Uveitis, Anterior
Serum Anti-carbonic Anhydrase Antibodies and Oxidant-Antioxidant Balance in Patients with Acute Anterior Uveitis.
Uveomeningoencephalitic Syndrome
Proteomics Profiling of Plasma Exosomes in VKH Patients
Vaccinia
Reconstitution of carbonic anhydrase activity of the cell-surface-binding protein of vaccinia virus.
Structural and functional characterization of a cell surface binding protein of vaccinia virus.
Vascular Calcification
Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification.
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Vasculitis
Anti-carbonic anhydrase III autoantibodies in vasculitis syndrome.
Venous Thromboembolism
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Venous Thrombosis
Hereditary heparin cofactor II deficiency and the risk of development of thrombosis.
Prevalence of heparin cofactor II deficiency in patients with a history of venous thrombosis.
Ventricular Dysfunction, Right
Carbonic Anhydrase IX in the Prediction of Right Ventricular Dysfunction in Patients With Hemodynamically Stable Acute Pulmonary Embolism.
Vesicular Stomatitis
A novel quasi-viral agent, MaTu, is a two-component system.
Viremia
Clinical evaluation of the digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels.
Virus Diseases
Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type-2 inflammation: a patent evaluation (WO2017/058370).
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I.
von Hippel-Lindau Disease
Expression of hypoxia-inducible carbonic anhydrases in brain tumors.
Vulvar Neoplasms
Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.
Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases.
Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer.
Wasting Syndrome
Carbonic anhydrase XII functions in health and disease.
Wilms Tumor
Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens.
Overexpression of carbonic anhydrase and HIF-1? in Wilms tumours.